



## Appendix W: References

1. Abdel-Razeq HN, Hijjawi SB, Jallad SG, Ababneh BA. Venous thromboembolism risk stratification in medically-ill hospitalized cancer patients. A comprehensive cancer center experience. *Journal of Thrombosis and Thrombolysis*. 2010; 30(3):286-93
2. Abdelkefi A, Ben Othman T, Kammoun L. Prevention of central venous line-related thrombosis by continuous infusion of low-dose unfractionated heparin, in patients with haemato-oncological disease. A randomized controlled trial. *Thrombosis and Haemostasis*. 2004; 92(3):654-661
3. Abdul SA, Tata LJ, Grainge MJ, West J. The incidence of first venous thromboembolism in and around pregnancy using linked primary and secondary care data: a population based cohort study from England and comparative meta-analysis. *PloS One*. 2013; 8(7):e70310
4. Abdul Sultan A, West J, Tata LJ, Fleming KM, Nelson-Piercy C, Grainge MJ. Risk of first venous thromboembolism in pregnant women in hospital: population based cohort study from England. *BMJ*. 2013; 347:f6099
5. Abernethy EA, Hartsuck JM. Postoperative pulmonary embolism. A prospective study utilizing low dose heparin. *American Journal of Surgery*. 1974; 128(6):739-742
6. Abraham-Inpijn L. Critical evaluation of low-dose heparin in laryngectomy. *Archivum Chirurgicum Neerlandicum*. 1979; 31(1):9-15
7. Abraham-Inpijn L, Vreeken J. Effect of low-dose heparin on incidence of postoperative thrombosis in orthopaedic patients. *Archivum Chirurgicum Neerlandicum*. 1975; 27(1):63-68
8. Abumuaileq RR, Abu-Assi E, Lopez-Lopez A, Raposeiras-Roubin S, Rodriguez-Manero M, Martinez-Sande L et al. Comparison between CHA2DS2-VASc and the new R2CHADS2 and ATRIA scores at predicting thromboembolic event in non-anticoagulated and anticoagulated patients with non-valvular atrial fibrillation. *BMC Cardiovascular Disorders*. 2015; 15:156
9. Acuna DL, Berg GM, Harrison BL, Wray T, Dorsch D, Sook C. Assessing the use of venous thromboembolism risk assessment profiles in the trauma population: is it necessary? *American Surgeon*. 2011; 77(6):783-9
10. Adam SS, McDuffie JR, Lachiewicz PF, Ortel TL, Williams JWJ. Comparative effectiveness of new oral anticoagulants and standard thromboprophylaxis in patients having total hip or knee replacement: a systematic review. *Annals of Internal Medicine*. 2013; 159(4):275-284
11. Adolf J, Knee H, Roder JD, van de Fliert E, Siewert JR. Thromboembolism prophylaxis with low molecular weight heparin in abdominal surgery. *Deutsche Medizinische Wochenschrift*. 1989; 114(2):48-53
12. Agarwal R, Hecht TEH, Lazo MC, Umscheid CA. Venous thromboembolism prophylaxis for patients undergoing bariatric surgery: a systematic review. *Surgery for Obesity and Related Diseases*. 2010; 6(2):213-220
13. Agnelli G. Apixaban was noninferior to enoxaparin plus warfarin in patients with acute venous thromboembolism. *Annals of Internal Medicine*. 2013; 159(8):JC2
14. Agnelli G, George DJ, Kakkar AK, Fisher W, Lassen MR, Mismetti P et al. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. *New England Journal of Medicine*. 2012; 366(7):601-609



15. Agnelli G, Piovella F, Buoncristiani P, Severi P, Pini M, D'Angelo A et al. Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery. *New England Journal of Medicine*. 1998; 339(2):80-85
16. Agnelli G, Prandoni P, Di Minno G, Cimminiello C, Scaglione F, Boracchi P et al. Thromboprophylaxis with low-molecular-weight heparins: an assessment of the methodological quality of studies. *Seminars in Thrombosis and Hemostasis*. 2015; 41(2):113-132
17. Ahn S, Lim KS, Lee YS, Lee JL. Validation of the clinical prediction rule for recurrent venous thromboembolism in cancer patients: the Ottawa score. *Supportive Care in Cancer*. 2013; 21(8):2309-13
18. Akhtar N, Azhar M, Mir S, Ashraf MN, Kayani SB. Safety of low molecular weight heparin and unfractionated heparin in prevention of venous thromboembolism (VTE). *Pakistan Journal of Medical and Health Sciences*. 2014; 8(4):896-899
19. Akl EA, Kahale L, Sperati F, Neumann I, Labedi N, Terrenato I et al. Low molecular weight heparin versus unfractionated heparin for perioperative thromboprophylaxis in patients with cancer. *Cochrane Database of Systematic Reviews* 2014, Issue 6. Art. No.: CD009447. DOI: 10.1002/14651858.CD009447.pub2
20. Akl EA, Kahale L, Terrenato I, Neumann I, Yosuico VED, Barba M et al. Oral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation. *Cochrane Database of Systematic Reviews* 2014, Issue 6. Art. No.: CD006466. DOI: 10.1002/14651858.CD006466.pub4.
21. Akl EA, Kamath G, Yosuico V, Kim SY, Barba M, Sperati F et al. Thromboprophylaxis for patients with cancer and central venous catheters: a systematic review and a meta-analysis. *Cancer*. 2008; 112(11):2483-2492
22. Akl EA, Ramly EP, Kahale LA, Yosuico VED, Barba M, Sperati F et al. Anticoagulation for people with cancer and central venous catheters. *Cochrane Database of Systematic Reviews* 2014, Issue 10. Art. No.: CD006468. DOI: 10.1002/14651858.CD006468.pub5.
23. Akl EA, Terrenato I, Barba M, Sperati F, Muti P, Schunemann HJ. Extended perioperative thromboprophylaxis in patients with cancer. A systematic review. *Thrombosis and Haemostasis*. 2008; 100(6):1176-1180
24. Akl EA, Terrenato I, Barba M, Sperati F, Sempos EV, Muti P et al. Low-molecular-weight heparin vs unfractionated heparin for perioperative thromboprophylaxis in patients with cancer: a systematic review and meta-analysis. *Archives of Internal Medicine*. 2008; 168(12):1261-1269
25. Al-Ani F, Shariff S, Siqueira L, Seyam A, Lazo-Langner A. Identifying venous thromboembolism and major bleeding in emergency room discharges using administrative data. *Thrombosis Research*. 2015; 136(6):1195-8
26. Alalaf SK, Jawad AK, Jawad RK, Ali MS, Al Tawil NG. Bemiparin for thromboprophylaxis after benign gynecologic surgery: a randomized clinical trial. *Journal of Thrombosis and Haemostasis*. 2015; 13(12):2161-7
27. Alalaf SK, Jawad RK, Muhammad PR, Ali MS, Al Tawil NG. Bemiparin versus enoxaparin as thromboprophylaxis following vaginal and abdominal deliveries: a prospective clinical trial. *BMC Pregnancy and Childbirth*. 2015; 15:72

28. Albertsen IE, Larsen TB, Rasmussen LH, Overvad TF, Lip GYH. Prevention of venous thromboembolism with new oral anticoagulants versus standard pharmacological treatment in acute medically ill patients: a systematic review and meta-analysis. *Drugs*. 2012; 72(13):1755-1764
29. Alfaro MJ, Paramo JA, Rocha E. Prophylaxis of thromboembolic disease and platelet-related changes following total hip replacement: a comparative study of aspirin and heparin-dihydroergotamine. *Thrombosis and Haemostasis*. 1986; 56(1):53-56
30. Alhazzani W, Lim W, Jaeschke RZ, Murad MH, Cade J, Cook DJ. Heparin thromboprophylaxis in medical-surgical critically ill patients: a systematic review and meta-analysis of randomized trials. *Critical Care Medicine*. 2013; 41(9):2088-2098
31. Ali I, Shokri H, Elsayed HH. Prophylaxis against venous thromboembolism in thoracic surgery patients: Lack of guidelines or inappropriate implementation? *Journal of the Egyptian Society of Cardio Thoracic Surgery*. 2017; 01
32. Alonso-Coello P, Ebrahim S, Guyatt GH, Tikkinen KA, Eckman MH, Neumann I et al. Evaluating patient values and preferences for thromboprophylaxis decision making during pregnancy: a study protocol. *BMC Pregnancy and Childbirth*. 2012; 12:40
33. Alotaibi G, Alsaleh K, Wu C, Mcmurtry MS. Dabigatran, rivaroxaban and apixaban for extended venous thromboembolism treatment: network meta-analysis. *International Angiology*. 2014; 33(4):301-308
34. Altinbas M, Coskun HS, Er O. A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. *Journal of Thrombosis and Haemostasis*. 2004; 2(8):1266-1271
35. Alvarenga YR. New anticoagulants for venous thromboembolism prophylaxis in major orthopedic surgeries. A systematic review of randomized controlled trials. *Jornal Vascular Brasileiro*. 2012; 11(1):1-2
36. American College of Obstetricians and Gynaecologists (ACOG). Thromboembolism in pregnancy. ACOG practice bulletin no. 123. Washington. American College of Obstetricians and Gynaecologists (ACOG), 2011. Available from: [http://www.guideline.gov/content.aspx?id=34439&search=venous+thromboembolism+or+dEEP+vein+thrombosis+or+dvt+or+pulmonary+embolism+and+\(prevention+or+prevent+or+prophylaxis\)](http://www.guideline.gov/content.aspx?id=34439&search=venous+thromboembolism+or+dEEP+vein+thrombosis+or+dvt+or+pulmonary+embolism+and+(prevention+or+prevent+or+prophylaxis))
37. Amin AN, Lin J, Lenhart G, Schulman KL. Clinical and economic outcomes in patients at risk of venous thromboembolism receiving appropriate enoxaparin or unfractionated heparin prophylaxis. *Thrombosis and Haemostasis*. 2009; 102(2):321-326
38. Aminian A, Andalib A, Khorgami Z, Cetin D, Burguera B, Bartholomew J et al. Who Should Get Extended Thromboprophylaxis After Bariatric Surgery?: A Risk Assessment Tool to Guide Indications for Post-discharge Pharmacoprophylaxis. *Annals of Surgery*. 2017; 265(1):143-150
39. Anderson DR. Aspirin after dalteparin was noninferior to continued dalteparin for preventing VTE after total hip arthroplasty. *Annals of Internal Medicine*. 2013; 159(6):JC12
40. Anderson DR, Dunbar MJ, Bohm ER, Belzile E, Kahn SR, Zukor D et al. Aspirin versus low-molecular-weight heparin for extended venous thromboembolism prophylaxis after total hip arthroplasty: a randomized trial. *Annals of Internal Medicine*. 2013; 158(11):800-806
41. Annemans L, Minjoulat-Rey MC, De Knock M, Vranckx K, Czarka M, Gabriel S et al. Cost consequence analysis of fondaparinux versus enoxaparin in the prevention of venous

- thromboembolism after major orthopaedic surgery in Belgium. *Acta Clinica Belgica*. 2004; 59(6):346-357
42. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy--III: Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. *Antiplatelet Trialists' Collaboration. British Medical Journal*. 1994; 308(6923):235-246
43. Antolovic D, Rakow A, Contin P, Ulrich A, Rahbari NN, Buchler MW et al. A randomised controlled pilot trial to evaluate and optimize the use of anti-platelet agents in the perioperative management in patients undergoing general and abdominal surgery--the APAP trial (ISRCTN45810007). *Langenbeck's archives of surgery*. 2012; 397(2):297-306
44. Arabi YM, Alsolamy S, Al-Dawood A, Al-Omari A, Al-Hameed F, Burns KEA et al. Thromboprophylaxis using combined intermittent pneumatic compression and pharmacologic prophylaxis versus pharmacologic prophylaxis alone in critically ill patients: Study protocol for a randomized controlled trial. *Trials*. 2016; 17:390
45. Arabi YM, Khedr M, Dara SI, Dhar GS, Bhat SA, Tamim HM et al. Use of intermittent pneumatic compression and not graduated compression stockings is associated with lower incident VTE in critically ill patients: A multiple propensity scores adjusted analysis. *Chest*. 2013; 144(1):152-159
46. Arcelus JI, Candocia S, Traverso CI, Fabrega F, Caprini JA, Hasty JH. Venous thromboembolism prophylaxis and risk assessment in medical patients. *Seminars in Thrombosis and Hemostasis*. 1991; 17 (Suppl 3):313-8
47. Arnold JD, Dart BW, Barker DE, Maxwell RA, Burkholder HC, Mejia VA et al. Unfractionated heparin three times a day versus enoxaparin in the prevention of deep vein thrombosis in trauma patients. *American Surgeon*. 2010; 76(6):563-570
48. Arrigo RT, Kalanithi P, Cheng I, Alamin T, Carragee EJ, Mindea SA et al. Charlson score is a robust predictor of 30-day complications following spinal metastasis surgery. *Spine*. 2011; 36(19):E1274-80
49. Aryal MR, Pandit A, Ghimire S, Pathak R, Karmacharya P, Poudel DR et al. Thromboprophylaxis with apixaban and the risk of pulmonary embolism in patients undergoing knee replacement surgery. *Journal of Community Hospital Internal Medicine Perspectives*. 2015; 5(4):27889
50. Aryal MR, Ukaigwe A, Pandit A, Karmacharya P, Pradhan R, Mainali NR et al. Meta-analysis of efficacy and safety of rivaroxaban compared with warfarin or dabigatran in patients undergoing catheter ablation for atrial fibrillation. *American Journal of Cardiology*. 2014; 114(4):577-582
51. As-Sultany M, Pagkalos J, Yeganeh S, Craigs CL, Korres N, West RM et al. Use of oral direct factor Xa inhibiting anticoagulants in elective hip and knee arthroplasty: a meta-analysis of efficacy and safety profiles compared with those of low-molecular-weight heparins. *Current Vascular Pharmacology*. 2013; 11(3):366-375
52. Assadian A, Knobl P, Hubl W, Senekowitsch C, Klingler A, Pfaffelmeyer N et al. Safety and efficacy of intravenous enoxaparin for carotid endarterectomy: a prospective randomized pilot trial. *Journal of Vascular Surgery*. 2008; 47(3):537-542

53. Atiq F, Van Den Bemt PMLA, Leebeek FWG, Van GT, Versmissen J. A systematic review on the accumulation of prophylactic dosages of low-molecular-weight heparins (LMWHs) in patients with renal insufficiency. *European Journal of Clinical Pharmacology*. 2015; 71(8):921-929
54. Attaran S, Somov P, Awad WI. Randomised high- and low-dose heparin prophylaxis in patients undergoing thoracotomy for benign and malignant disease: effect on thromboelastography. *European Journal of Cardio-Thoracic Surgery*. 2010; 37(6):1384-1390
55. Auer R, Scheer A, Wells PS, Boushey R, Asmis T, Jonker D et al. The use of extended perioperative low molecular weight heparin (tinzaparin) to improve disease-free survival following surgical resection of colon cancer: a pilot randomized controlled trial. *Blood Coagulation and Fibrinolysis*. 2011; 22(8):760-762
56. Avidan MS, Smith JR, Skrupky LP, Hill L, Jacobsohn E, Burnside B et al. The occurrence of antibodies to heparin-platelet factor 4 in cardiac and thoracic surgical patients receiving desirudin or heparin for postoperative venous thrombosis prophylaxis. *Thrombosis Research*. 2011; 128(6):524-529
57. Avikainen V, von Bonsdorff H, Partio E, Kaira P, Hakkinen S, Usenius JP et al. Low molecular weight heparin (enoxaparin) compared with unfractionated heparin in prophylaxis of deep venous thrombosis and pulmonary embolism in patients undergoing hip replacement. *Annales Chirurgiae et Gynaecologiae*. 1995; 84(1):85-90
58. Ay C, Dunkler D, Simanek R, Thaler J, Koder S, Marosi C et al. Prediction of venous thromboembolism in patients with cancer by measuring thrombin generation: results from the Vienna Cancer and Thrombosis Study. *Journal of Clinical Oncology*. 2011; 29(15):2099-103
59. Ayhan H, Iyigun E, Ince S, Can MF, Hatipoglu S, Saglam M. Comparison of three different protocols in the prevention of postoperative deep vein thrombosis in patients at high-risk: Randomized clinical study. *European Surgical Research*. 2013; 50:64-65
60. Ayhan H, Iyigun E, Ince S, Can MF, Hatipoglu S, Saglam M. A randomised clinical trial comparing the patient comfort and efficacy of three different graduated compression stockings in the prevention of postoperative deep vein thrombosis. *Journal of Clinical Nursing*. 2015; 24(15-16):2247-2257
61. B G. Randomised, controlled trial of low-dose heparin for prevention of fatal pulmonary embolism in patients with infectious diseases. The heparin prophylaxis study group. *Lancet*. 1996; 347(9012):1357-1361
62. Bachmann F, McKenna R, Meredith P, Carta S. Intermittent pneumatic compression of leg and thigh: a new successful method for the prevention of postoperative thrombosis. *Schweizerische Medizinische Wochenschrift*. 1976; 106(50):1819-1821
63. Bagaria SJ, Bagaria VB. Strategies for diagnosis and prevention of venous thromboembolism during pregnancy. *Journal of Pregnancy*. 2011; 2011:206858
64. Bain E, Wilson A, Tooher R, Gates S, Davis LJ, Middleton P. Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period. *Cochrane Database of Systematic Reviews*. 2014; (2)
65. Baker P, Petheram TG, Kurtz S, Konttinen YT, Gregg P, Deehan D. Patient reported outcome measures after revision of the infected TKR: comparison of single versus two-stage revision. *Knee Surgery, Sports Traumatology, Arthroscopy*. 2013; 21(12):2713-20



66. Bakirhan K, Strakhan M. Pharmacologic prevention of venous thromboembolism in obese patients. *Journal of Thrombosis and Thrombolysis*. 2013; 36(3):247-257
67. Balas PE. Efficacy and safety of nadroparin (Fraxiparine) versus placebo in the prophylactic treatment of deep vein thrombosis in patients with high thrombo-embolic risk undergoing general surgery. *Thrombosis Research*. 1992; 65(Suppl 1):S113
68. Bamber L, Wang MY, Prins MH, Ciniglio C, Bauersachs R, Lensing AWA et al. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic deep-vein thrombosis. *Thrombosis and Haemostasis*. 2013; 110(4):732-741
69. Bani-Hani M, Titi MA, Jaradat I, Al-Khaffaf H. Interventions for preventing venous thromboembolism following abdominal aortic surgery. *Cochrane Database of Systematic Reviews* 2008, Issue 1. Art. No.: CD005509. DOI: 10.1002/14651858.CD005509.pub2.
70. Barbar S, Noventa F, Rossetto V, Ferrari A, Brandolin B, Perlati M et al. A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score. *Journal of Thrombosis and Haemostasis*. 2010; 8(11):2450-7
71. Barber EL, Clarke-Pearson DL. The limited utility of currently available venous thromboembolism risk assessment tools in gynecological oncology patients. *American Journal of Obstetrics and Gynecology*. 2016; 215(4):445.e1-9
72. Barbui T, Cassinelli G, Cortelazzo S, D'Alonzo U, Fantoni P, Lavorato F. Comparison of low molecular weight heparin CY 216 and unfractionated heparin in preventing post-operative venous thromboembolism in general surgery: a preliminary results of a cooperative study. *Fibrinolysis*. 1990; 4(Suppl 1):79
73. Barr DA, Irvine S, Ritchie ND, McCutcheon J, Seaton RA. Risk of venous thromboembolism in patients treated for bacterial infection in the community with outpatient parenteral antimicrobial therapy. *QJM*. 2014; 107(3):207-11
74. Barrellier MT, Lebel B, Parienti JJ, Mismetti P, Dutheil JJ, Vielpeau C et al. Short versus extended thromboprophylaxis after total knee arthroplasty: a randomized comparison. *Thrombosis Research*. 2010; 126(4):e298-e304
75. Barrera LM, Perel P, Ker K, Cirocchi R, Farinella E, Morales Uribe CH. Thromboprophylaxis for trauma patients. *Cochrane Database of Systematic Reviews* 2013, Issue 3. Art. No.: CD008303. DOI: 10.1002/14651858.CD008303.pub2.
76. Basta MN, Bauder AR, Kovach SJ, Fischer JP. Assessing the predictive accuracy of the American College of Surgeons National Surgical Quality Improvement Project Surgical Risk Calculator in open ventral hernia repair. *American Journal of Surgery*. 2016; 212(2):272-81
77. Bath PMW, England TJ. Thigh-length compression stockings and DVT after stroke. *Lancet*. 2009; 373:1923-1924
78. Bauer KA, Eriksson B, Lassen MR, Turpie AG. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. *New England Journal of Medicine*. 2001; 345(18):1305-1310
79. Bauersachs R, Schellong SM, Haas S, Tebbe U, Gerlach H-E, Abletshauser C et al. CERTIFY: Prophylaxis of venous thromboembolism in patients with severe renal insufficiency. *Thrombosis and Haemostasis*. 2011; 105(6):981-988



80. Bauersachs RM, Dudenhausen J, Faridi A, Fischer T, Fung S, Geisen U et al. Risk stratification and heparin prophylaxis to prevent venous thromboembolism in pregnant women. *Thrombosis and Haemostasis*. 2007; 98(6):1237-45
81. Baumgartner A, Jacot N, Moser G, Krahenbuhl B. Prevention of postoperative deep vein thrombosis by one daily injection of low molecular weight heparin and dihydroergotamine. *Vasa*. 1989; 18(2):152-156
82. Beaudet A, Clegg J, Thuresson PO, Lloyd A, McEwan P. Review of utility values for economic modeling in type 2 diabetes. *Value in Health*. 2014; 17(4):462-70
83. Becattini C, Agnelli G, Manina G, Noya G, Rondelli F. Venous thromboembolism after laparoscopic bariatric surgery for morbid obesity: clinical burden and prevention. *Surgery for Obesity and Related Diseases*. 2012; 8(1):108-115
84. Beghi C, Fragnito C, Antonelli A, Reverberi C, Ferrari P, Saccani S et al. Prevention of deep venous thrombosis by a new low molecular weight heparin (Fluxum) in cardiac surgery. *International Angiology*. 1993; 12(4):383-386
85. Beitland S, Sandven I, Kjaervik LK, Sandset PM, Sunde K, Eken T. Thromboprophylaxis with low molecular weight heparin versus unfractionated heparin in intensive care patients: a systematic review with meta-analysis and trial sequential analysis. *Intensive Care Medicine*. 2015; 41(7):1209-1219
86. Bekelis K, Desai A, Bakhoun SF, Missios S. A predictive model of complications after spine surgery: the National Surgical Quality Improvement Program (NSQIP) 2005-2010. *Spine Journal: Official Journal of the North American Spine Society*. 2014; 14(7):1247-55
87. Bekelis K, Kalakoti P, Nanda A, Missios S. A predictive model of unfavorable outcomes after benign intracranial tumor resection. *World Neurosurgery*. 2015; 84(1):82-9
88. Bekelis K, Missios S, Mackenzie TA, Fischer A, Labropoulos N, Eskey C. A predictive model of outcomes during cerebral aneurysm coiling. *Journal of Neurointerventional Surgery*. 2014; 6(5):342-8
89. Belch JJ, Lowe GDO, Ward AG. Prevention of deep vein thrombosis in medical patients by low-dose heparin. *Scottish Medical Journal*. 1981; 26(2):115-117
90. Ben-Aharon I, Stemmer SM, Leibovici L, Shpilberg O, Sulkes A, Gafter-Gvili A. Low molecular weight heparin (LMWH) for primary thrombo-prophylaxis in patients with solid malignancies - systematic review and meta-analysis. *Acta Oncologica*. 2014; 53(9):1230-1237
91. Bergmann JF, Neuhart E. A multicenter randomized double-blind study of enoxaparin compared with unfractionated heparin in the prevention of venous thromboembolic disease in elderly in-patients bedridden for acute medical illness. *Thrombosis and Haemostasis*. 1996; 76(4):529-534
92. Bergqvist D, Benoni G, Björgell O, Fredin H, Hedlundh U, Nicolas S et al. Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. *New England Journal of Medicine*. 1996; 335(10):696-700
93. Bergqvist D, Efsing HO, Hallbook T, Hedlund T. Thromboembolism after elective and post-traumatic hip surgery--a controlled prophylactic trial with dextran 70 and low-dose heparin. *Acta Chirurgica Scandinavica*. 1979; 145(4):213-218

94. Berkin JA, Lee C, Landsberger E, Chazotte C, Bernstein PS, Goffman D. Scorecard implementation improves identification of postpartum patients at risk for venous thromboembolism. *Journal of Healthcare Risk Management*. 2016; 36(1):8-13
95. Bern MM, Bierbaum B, Wetzner S, Brennan W, McAlister S. Very low dose warfarin as prophylaxis against ultrasound detected deep vein thrombosis following primary hip replacement. *American Journal of Hematology*. 2002; 71(2):69-74
96. Bern MM, Ward D, Miley G, Spitz D, Spigelman Z, Mattingly D et al. Prospective randomized study of thromboembolic disease (TED) prophylaxis after knee or hip replacement: Fixed low dose warfarin vs. variable dose warfarin vs. fondaparinux, each given for 4 weeks. *Pathophysiology of Haemostasis and Thrombosis*. 2010; 37(Suppl 1):A145
97. Beyer-Westendorf J, Donath L, Lutzner J, Werth S, Radke O, Guenther K-P et al. Efficacy and safety of VTE prophylaxis with oral rivaroxaban compared to fondaparinux or low-molecular weight heparin in a large cohort of consecutive patients undergoing major orthopaedic surgery. *Blood*. 2011; 118(21)
98. Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. *American Journal of Medicine*. 1998; 105(2):91-99
99. Bikdeli B, Sharif-Kashani B, Shahabi P, Raeissi S, Shahrivari M, Shoraka AR et al. Comparison of three risk assessment methods for venous thromboembolism prophylaxis. *Blood Coagulation and Fibrinolysis*. 2013; 24(2):157-63
100. Bilgi K, Muthusamy A, Subair M, Srinivasan S, Kumar A, Ravi R et al. Assessing the risk for development of Venous Thromboembolism (VTE) in surgical patients using Adapted Caprini scoring system. *International Journal Of Surgery*. 2016; 30:68-73
101. Bin Abdulhak AA, Khan AR, Tleyjeh IM, Spertus JA, Sanders SU, Steigerwalt KE et al. Safety and efficacy of interrupted dabigatran for peri-procedural anticoagulation in catheter ablation of atrial fibrillation: a systematic review and meta-analysis. *Europace: European Pacing, Arrhythmias, and Cardiac Electrophysiology*. 2013; 15(10):1412-1420
102. Bircan A, Karadeniz N, Ozden A, Cakir M, Varol E, Oyar O et al. A simple clinical model composed of ECG, shock index, and arterial blood gas analysis for predicting severe pulmonary embolism. *Clinical and Applied Thrombosis/Hemostasis*. 2011; 17(2):188-96
103. Bischof M, Leuppi JD, Sendi P. Cost-effectiveness of extended venous thromboembolism prophylaxis with fondaparinux in hip surgery patients. *Expert Review of Pharmacoeconomics and Outcomes Research*. 2006; 6(2):171-180
104. Bjorvatn A, Kristiansen F. Fondaparinux sodium compared with enoxaparin sodium: A cost-effectiveness analysis. *American Journal of Cardiovascular Drugs*. 2005; 5(2):121-130
105. Blackshear WM, Jr., Prescott C, LePain F, Benoit S, Dickstein R, Seifert KB. Influence of sequential pneumatic compression on postoperative venous function. *Journal of Vascular Surgery*. 1987; 5(3):432-436
106. Blanchard J, Meuwly JY, Leyvraz PF, Miron MJ, Bounameaux H, Hoffmeyer P et al. Prevention of deep-vein thrombosis after total knee replacement. Randomised comparison between a low-molecular-weight heparin (nadroparin) and mechanical prophylaxis with a foot-pump system. *Journal of Bone and Joint Surgery (British Volume)*. 1999; 81(4):654-659
107. Blondon M, Hugon-Rodin J. A clinical risk score to predict the incidence of postpartum venous thromboembolism. *Evidence Based Medicine*. 2017; 22(3):98



108. Bloom BJ, Filion KB, Atallah R, Eisenberg MJ. Meta-analysis of randomized controlled trials on the risk of bleeding with dabigatran. *American Journal of Cardiology*. 2014; 113(6):1066-1074
109. Board NE. National Joint Registry 13th Annual Report. 2016. Available from: <http://www.njrreports.org.uk/Portals/0/PDFdownloads/NJR%2013th%20Annual%20Report%202016.pdf>
110. Bockheim HM, McAllen KJ, Baker R, Barletta JF. Mechanical prophylaxis to prevent venous thromboembolism in surgical patients: a prospective trial evaluating compliance. *Journal of Critical Care*. 2009; 24(2):192-196
111. Boehringer Ingelheim. Asantin DVT nach myokardinfarkt (internal report). Bracknell. Boehringer Ingelheim, 1981.
112. Boehringer Ingelheim. Dabigatran Etxilate vs Enoxaparin in Prevention of Venous Thromboembolism (VTE) Post Total Knee Replacement. NCT00152971. 2012. Available from: <https://clinicaltrials.gov/ct2/show/NCT00152971> Last accessed: 28/06/17.
113. Boese CK, Weis M, Phillips T, Lawton-Peters S, Gallo T, Centeno L. The efficacy of continuous passive motion after total knee arthroplasty: A comparison of three protocols. *Journal of Arthroplasty*. 2014; 29(6):1158-1162
114. Bogari H, Patanwala AE, Cosgrove R, Katz M. Risk-assessment and pharmacological prophylaxis of venous thromboembolism in hospitalized patients with chronic liver disease. *Thrombosis Research*. 2014; 134(6):1220-3
115. Bohl DD, Maltenfort MG, Huang R, Parvizi J, Lieberman JR, Della Valle CJ. Development and Validation of a Risk Stratification System for Pulmonary Embolism After Elective Primary Total Joint Arthroplasty. *Journal of Arthroplasty*. 2016; 31(9 Suppl):187-91
116. Boneu B. An international multicentre study: Clivarin in the prevention of venous thromboembolism in patients undergoing general surgery. Report of the international clivarin Assessment Group. *Blood Coagulation and Fibrinolysis*. 1993; 4(Suppl 1):S21-S22
117. Bookhart BK, Haskell L, Bamber L, Wang M, Schein J, Mody SH. Length of stay and economic consequences with rivaroxaban vs enoxaparin/vitamin K antagonist in patients with DVT and PE: findings from the North American EINSTEIN clinical trial program. *Journal of Medical Economics*. 2014; 17(10):691-695
118. Borgstrom S, Greitz T, Van der Linden W, Molin J, Rudics I. Anticoagulation prophylaxis of venous thrombosis in patients with fractured neck of the femur. *Acta Chirurgica Scandinavica*. 1965; 129:500-508
119. Borris L. Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement: The RECORD study programme. *Pathophysiology of Haemostasis and Thrombosis*. 2010; 37(Suppl 1):105
120. Bottaro FJ, Elizondo MC, Doti C, Bruetman JE, Perez Moreno PD, Bullorsky EO et al. Efficacy of extended thrombo-prophylaxis in major abdominal surgery: what does the evidence show? A meta-analysis. *Thrombosis and Haemostasis*. 2008; 99(6):1104-1111
121. Botteman MF, Caprini J, Stephens JM, Nadipelli V, Bell CF, Pashos CL et al. Results of an economic model to assess the cost-effectiveness of enoxaparin, a low-molecular-weight heparin, versus warfarin for the prophylaxis of deep vein thrombosis and associated long-term complications in total hip replacement surgery in the United States. *Clinical Therapeutics*. 2002; 24(11):1960-1986

122. Bouman AC, Ten Cate-Hoek AJ, Dirksen CD, Joore MA. Eliciting patients' preferences for elastic compression stocking therapy after deep vein thrombosis: potential for improving compliance. *Journal of Thrombosis and Haemostasis*. 2016; 14(3):510-7
123. Boutros IR, Landham PR, Brown RR, Gosali HS. The use of graduated compression stockings in association with fondaparinux in surgery of the hip: A multicentre, multinational, randomised, open-label, parallel-group comparative study. *Journal of Bone and Joint Surgery - Series B*. 2008; 90(11):1535-1536
124. Bozas G, Muazzam IA, Ilyas W, Maraveyas A. PO-39 - Primary thromboprophylaxis for ambulatory patients with advanced metastatic pancreatic cancer. A practical implementation of lessons from published experience. *Thrombosis Research*. 2016; 140 Suppl 1:S191
125. Braidy N, Bui K, Bajorek B. Evaluating the impact of new anticoagulants in the hospital setting. *Pharmacy Practice*. 2011; 9(1):1-10
126. Bramlage P, Michaelis HC, Melzer N. Comparison of 3,000 and 5,000 IU aXa/day certoparin in the prevention of deep-vein thrombosis after total hip replacement. *Thrombosis Journal*. 2012; 10(1):10
127. Brekelmans MP, Kappelhof M, Nieuwkerk PT, Nierman M, Buller HR, Coppens M. Preference for direct oral anticoagulants in patients treated with vitamin K antagonists for venous thromboembolism. *Netherlands Journal of Medicine*. 2017; 75(2):50-55
128. Breuer L, Ringwald J, Schwab S, Kohrmann M. Ischemic stroke in an obese patient receiving dabigatran. *New England Journal of Medicine*. 2013; 368(25):2440-2
129. Briel RC, Doller P, Hermann CP. [Prevention of thromboembolism in hysterectomies with low molecular weight heparin Fragmin]. *Geburtshilfe und Frauenheilkunde*. 1988; 48(3):160-164
130. Brismar B, Hardstedt C, Jacobson S, Kager L, Malmborg AS. Reduction of catheter-associated thrombosis in parenteral nutrition by intravenous heparin therapy. *Archives of Surgery*. 1982; 117(9):1196-1199
131. Brockbank J, Wolowacz S. Economic Evaluations of New Oral Anticoagulants for the Prevention of Venous Thromboembolism After Total Hip or Knee Replacement: A Systematic Review. *Pharmacoeconomics*. 2017; 35(5):517-535
132. Brotman DJ, Shihab HM, Prakasa KR, Kebede S, Haut ER, Sharma R et al. Pharmacologic and mechanical strategies for preventing venous thromboembolism after bariatric surgery: a systematic review and meta-analysis. *JAMA surgery*. 2013; 148(7):675-686
133. Brown GA. Venous thromboembolism prophylaxis after major orthopaedic surgery: a pooled analysis of randomized controlled trials. *Journal of Arthroplasty*. 2009; 24(6 Suppl):77-83
134. Brown R, Lip GY, Gallego P. Dabigatran etexilate for venous thromboembolism: a safety evaluation. *Expert opinion on drug safety*. 2014; 13(5):639-647
135. Bruins Slot KMH, Berge E. Factor Xa inhibitors vs warfarin for preventing stroke and thromboembolism in patients with atrial fibrillation. *JAMA - Journal of the American Medical Association*. 2014; 311(11):1150-1151
136. Bruun-Olsen V, Heiberg KE, Mengshoel AM. Continuous passive motion as an adjunct to active exercises in early rehabilitation following total knee arthroplasty - a randomized controlled trial. *Disability and Rehabilitation*. 2009; 31(4):277-83

137. Bump GM, Dandu M, Kaufman SR, Shojanian KG, Flanders SA. How complete is the evidence for thromboembolism prophylaxis in general medicine patients? A meta-analysis of randomized controlled trials. *Journal of Hospital Medicine*. 2009; 4(5):289-297
138. Bushwitz J, Leclaire A, He J, Mozingo D. Venous thromboembolic complications in burn patients receiving heparin or enoxaparin as prophylaxis. *Value in Health*. 2010; 13(3):A152
139. Bynke O, Hillman J, Lassvik C. Does peroperative external pneumatic leg muscle compression prevent post-operative venous thrombosis in neurosurgery? *Acta Neurochirurgica*. 1987; 88(1-2):46-48
140. CADTH. Low-molecular weight heparins versus warfarin for the long-term prevention or treatment of deep vein thrombosis or pulmonary embolism: a review of the clinical and cost-effectiveness. Toronto. Canadian Agency for Drugs and Technologies in Health (CADTH), 2013. Available from: <https://www.cadth.ca/media/pdf/htis/jun-2013/RC0455%20-%20LMWH%20for%20DVT%20or%20PE%20Final%20%20ABS.pdf>
141. CADTH. Low molecular weight heparins versus unfractionated heparin for thromboprophylaxis in surgery, cancer and general medicine: a review of the cost-effectiveness and safety. Toronto. Canadian Agency for Drugs and Technologies in Health (CADTH), 2013. Available from: <https://www.cadth.ca/media/pdf/htis/jul-2013/RC0460%20LMWH%20vs%20UFH%20final.pdf>
142. CADTH. Timing of enoxaparin administration for the prophylaxis of venous thromboembolism: clinical evidence and guidelines. Toronto. Canadian Agency for Drugs and Technologies in Health (CADTH), 2013. Available from: <https://www.cadth.ca/media/pdf/htis/jun-2013/RB0587%20VTE%20Prophylaxis%20Final.pdf>
143. Calisir C, Yavas US, Ozkan IR, Alatas F, Cevik A, Ergun N et al. Performance of the Wells and revised Geneva scores for predicting pulmonary embolism. *European Journal of Emergency Medicine*. 2009; 16(1):49-52
144. Caloghera C, Bordos D, Miculit F, Aboubakr W, Teodorescu C, Vancea D. Prevention of postoperative thromboembolism with small doses of heparin. *Revista de Chirurgie, Oncologie, Radiologie, ORL, Oftalmologie, Stomatologie Chirurgie*. 1984; 33(3):161-167
145. Campbell MJ. Full audit cycle assessing how current antenatal inpatients are risk assessed for venous thromboembolic (VTE) disease as an inpatient and antenatally at Ninewells Hospital, Dundee, Scotland, October 2012. *BJOG: An International Journal of Obstetrics and Gynaecology*. 2013; 120:472
146. Camporese G, Bernardi E, Prandoni P, Noventa F, Verlato F, Cordova R et al. Graduated compression stockings versus low molecular-weight heparin for prevention of deep vein thrombosis after knee arthroscopy. a randomized trial. *Pathophysiology of Haemostasis and Thrombosis*. 2008; 36(Suppl 1):A21
147. Cappato R, Ezekowitz MD, Klein AL, Camm AJ, Ma CS, Le Heuzey JY et al. Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. *European Heart Journal*. 2014; 35(47):3346-3355
148. Cappato R, Marchlinski FE, Hohnloser SH, Naccarelli GV, Xiang J, Wilber DJ et al. Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation. *European Heart Journal*. 2015; 36(28):1805-1811
149. Capri S, Ageno W, Imberti D, Palareti G, Piovella F, Scannapieco G et al. Extended prophylaxis of venous thromboembolism with fondaparinux in patients undergoing major orthopaedic



- surgery in Italy: a cost-effectiveness analysis. *Internal and Emergency Medicine*. 2010; 5(1):33-40
150. Caprini JA. Thrombosis risk assessment as a guide to quality patient care. *Disease-a-Month*. 2005; 51(2-3):70-8
151. Caprini JA, Arcelus JJ, Hasty JH, Tamhane AC, Fabrega F. Clinical assessment of venous thromboembolic risk in surgical patients. *Seminars in Thrombosis and Hemostasis*. 1991; 17 (Suppl 3):304-12
152. Caprini JA, Arcelus JJ, Reyna JJ. Effective risk stratification of surgical and nonsurgical patients for venous thromboembolic disease. *Seminars in Hematology*. 2001; 38(2 Suppl 5):12-9
153. Caprini JA, Botteman MF, Stephens JM, Nadipelli V, Ewing MM, Brandt S et al. Economic burden of long-term complications of deep vein thrombosis after total hip replacement surgery in the United States. *Value in Health*. 2003; 6(1):59-74
154. Carpenter CR, Keim SM, Seupaul RA, Pines JM. Differentiating low-risk and Nn-risk PE patients: The PERC Score. *Journal of Emergency Medicine*. 2009; 36(3):317-322
155. Carrier M, Le GG, Tay J, Wu CM, Lee AY. Thromboprophylaxis in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide and lenalidomide: A systematic review and meta-analysis. *Blood*. 2010; 116(21)
156. Carson W, Schilling B, Simons WR, Parks C, Choe Y, Faria C et al. Comparative effectiveness of dalteparin and enoxaparin in a hospital setting. *Journal of Pharmacy Practice*. 2012; 25(2):180-189
157. Casele H, Haney EI, James A, Rosene-Montella K, Carson M. Bone density changes in women who receive thromboprophylaxis in pregnancy. *American Journal of Obstetrics and Gynecology*. 2006; 195(4):1109-13
158. Casella IB, Puech-Leao P. Generic versus branded enoxaparin in prophylaxis and treatment of vein thrombosis. *Revista da Associacao Medica Brasileira*. 2015; 61(1):44-50
159. Castellano JJ, Rojas AM, Karia R, Hunter T, Slover J, Moroz A. A randomized, double-blind, placebo-controlled study of neuromuscular electrical stimulation (NMES) use for recovery after elective total hip replacement surgery. *Bulletin of the Hospital for Joint Diseases*. 2016; 74(4):275-281
160. Catania G, Salanitri G. Prevention of postoperative deep vein thrombosis by two different heparin types. *International Journal of Clinical Pharmacology, Therapy and Toxicology*. 1988; 26(6):304-309
161. Cavallo F, Raimondo F, Harda I, Lupo B, Romano A, Catalano L et al. A phase III study of enoxaparin vs aspirin as thromboprophylaxis for newly diagnosed myeloma patients treated with lenalidomide-based regimen. *Blood*. 2010; 116(21)
162. Cavazza S, Rainaldi MP, Adduci A, Palareti G. Thromboprophylaxis following cesarean delivery: one site prospective pilot study to evaluate the application of a risk score model. *Thrombosis Research*. 2012; 129(1):28-31
163. Chagnon I, Bounameaux H, Aujesky D, Roy PM, Gourdier AL, Cornuz J et al. Comparison of two clinical prediction rules and implicit assessment among patients with suspected pulmonary embolism. *American Journal of Medicine*. 2002; 113(4):269-75

164. Chahinian AP, Probert KJ, Ware JH, Zimmer B, Perry MC, Hirsh V. A randomized trial of anticoagulation with warfarin and of alternating chemotherapy in Extensive small-cell lung cancer by the Cancer and Leukemia Group B. *Journal of Clinical Oncology*. 1989; 7(8):993-1002
165. Chalayer E, Bourmaud A, Tinquaut F, Chauvin F, Tardy B. Cost-effectiveness analysis of low-molecular-weight heparin versus aspirin thromboprophylaxis in patients newly diagnosed with multiple myeloma. *Thrombosis Research*. 2016; 145:119-125
166. Chan NC, Siegal D, Lauw MN, Ginsberg JS, Eikelboom JW, Guyatt GH et al. A systematic review of contemporary trials of anticoagulants in orthopaedic thromboprophylaxis: suggestions for a radical reappraisal. *Journal of Thrombosis and Thrombolysis*. 2015; 40(2):231-239
167. Chapelle C, Rosencher N, Jacques Zufferey P, Mismetti P, Cucherat M, Laporte S et al. Prevention of venous thromboembolic events with low-molecular-weight heparin in the non-major orthopaedic setting: meta-analysis of randomized controlled trials. *Arthroscopy*. 2014; 30(8):987-996
168. Chatterjee S, Weinberg I, Yeh RW, Chakraborty A, Sardar P, Weinberg MD et al. Risk factors for intracranial haemorrhage in patients with pulmonary embolism treated with thrombolytic therapy Development of the PE-CH Score. *Thrombosis and Haemostasis*. 2017; 117(2):246-251
169. Chauleur C, Quenet S, Varlet MN, Seffert P, Laporte S, Decousus H et al. Feasibility of an easy-to-use risk score in the prevention of venous thromboembolism and placental vascular complications in pregnant women: a prospective cohort of 2736 women. *Thrombosis Research*. 2008; 122(4):478-84
170. Che DH, Cao JY, Shang LH, Man YC, Yu Y. The efficacy and safety of low-molecular-weight heparin use for cancer treatment: a meta-analysis. *European Journal of Internal Medicine*. 2013; 24(5):433-439
171. Chelladurai Y, Stevens KA, Haut ER, Brotman DJ, Sharma R, Shermock KM et al. Venous thromboembolism prophylaxis in patients with traumatic brain injury: a systematic review. *F1000Research*. 2013; 2:132
172. Chen JY, Chao TH, Guo YL, Hsu CH, Huang YY, Chen JH et al. A simplified clinical model to predict pulmonary embolism in patients with acute dyspnea. *International Heart Journal*. 2006; 47(2):259-71
173. Chen K-P, Huang C-X, Huang D-J, Cao K-J, Ma C-S, Wang F-Z et al. Anticoagulation therapy in Chinese patients with non-valvular atrial fibrillation: A prospective, multi-center, randomized, controlled study. *Chinese Medical Journal*. 2012; 125(24):4355-4360
174. Cheng SS, Nordenholz K, Matero D, Pearlman N, McCarter M, Gajdos C et al. Standard subcutaneous dosing of unfractionated heparin for venous thromboembolism prophylaxis in surgical ICU patients leads to subtherapeutic factor Xa inhibition. *Intensive Care Medicine*. 2012; 38(4):642-648
175. Chiasson TC, Manns BJ, Stelfox HT. An economic evaluation of venous thromboembolism prophylaxis strategies in critically ill trauma patients at risk of bleeding. *PLoS Medicine*. 2009; 6(6)

176. Child S, Sheaff R, Boiko O, Bateman A, Gericke CA. Has incentive payment improved venous thrombo-embolism risk assessment and treatment of hospital in-patients? *F1000Research*. 2013; 2:41
177. Chin PL, Amin MS, Yang KY, Yeo SJ, Lo NN. Thromboembolic prophylaxis for total knee arthroplasty in Asian patients: a randomised controlled trial. *Journal of Orthopaedic Surgery*. 2009; 17(1):1-5
178. Cho KY, Kim KI, Khurana S, Bae DK, Jin W. Is routine chemoprophylaxis necessary for prevention of venous thromboembolism following knee arthroplasty in a low incidence population? *Archives of Orthopaedic and Trauma Surgery*. 2013; 133(4):551-559
179. Choi SH, Shim JH, Park CH, Song KY. Low molecular-weight heparin for thromboprophylaxis in patients undergoing gastric cancer surgery: an experience from one Korean institute. *Annals of surgical treatment and research*. 2014; 86(1):22-27
180. Christensen TD, Vad H, Pedersen S, Hornbech K, Zois NE, Licht PB et al. Coagulation profile in patients undergoing video-assisted thoracoscopic lobectomy: A randomized, controlled trial. *PloS One*. 2017; 12 (2) (no pagination)(e0171809)
181. Clark WB, MacGregor AB, Prescott RJ, Ruckley CV. Pneumatic compression of the calf and postoperative deep-vein thrombosis. *Lancet*. 1974; 2(7871):5-7
182. Clemens A, van Ryn J, Sennewald R, Yamamura N, Stangier J, Feuring M et al. Switching from enoxaparin to dabigatran etexilate: pharmacokinetics, pharmacodynamics, and safety profile. *European Journal of Clinical Pharmacology*. 2012; 68(5):607-616
183. CLOTS (Clots in Legs Or sTockings after Stroke) Trial Collaboration. Thigh-length versus below-knee stockings for deep venous thrombosis prophylaxis after stroke: a randomized trial. *Annals of Internal Medicine*. 2010; 153(9):553-562
184. CLOTS (Clots in Legs Or sTockings after Stroke) Trials Collaboration. Effect of intermittent pneumatic compression on disability, living circumstances, quality of life, and hospital costs after stroke: secondary analyses from CLOTS 3, a randomised trial. *Lancet Neurology*. 2014; 13(12):1186-1192
185. CLOTS (Clots in Legs Or sTockings after Stroke) Trials Collaboration, Dennis M, Sandercock P, Reid J, Graham C, Forbes J et al. Effectiveness of intermittent pneumatic compression in reduction of risk of deep vein thrombosis in patients who have had a stroke (CLOTS 3): a multicentre randomised controlled trial. *Lancet*. 2013; 382(9891):516-524
186. CLOTS Trials Collaboration, Dennis M, Sandercock P, Reid J, Graham C, Murray G et al. The effect of graduated compression stockings on long-term outcomes after stroke: the CLOTS trials 1 and 2. *Stroke*. 2013; 44(4):1075-1079
187. CLOTS Trials Collaboration, Dennis M, Sandercock PAG, Reid J, Graham C, Murray G et al. Effectiveness of thigh-length graduated compression stockings to reduce the risk of deep vein thrombosis after stroke (CLOTS trial 1): a multicentre, randomised controlled trial. *Lancet*. 2009; 373(9679):1958-1965
188. Cohen A, Drost P, Marchant N, Mitchell S, Orme M, Rublee D et al. The efficacy and safety of pharmacological prophylaxis of venous thromboembolism following elective knee or hip replacement: systematic review and network meta-analysis. *Clinical and Applied Thrombosis/Hemostasis*. 2012; 18(6):611-627

189. Cohen A, Stellbrink C, Le Heuzey JY, Faber T, Aliot E, Banik N et al. SAFETY of Fondaparinux in transoesophageal echocardiography-guided Electric cardioversion of Atrial Fibrillation (SAFE-AF) study: a pilot study. *Archives of Cardiovascular Diseases*. 2015; 108(2):122-131
190. Cohen AT, Alikhan R, Arcelus JJ, Bergmann JF, Haas S, Merli GJ et al. Assessment of venous thromboembolism risk and the benefits of thromboprophylaxis in medical patients. *Thrombosis and Haemostasis*. 2005; 94(4):750-9
191. Cohen AT, Batson S, Hamilton M, Masseria C, Mitchell S, Phatak H. Comparison of apixaban, dabigatran, rivaroxaban, and edoxaban in the acute treatment and prevention of venous thromboembolism: Systematic review and network meta-analysis. *Value in Health*. 2015; 18(3):A132
192. Cohen AT, Bauersachs R, Gitt AK, Mismetti P, Monreal M, Willich SN et al. Health state in patients with venous thromboembolism on conventional and Non-VKA oral anticoagulants as assessed with the EQ-5D-5L questionnaire: Prefer in VTE registry. *Value in Health*. 2014; 17(7):A493-A494
193. Cohen AT, Granziera S. Excellence, quality and limitations of the NICE venous thromboembolism score tool: how can it be improved? *British Journal of Haematology*. 2014; 167(5):702-4
194. Cohen AT, Hamilton M, Mitchell SA, Phatak H, Liu X, Bird A et al. Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis. *PLoS ONE [Electronic Resource]*. 2015; 10(12):e0144856
195. Cohen AT, Spiro TE, Buller HR, Haskell L, Hu D, Hull R et al. Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol. *Journal of Thrombosis and Thrombolysis*. 2011; 31(4):407-416
196. Cohen AT, Spiro TE, Burton P, Buller HR, Haskell L, Hu D-Y et al. The MAGELLAN study: An analysis of outcomes utilizing d-dimer. *Blood*. 2011; 118(21)
197. Cohen H, Dore CJ, Clawson S, Hunt BJ, Isenberg D, Khamashta M et al. Rivaroxaban in antiphospholipid syndrome (RAPS) protocol: a prospective, randomized controlled phase II/III clinical trial of rivaroxaban versus warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE. *Lupus*. 2015; 24(10):1087-1094
198. Cohen ME, Bilimoria KY, Ko CY, Hall BL. Development of an American college of surgeons national surgery quality improvement program: morbidity and mortality risk calculator for colorectal surgery. *Journal of the American College of Surgeons*. 2009; 208(6):1009-16
199. Cohn SM, Moller BA, Feinstein AJ, Burns GA, Ginzburg E, Hammers LW. Prospective trial of low-molecular-weight heparin versus unfractionated heparin in moderately injured patients. *Vascular Surgery*. 1999; 33(2):219-223
200. Coleman CI, Peacock WF, Fermann GJ, Crivera C, Weeda ER, Hull M et al. External validation of a multivariable claims-based rule for predicting in-hospital mortality and 30-day post-pulmonary embolism complications. *BMC Health Services Research*. 2016; 16(1):610
201. Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. *Antiplatelet Trialists' Collaboration*. *British Medical Journal*. 1994; 308(6921):81-106
202. Collen JF, Jackson JL, Shorr AF, Moores LK. Prevention of venous thromboembolism in neurosurgery: a metaanalysis. *Chest*. 2008; 134(2):237-249

203. Colwell CW, Jr., Collis DK, Paulson R, McCutchen JW, Bigler GT, Lutz S et al. Comparison of enoxaparin and warfarin for the prevention of venous thromboembolic disease after total hip arthroplasty. Evaluation during hospitalization and three months after discharge. *Journal of Bone and Joint Surgery (American Volume)*. 1999; 81(7):932-940
204. Colwell CW, Jr., Spiro TE, Trowbridge AA, Morris BA, Kwaan HC, Blaha JD et al. Use of enoxaparin, a low-molecular-weight heparin, and unfractionated heparin for the prevention of deep venous thrombosis after elective hip replacement. A clinical trial comparing efficacy and safety. Enoxaparin Clinical Trial Group. *Journal of Bone and Joint Surgery*. 1994; 76(1):3-14
205. Colwell CW, Spiro TE, Trowbridge AA, Stephens JW, Gardiner GA, Ritter MA. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep venous thrombosis after elective knee arthroplasty. Enoxaparin Clinical Trial Group. *Clinical Orthopaedics and Related Research*. 1995; 321:19-27
206. Colwell Jr CW, Froimson MI, Anseth SD, Giori NJ, Hamilton WG, Barrack RL et al. A mobile compression device for thrombosis prevention in hip and knee arthroplasty. *Journal of Bone and Joint Surgery - American Volume*. 2014; 96(3):177-183
207. Commercial Medicines Unit (CMU), Department of Health. Electronic market information tool (EMIT). 2015. Available from: <http://cmu.dh.gov.uk/electronic-market-information-tool-emit/> Last accessed: 22/08/2017.
208. Comp PC, Spiro TE, Friedman RJ, Whitsett TL, Johnson GJ, Gardiner GA, Jr. et al. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. *Journal of Bone and Joint Surgery (American Volume)*. 2001; 83(3):336-345
209. Comp PC, Spiro TE, Friedman RJ, Whitsett TL, Johnson GJ, Gardiner GA, Jr. et al. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. Enoxaparin Clinical Trial Group. *Journal of Bone and Joint Surgery (American Volume)*. 2001; 83-a(3):336-45
210. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A et al. Dabigatran versus warfarin in patients with atrial fibrillation. *New England Journal of Medicine*. 2009; 361(12):1139-51
211. Constans J, Boutinet C, Salmi LR, Saby JC, Nelzy ML, Baudouin P et al. Comparison of four clinical prediction scores for the diagnosis of lower limb deep venous thrombosis in outpatients. *American Journal of Medicine*. 2003; 115(6):436-40
212. Cook D. Dalteparin did not differ from unfractionated heparin for reducing proximal DVT in critically ill patients. *Annals of Internal Medicine*. 2011; 155(2):JC1-JC7
213. Cornette J, Jacquemyn Y, Vercauteren M, Buytaert P. A randomised trial to compare the effect of pre- or postoperative nandroparin on blood loss during elective caesarean section. *Phlebology*. 2002; 17(2):67-69
214. Cornuz J, Ghali WA, Hayoz D, Stoianov R, Depairon M, Yersin B. Clinical prediction of deep venous thrombosis using two risk assessment methods in combination with rapid quantitative D-dimer testing. *American Journal of Medicine*. 2002; 112(3):198-203
215. Correia LC, Goes C, Ribeiro H, Cunha M, Paula R, Esteves JP. Prevalence and predictors of pulmonary embolism in patients with acutely decompensated heart failure. *Arquivos Brasileiros de Cardiologia*. 2012; 98(2):120-5



216. Cosmi B, Filippini M, Tonti D, Avruscio G, Ghirarduzzi A, Bucherini E et al. A randomized double-blind study of low-molecular-weight heparin (parnaparin) for superficial vein thrombosis: STEFLUX (Superficial ThromboEmbolism and Fluxum). *Journal of Thrombosis and Haemostasis*. 2012; 10(6):1026-1035
217. Costa ML, Griffin XL, Achten J, Metcalfe D, Judge A, Pinedo-Villanueva R et al. World Hip Trauma Evaluation (WHiTE): framework for embedded comprehensive cohort studies. *BMJ Open*. 2016; 6(10):e011679
218. Costa R, Da Silva KR, Rached R, Martinelli Filho M, Carnevale FC, Moreira LFP et al. Prevention of venous thrombosis by warfarin after permanent transvenous leads implantation in high-risk patients. *Pacing and Clinical Electrophysiology*. 2009; 32 (Suppl 1):S247-S251
219. Couban S, Goodyear M, Burnell M, Dolan S, Wasi P, Barnes D et al. Randomized placebo-controlled study of low-dose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancer. *Journal of Clinical Oncology*. 2005; 23(18):4063-4069
220. Couture E, Cerantola M, Farand P, Berube S, Dalery K, Gervais A et al. Risk profile and impact of pharmacological thromboprophylaxis on bleeding event and outcome: Insights from a contemporary STEMI prospective registry. *Canadian Journal of Cardiology*. 2016; 32 (10 Supplement 1):S254-S255
221. Crane S, Jaconelli T, Eragat M. Retrospective validation of the pulmonary embolism rule-out criteria rule in 'PE unlikely' patients with suspected pulmonary embolism. *European Journal of Emergency Medicine*. 2016; 19:19
222. Creagh MD, Dehnel A, Rider L, McSorley A, Carson P, Asri R. Does systematic risk assessment in pregnancy identify women at risk for venous thromboembolism and so avoid thrombosis? Experience of an 18 month programme based on national guidance. *Journal of Thrombosis and Haemostasis*. 2013; 11:867
223. Cui J, Wu B, Liu C, Li Z. A systematic review and adjusted indirect comparison of oral anticoagulants. *Orthopedics*. 2014; 37(11):763-771
224. Curtis L, Burns A. Unit costs of health and social care 2016. Canterbury. Personal Social Services Research Unit University of Kent, 2016. Available from: <http://www.pssru.ac.uk/project-pages/unit-costs/2016/>
225. Cushman M, O'Meara ES, Heckbert SR, Zakai NA, Rosamond W, Folsom AR. Body size measures, hemostatic and inflammatory markers and risk of venous thrombosis: The Longitudinal Investigation of Thromboembolism Etiology. *Thrombosis Research*. 2016; 144:127-32
226. Dahl OE, Andreassen G, Aspelin T, Muller C, Mathiesen P, Nyhus S et al. Prolonged thromboprophylaxis following hip replacement surgery--results of a double-blind, prospective, randomised, placebo-controlled study with dalteparin (Fragmin). *Thrombosis and Haemostasis*. 1997; 77(1):26-31
227. Dahl OE, Andreassen G, Aspelin T, Müller C, Mathiesen P, Nyhus S et al. Prolonged thromboprophylaxis following hip replacement surgery -- results of a double-blind, prospective, randomised, placebo-controlled study with dalteparin (Fragmin). *Thrombosis and Haemostasis*. 1997; 77(1):26-31

228. Dahl OE, Pleil AM. Investment in prolonged thromboprophylaxis with dalteparin improves clinical outcomes after hip replacement. *Journal of Thrombosis and Haemostasis*. 2003; 1(5):896-906
229. Dal AM, Allara E, Montani D, Milani S, Frassati C, Cossu S et al. Flushing the central venous catheter: Is heparin necessary? *Journal of Vascular Access*. 2014; 15(4):241-248
230. Dar TI, Wani K, Ashraf M, Malik A, Ahmad S, Gojwari T et al. Low molecular weight heparin in prophylaxis of deep vein thrombosis in Asian general surgical patients: A Kashmir experience. *Indian Journal of Critical Care Medicine*. 2012; 16(2):71-74
231. Dargaud Y, Rugeri L, Ninet J, Negrier C, Trzeciak MC. Management of pregnant women with increased risk of venous thrombosis. *International Journal of Gynaecology and Obstetrics*. 2005; 90(3):203-7
232. Dargaud Y, Rugeri L, Vergnes MC, Arnuti B, Miranda P, Negrier C et al. A risk score for the management of pregnant women with increased risk of venous thromboembolism: a multicentre prospective study. *British Journal of Haematology*. 2009; 145(6):825-35
233. Datta I, Ball CG, Rudmik L, Hameed SM, Kortbeek JB. Complications related to deep venous thrombosis prophylaxis in trauma: a systematic review of the literature. *Journal of Trauma Management and Outcomes*. 2010; 4:1
234. Davies LM, Richardson GA, Cohen AT. Economic evaluation of enoxaparin as postdischarge prophylaxis for deep vein thrombosis (DVT) in elective hip surgery. *Value in Health*. 2000; 3(6):397-406
235. Davies MG, Hart JP, El-Sayed HF. Efficacy of prophylactic inferior vena caval filters in prevention of pulmonary embolism in the absence of deep venous thrombosis. *Journal of Vascular Surgery*. 2016; 4(1):127-130.e1
236. De A, Roy P, Garg VK, Pandey NK. Low-molecular-weight heparin and unfractionated heparin in prophylaxis against deep vein thrombosis in critically ill patients undergoing major surgery. *Blood Coagulation and Fibrinolysis*. 2010; 21(1):57-61
237. de Bastos M, Barreto SM, Caiafa JS, Boguchi T, Silva JL, Rezende SM. Derivation of a risk assessment model for hospital-acquired venous thrombosis: the NAVAL score. *Journal of Thrombosis and Thrombolysis*. 2016; 41(4):628-35
238. De Veciana M, Trail P, Dattel B. Dalteparin versus unfractionated heparin for prophylactic anticoagulation during pregnancy. *American Journal of Obstetrics and Gynecology*. 2001; 185(6):S182
239. Dechavanne M, Saudin F, Viala JJ, Kher A, Bertrix L, de Mourgues G. Prevention of venous thrombosis. Success of high doses of heparin during total hip replacement for osteoarthritis. *La Nouvelle Presse Médicale*. 1974; 3(20):1317-1319
240. Dechavanne M, Ville D, Berruyer M, Trepo F, Dalery F, Clermont N et al. Randomized trial of a low-molecular-weight heparin (Kabi 2165) versus adjusted-dose subcutaneous standard heparin in the prophylaxis of deep-vein thrombosis after elective hip surgery. *Haemostasis*. 1989; 19(1):5-12
241. Dechavanne M, Ville D, Viala JJ, Kher A, Faivre J, Pousset MB et al. Controlled trial of platelet anti-aggregating agents and subcutaneous heparin in prevention of postoperative deep vein thrombosis in high risk patients. *Haemostasis*. 1975; 4(2):94-100

242. Decousus H, Leizorovicz A, Parent F, Page Y, Tardy B, Girard P et al. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis: interruption cave study group. *New England Journal of Medicine*. 1998; 338(7):409-415
243. Decousus H, Tapson VF, Bergmann JF, Chong BH, Froehlich JB, Kakkar AK et al. Factors at admission associated with bleeding risk in medical patients: findings from the IMPROVE investigators. *Chest*. 2011; 139(1):69-79
244. Deeks ED. Apixaban: a review of its use in the prevention of venous thromboembolism after knee or hip replacement surgery. *Drugs*. 2012; 72(9):1271-1291
245. Delcroix M, Lang I, Pepke-Zaba J, Jansa P, D'Armini AM, Snijder R et al. Long-Term Outcome of Patients With Chronic Thromboembolic Pulmonary Hypertension: Results From an International Prospective Registry. *Circulation*. 2016; 133(9):859-71
246. den Ottolander GJH, van der Mass APC, Veen MR. The preventive value against venous thrombosis by treatment with ASA and RA-233 in patients with decompensated heart disease. Washington. Proceedings of III congress of International Society for Thrombosis and Haemostasis, 1972.
247. Dennis M, Graham C, Smith J, Forbes J, Sandercock P. Which stroke patients gain most from intermittent pneumatic compression: Further analyses of the CLOTS 3 trial. *International Journal of Stroke*. 2015; 10(A100):103-107
248. Dennis M, Sandercock P, Graham C, Forbes J, Smith J. The Clots in Legs Or sTockings after Stroke (CLOTS) 3 trial: a randomised controlled trial to determine whether or not intermittent pneumatic compression reduces the risk of post-stroke deep vein thrombosis and to estimate its cost-effectiveness. *Health Technology Assessment*. 2015; 19(76):1-90
249. Department of Health. NHS Outcomes Framework: at-a-glance: List of outcomes and indicators in the NHS Outcomes Framework for 2016-17. 2016. Available from: [https://www.gov.uk/government/uploads/system/uploads/attachment\\_data/file/513157/NHSOF\\_at\\_a\\_glance.pdf](https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/513157/NHSOF_at_a_glance.pdf)
250. Department of Health. NHS reference costs 2015-16. 2016. Available from: <https://www.gov.uk/government/publications/nhs-reference-costs-2015-to-2016> Last accessed: 09/08/2017.
251. Desai AK, Pang J, Aparnath M, Ilowite J. Utility of Inferior Vena Cava Filters in Severe Pulmonary Embolism, Catheter-directed Therapy in Massive and Submassive Pulmonary Embolism, and HAS-BLED Score to Determine Risk of Major Hemorrhage in Pulmonary Embolism. *American Journal of Respiratory and Critical Care Medicine*. 2016; 193(11):1301-3
252. Di Biase L, Burkhardt JD, Santangeli P, Mohanty P, Sanchez JE, Horton R et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the role of coumadin in preventing thromboembolism in atrial fibrillation (AF) patients undergoing catheter ablation (COMPARE) randomized trial. *Circulation*. 2014; 129(25):2638-2644
253. Di Marca S, Cilia C, Campagna A, D'Arrigo G, Abd ElHafeez S, Tripepi G et al. Comparison of Wells and revised Geneva rule to assess pretest probability of pulmonary embolism in high-risk hospitalized elderly adults. *Journal of the American Geriatrics Society*. 2015; 63(6):1091-7

254. Di Nisio M, Peinemann F, Porreca E, Rutjes AW. Primary prophylaxis for venous thromboembolism in patients undergoing cardiac or thoracic surgery. *Cochrane Database of Systematic Reviews* 2015, Issue 6. Art. No.: CD009658. DOI: 10.1002/14651858.CD009658.pub2.
255. Di Nisio M, Porreca E, Otten HM, Rutjes AWS. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy. *Cochrane Database of Systematic Reviews* 2014, Issue 8. Art. No.: CD008500. DOI: 10.1002/14651858.CD008500.pub3.
256. Di Nisio M, Raskob G, Buller HR, Grosso MA, Zhang G, Winters SM et al. Prediction of major and clinically relevant bleeding in patients with VTE treated with edoxaban or vitamin K antagonists. *Thrombosis and Haemostasis*. 2017; 02:02
257. Diamantopoulos A, Lees M, Wells PS, Forster F, Ananthapavan J, McDonald H. Cost-effectiveness of rivaroxaban versus enoxaparin for the prevention of postsurgical venous thromboembolism in Canada. *Thrombosis and Haemostasis*. 2010; 104(4):760-770
258. Diaz JP, Soto MH, Marquez M, Escobar JY. Cost-minimization analysis of tinzaparin sodium compared to other low-molecular-weight heparins for patients with deep venous thrombosis. *Value in Health*. 2015; 18(3):A143
259. Dietch ZC, Petroze RT, Thames M, Willis R, Sawyer RG, Williams MD. The "high-risk" deep venous thrombosis screening protocol for trauma patients: Is it practical? *The Journal of Trauma and Acute Care Surgery*. 2015; 79(6):970-5
260. DiSerio FJ, Sasahara AA. United States trial of dihydroergotamine and heparin prophylaxis of deep vein thrombosis. *American Journal of Surgery*. 1985; 150(4A):25-32
261. Dong MF, Ma ZS, Ma SJ, Chai SD, Tang PZ, Yao DK et al. Anticoagulation therapy with combined low dose aspirin and warfarin following mechanical heart valve replacement. *Thrombosis Research*. 2011; 128(5):e91-e94
262. Dong WJ, Qian HJ, Qian Y, Zhou L, Hu SL. Fondaparinux vs. enoxaparin for the prevention of venous thromboembolism after total hip replacement: A meta-analysis. *Experimental and Therapeutic Medicine*. 2016; 12(2):969-974
263. Dooley C, Kaur R, Sobieraj DM. Comparison of the efficacy and safety of low molecular weight heparins for venous thromboembolism prophylaxis in medically ill patients. *Current Medical Research and Opinion*. 2014; 30(3):367-380
264. Douketis J, Cook D, Meade M, Guyatt G, Geerts W, Skrobik Y et al. Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin: an assessment of safety and pharmacodynamics: the DIRECT study. *Archives of Internal Medicine*. 2008; 168(16):1805-1812
265. Douketis JD, Spyropoulos AC, Kaatz S, Becker RC, Caprini JA, Dunn AS et al. Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation. *New England Journal of Medicine*. 2015; 373(9):823-33
266. Dranitsaris G, Jelincic V, Choe Y. Meta-regression analysis to indirectly compare prophylaxis with dalteparin or enoxaparin in patients at high risk for venous thromboembolic events. *Clinical and Applied Thrombosis/Hemostasis*. 2012; 18(3):233-242
267. Dranitsaris G, Kahn SR, Stumpo C, Paton TW, Martineau J, Smith R et al. Pharmacoeconomic analysis of fondaparinux versus enoxaparin for the prevention of thromboembolic events in orthopedic surgery patients. *American Journal of Cardiovascular Drugs*. 2004; 4(5):325-333

268. Dranitsaris G, Shane LG, Crowther M, Feugere G, Woodruff S. Dalteparin versus vitamin K antagonists for the prevention of recurrent venous thromboembolism in patients with cancer and renal impairment: a Canadian pharmacoeconomic analysis. *Clinicoeconomics & Outcomes Research*. 2017; 9:65-73
269. Dranitsaris G, Stumpo C, Smith R, Bartle W. Extended dalteparin prophylaxis for venous thromboembolic events: cost-utility analysis in patients undergoing major orthopedic surgery. *American Journal of Cardiovascular Drugs*. 2009; 9(1):45-58
270. Drescher FS, Sirovich BE, Lee A, Morrison DH, Chiang WH, Larson RJ. Aspirin versus anticoagulation for prevention of venous thromboembolism major lower extremity orthopedic surgery: a systematic review and meta-analysis. *Journal of Hospital Medicine*. 2014; 9(9):579-585
271. Dronkers CE, Tan M, Mol GC, Iglesias Del Sol A, van de Ree MA, Huisman MV et al. Evaluation of the new simple and objective clinical decision rule "I-DVT" in patients with clinically suspected acute deep vein thrombosis. *Thrombosis Research*. 2016; 141:112-8
272. Duran A, Sengupta N, Diamantopoulos A, Forster F, Kwong L, Lees M. Cost and outcomes associated with rivaroxaban vs enoxaparin for the prevention of postsurgical venous thromboembolism from a US payer's perspective. *Journal of Medical Economics*. 2011; 14(6):824-834
273. Duran A, Sengupta N, Diamantopoulos A, Forster F, Kwong L, Lees M. Cost effectiveness of rivaroxaban versus enoxaparin for prevention of post-surgical venous thromboembolism from a US payer's perspective. *Pharmacoeconomics*. 2012; 30(2):87-101
274. Eckman MH, Erban JK, Singh SK, Kao GS. Screening for the risk for bleeding or thrombosis. *Annals of Internal Medicine*. 2003; 138(3):W15-24
275. Edwards JZ, Pulido PA, Ezzet KA, Copp SN, Walker RH, Colwell CWJ. Portable compression device and low-molecular-weight heparin compared with low-molecular-weight heparin for thromboprophylaxis after total joint arthroplasty. *Journal of Arthroplasty*. 2008; 23(8):1122-1127
276. Effect of aspirin on postoperative venous thrombosis. Report of the Steering Committee of a trial sponsored by the Medical Research Council. *Lancet*. 1972; 2(7775):441-445
277. Eichinger S, Heinze G, Jandek LM, Kyrle PA. Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna prediction model. *Circulation*. 2010; 121(14):1630-6
278. Eichinger S, Heinze G, Kyrle PA. D-dimer levels over time and the risk of recurrent venous thromboembolism: an update of the Vienna prediction model. *Journal of the American Heart Association*. 2014; 3(1):e000467
279. Eikelboom JW, Kearon C, Guyatt G, Sessler DI, Yusuf S, Cook D et al. Perioperative Aspirin for Prevention of Venous Thromboembolism: The PeriOperative ISchemia Evaluation-2 Trial and a Pooled Analysis of the Randomized Trials. *Anesthesiology*. 2016; 125(6):1121-1129
280. Eikelboom JW, Quinlan DJ, O'Donnell M. Major bleeding, mortality, and efficacy of fondaparinux in venous thromboembolism prevention trials. *Circulation*. 2009; 120(20):2006-2011
281. Elbadawi A, Saad M, Nairooz R. Aspirin Use Prior to Coronary Artery Bypass Grafting Surgery: a Systematic Review. *Current Cardiology Reports*. 2017; 19 (2) (no pagination)(18)

282. Elf JL, Strandberg K, Nilsson C, Svensson PJ. Clinical probability assessment and D-dimer determination in patients with suspected deep vein thrombosis, a prospective multicenter management study. *Thrombosis Research*. 2009; 123(4):612-6
283. Elit LM, Lee AY, Parpia S, Swystun LL, Liaw PC, Hoskins P et al. Dalteparin low molecular weight heparin (LMWH) in ovarian cancer: a phase II randomized study. *Thrombosis Research*. 2012; 130(6):894-900
284. Elsasser GN, Goodman MD, Destache CJ, Frey DR, Hadi Z. Preprinted risk assessment and prophylaxis order form for venous thromboembolism. *American Journal of Health-System Pharmacy*. 2007; 64(12):1294-8
285. Elton L, Lamb F, Marsden P. The risk assessment and management of venous thromboembolism in pregnancy: An audit against current newcastle-upon-tyne hospitals and RCOG guidelines. *International Journal of Gynecology and Obstetrics*. 2015; 131:E236
286. Encke A, Stock C, Dumke HO. Doppelblindstudie zur postoperativen thromboseprophylaxe mit dipyridamol/acetylsalicylsäure. *Der Chirurg*. 1976; 47(12):670-673
287. Ende-Verhaar YM, Cannegieter SC, Vonk Noordegraaf A, Delcroix M, Pruszczyk P, Mairuhu AT et al. Incidence of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism: a contemporary view of the published literature. *European Respiratory Journal*. 2017; 49(2)
288. Eriksson B, Dahl OE, Rosencher N, Kurth A, Niek van Dijk C, Frostick S et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. *Lancet*. 2007; 370(9591):949-956
289. Eriksson B, I, Kälebo P, Anthymyr BA, Wadenvik H, Tengborn L, Risberg B. Prevention of deep-vein thrombosis and pulmonary embolism after total hip replacement. Comparison of low-molecular-weight heparin and unfractionated heparin. *Journal of Bone and Joint Surgery*. 1991; 73(4):484-493
290. Eriksson B, I., Borris L, Dahl OE, Haas S, Huisman MV, Kakkar AK et al. Oral, direct factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement. *Journal of Thrombosis and Haemostasis*. 2006; 4(1):121-128
291. Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. *New England Journal of Medicine*. 2008; 358(26):2765-2775
292. Eriksson BI, Dahl OE, Huo MH, Kurth AA, Hantel S, Hermansson K et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II\*). A randomised, double-blind, non-inferiority trial. *Thrombosis and Haemostasis*. 2011; 105(4):721-729
293. Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP et al. Dabigatran etexilate versus enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. *Journal of Thrombosis and Haemostasis*. 2007; 5(11):2178-2185
294. Eriksson BI, Kakkar AK, Turpie AGG, Gent M, Bandel TJ, Homering M et al. Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement. *Journal of Bone and Joint Surgery (British Volume)*. 2009; 91(5):636-644

295. Eriksson BI, Turpie AGG, Lassen MR, Prins MH, Agnelli G, Kalebo P et al. Prevention of venous thromboembolism with an oral factor Xa inhibitor, YM150, after total hip arthroplasty. A dose finding study (ONYX-2). *Journal of Thrombosis and Haemostasis*. 2010; 8(4):714-721
296. Erkens PM, Gandara E, Wells PS, Shen AY, Bose G, Le Gal G et al. Does the pulmonary embolism severity Index accurately identify low risk patients eligible for outpatient treatment? *Thrombosis Research*. 2012; 129(6):710-4
297. Eskander MB, Limb D, Stone MH, Furlong AJ, Shardlow D, Stead D et al. Sequential mechanical and pharmacological thromboprophylaxis in the surgery of hip fractures. A pilot study. *International Orthopaedics*. 1997; 21(4):259-261
298. Evans RS, Linford LH, Sharp JH, White G, Lloyd JF, Weaver LK. Computer identification of symptomatic deep venous thrombosis associated with peripherally inserted venous catheters. *AMIA Annual Symposium Proceedings/AMIA Symposium*. 2007:226-30
299. Evans RS, Lloyd JF, Aston VT, Woller SC, Tripp JS, Elliott CG et al. Computer surveillance of patients at high risk for and with venous thromboembolism. *AMIA Annual Symposium Proceedings/AMIA Symposium*. 2010; 2010:217-21
300. Fang MC, Go AS, Chang Y, Borowsky LH, Pomernacki NK, Udaltsova N et al. A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. *Journal of the American College of Cardiology*. 2011; 58(4):395-401
301. Faunø P, Suomalainen O, Rehnberg V, Hansen TB, Krøner K, Soimakallio S et al. Prophylaxis for the prevention of venous thromboembolism after total knee arthroplasty. A comparison between unfractionated and low-molecular-weight heparin. *Journal of Bone and Joint Surgery*. 1994; 76(12):1814-1818
302. Feller JA, Parkin JD, Phillips GW, Hannon PJ, Hennessy O, Huggins RM. Prophylaxis against venous thrombosis after total hip arthroplasty. *Australian and New Zealand Journal of Surgery*. 1992; 62(8):606-610
303. Feng W, Wu K, Liu Z, Kong G, Deng Z, Chen S et al. Oral direct factor Xa inhibitor versus enoxaparin for thromboprophylaxis after hip or knee arthroplasty: Systemic review, traditional meta-analysis, dose-response meta-analysis and network meta-analysis. *Thrombosis Research*. 2015; 136(6):1133-44
304. Finks JF, English WJ, Carlin AM, Krause KR, Share DA, Banerjee M et al. Predicting risk for venous thromboembolism with bariatric surgery: results from the Michigan Bariatric Surgery Collaborative. *Annals of Surgery*. 2012; 255(6):1100-4
305. Finnish Medical Society Duodecim. Deep vein thrombosis. EBM guidelines. Duodecim Medical Publication Ltd, 2013. Available from: [http://www.ebm-guidelines.com/ebmg/ltk.free?p\\_artikkeli=ebm00108](http://www.ebm-guidelines.com/ebmg/ltk.free?p_artikkeli=ebm00108)
306. Finnish Medical Society Duodecim. Prevention of venous thromboembolism. EBM guidelines. Duodecim Medical Publication Ltd, 2014. Available from: [http://www.ebm-guidelines.com/ebmg/ltk.free?p\\_artikkeli=ebm00109](http://www.ebm-guidelines.com/ebmg/ltk.free?p_artikkeli=ebm00109)
307. Fisher WD, Agnelli G, George DJ, Kakkar AK, Lassen MR, Mismetti P et al. Extended venous thromboembolism prophylaxis in patients undergoing hip fracture surgery - the SAVE-HIP3 study. *Bone and Joint Journal*. 2013; 95-B(4):459-466
308. Fitzgerald RH, Jr., Spiro TE, Trowbridge AA, Gardiner GA, Jr., Whitsett TL, O'Connell MB et al. Prevention of venous thromboembolic disease following primary total knee arthroplasty. A



- randomized, multicenter, open-label, parallel-group comparison of enoxaparin and warfarin. *Journal of Bone and Joint Surgery*. 2001; 83-A(6):900-906
309. Flanders SA, Greene MT, Grant P, Kaatz S, Paje D, Lee B et al. Hospital performance for pharmacologic venous thromboembolism prophylaxis and rate of venous thromboembolism : a cohort study. *JAMA Internal Medicine*. 2014; 174(10):1577-84
310. Flicoteaux H, Kher A, Jean N, Blery M, Judet T, Honnart F et al. Comparison of low dose heparin and low dose heparin combined with aspirin in prevention of deep vein thrombosis after total hip replacement. *Pathologie Biologie*. 1977; 25(Suppl):55-58
311. Fordyce MJ, Baker AS, Staddon GE. Efficacy of fixed minidose warfarin prophylaxis in total hip replacement. *British Medical Journal*. 1991; 303(6796):219-220
312. Fordyce MJ, Ling RS. A venous foot pump reduces thrombosis after total hip replacement. *Journal of Bone and Joint Surgery (British Volume)*. 1992; 74(1):45-49
313. Fraisse F, Holzapfel L, Couland JM. Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD. *American Journal of Respiratory and Critical Care Medicine*. 2000; 161(4):1109-1114
314. Francis CW, Pellegrini VD, Leibert KM, Totterman S, Azodo MV, Harris CM et al. Comparison of two warfarin regimens in the prevention of venous thrombosis following total knee replacement. *Thrombosis and Haemostasis*. 1996; 75(5):706-711
315. Francis CW, Pellegrini VD, Totterman S, Boyd AD, Marder VJ, Liebert KM et al. Prevention of deep-vein thrombosis after total hip arthroplasty. Comparison of warfarin and dalteparin. *Journal of Bone and Joint Surgery (American Volume)*. 1997; 79(9):1365-1372
316. Franco Moreno AI, Garcia Navarro MJ, Ortiz Sanchez J, Martin Diaz RM, Madronal Cerezo E, de Ancos Aracil CL et al. A risk score for prediction of recurrence in patients with unprovoked venous thromboembolism (DAMOVES). *European Journal of Internal Medicine*. 2016; 29:59-64
317. Freeman A, Horner T, Pendleton RC, Rondina MT. Prospective comparison of three enoxaparin dosing regimens to achieve target anti-factor Xa levels in hospitalized, medically ill patients with extreme obesity. *American Journal of Hematology*. 2012; 87(7):740-743
318. Freick H, Haas S. Prevention of deep vein thrombosis by low-molecular-weight heparin and dihydroergotamine in patients undergoing total hip replacement. *Thrombosis Research*. 1991; 63(1):133-143
319. Friedman RJ, Davidson BL, Heit J, Kessler C, Elliott CG. RD heparin compared with warfarin for prevention of venous thromboembolic disease following total hip or knee arthroplasty. RD Heparin Arthroplasty Group. *Journal of Bone and Joint Surgery (American Volume)*. 1994; 76(8):1174-1185
320. Fuji T, Fujita S, Ujihira T, Sato T. Dabigatran etexilate prevents venous thromboembolism after total knee arthroplasty in Japanese patients with a safety profile comparable to placebo. *Journal of Arthroplasty*. 2010; 25(8):1267-74
321. Fuji T, Fujita S, Kawai Y, Abe Y, Kimura T, Fukuzawa M et al. A randomized, open-label trial of edoxaban in Japanese patients with severe renal impairment undergoing lower-limb orthopedic surgery. *Thrombosis Journal*. 2015; 13(1)





322. Fuji T, Fujita S, Kawai Y, Nakamura M, Kimura T, Fukuzawa M et al. Efficacy and safety of edoxaban versus enoxaparin for the prevention of venous thromboembolism following total hip arthroplasty: STARS J-V. *Thrombosis Journal*. 2015; 13:27
323. Fuji T, Fujita S, Kawai Y, Nakamura M, Kimura T, Kiuchi Y et al. Safety and efficacy of edoxaban in patients undergoing hip fracture surgery. *Thrombosis Research*. 2014; 133(6):1016-1022
324. Fuji T, Fujita S, Kimura T, Ibusuki K, Abe K, Tachibana S et al. Clinical benefit of graduated compression stockings for prevention of venous thromboembolism after total knee arthroplasty: post hoc analysis of a phase 3 clinical study of edoxaban. *Thrombosis Journal [Electronic Resource]*. 2016; 14:13
325. Fuji T, Fujita S, Ochi T. Fondaparinux prevents venous thromboembolism after joint replacement surgery in Japanese patients. *International Orthopaedics*. 2008; 32(4):443-451
326. Fuji T, Fujita S, Tachibana S, Kawai Y. A dose-ranging study evaluating the oral factor Xa inhibitor edoxaban for the prevention of venous thromboembolism in patients undergoing total knee arthroplasty. *Journal of Thrombosis and Haemostasis*. 2010; 8(11):2458-2468
327. Fuji T, Nakamura M, Takeuchi M. Daxaban for the prevention of venous thromboembolism in Asian patients undergoing orthopedic surgery: results from 2 randomized, placebo-controlled, double-blind studies. *Clinical and Applied Thrombosis/Hemostasis*. 2014; 20(2):199-211
328. Fuji T, Ochi T, Niwa S, Fujita S. Prevention of postoperative venous thromboembolism in Japanese patients undergoing total hip or knee arthroplasty: Two randomized, double-blind, placebo-controlled studies with three dosage regimens of enoxaparin. *Journal of Orthopaedic Science*. 2008; 13(5):442-451
329. Fuji T, Wang CJ, Fujita S, Kawai Y, Nakamura M, Kimura T et al. Safety and efficacy of edoxaban, an oral factor Xa inhibitor, versus enoxaparin for thromboprophylaxis after total knee arthroplasty: the STARS E-3 trial. *Thrombosis Research*. 2014; 134(6):1198-1204
330. Gage BF, Yan Y, Milligan PE, Waterman AD, Culverhouse R, Rich MW et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). *American Heart Journal*. 2006; 151(3):713-9
331. Galanter WL, Thambi M, Rosencranz H, Shah B, Falck S, Lin FJ et al. Effects of clinical decision support on venous thromboembolism risk assessment, prophylaxis, and prevention at a university teaching hospital. *American Journal of Health-System Pharmacy*. 2010; 67(15):1265-73
332. Galie N, Humbert M, Vachiery J, Gibbs S, Lang I, Torbicki A et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. *European Heart Journal*. 2016; 37:67-119
333. Gallagher M, Oliver K, Hurwitz M. Improving the use of venous thromboembolism prophylaxis in an Australian teaching hospital. *Quality & Safety in Health Care*. 2009; 18(5):408-12
334. Gallus A, Raman K, Darby T. Venous thrombosis after elective hip replacement--the influence of preventive intermittent calf compression and of surgical technique. *British Journal of Surgery*. 1983; 70(1):17-19

335. Garcea D, Martuzzi F, Santelmo N, Savoia M, Casertano MG, Furno A et al. Post-surgical deep vein thrombosis prevention: evaluation of the risk/benefit ratio of fractionated and unfractionated heparin. *Current Medical Research and Opinion*. 1992; 12(9):572-583
336. Gates S, Brocklehurst P, Ayers S, Bowler U, Group. TiPA. Thromboprophylaxis and pregnancy: two randomized controlled pilot trials that used low-molecular-weight heparin. *American Journal of Obstetrics and Gynecology*. 2004; 191(4):1296-1303
337. Gates S, Brocklehurst P, Davis LJ. Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period. *Cochrane Database of Systematic Reviews* 2002, Issue 2. Art. No.: CD001689. DOI: 10.1002/14651858.CD001689
338. Gazzaniga GM, Angelini G, Pastorino G, Santoro E, Lucchini M, Dal Pra ML. Enoxaparin in the prevention of deep venous thrombosis after major surgery: multicentric study. The Italian Study Group. *International Surgery*. 1993; 78(3):271-275
339. Gearhart MM, Luchette FA, Proctor MC, Lutomski DM, Witsken C, James L et al. The risk assessment profile score identifies trauma patients at risk for deep vein thrombosis. *Surgery*. 2000; 128(4):631-40
340. Geerts WH, Jay RM, Code KI. A comparison of low-dose heparin with low-molecular-weight heparin as prophylaxis against venous thromboembolism after major trauma. *New England Journal of Medicine*. 1996; 335(10):701-707
341. Gerhart TN, Yett HS, Robertson LK, Lee MA, Smith M, Salzman EW. Low-molecular-weight heparinoid compared with warfarin for prophylaxis of deep-vein thrombosis in patients who are operated on for fracture of the hip. A prospective, randomized trial. *Journal of Bone and Joint Surgery (American Volume)*. 1991; 73(4):494-502
342. Gerotziafas GT, Taher A, Abdel-Razeq H, AboElnazar E, Spyropoulos AC, El Shemmari S et al. A Predictive Score for Thrombosis Associated with Breast, Colorectal, Lung, or Ovarian Cancer: The Prospective COMPASS-Cancer-Associated Thrombosis Study. *Oncologist*. 2017; 26:26
343. Gibson H, Thamban S. Improving venous thromboprophylaxis in London maternity unit. *BJOG: An International Journal of Obstetrics and Gynaecology*. 2014; 121:127
344. Gibson JL, Ekevall K, Walker I, Greer IA. Puerperal thromboprophylaxis: comparison of the anti-Xa activity of enoxaparin and unfractionated heparin. *British Journal of Obstetrics and Gynaecology*. 1998; 105(7):795-797
345. Gibson NS, Sohne M, Kruip MJ, Tick LW, Gerdes VE, Bossuyt PM et al. Further validation and simplification of the Wells clinical decision rule in pulmonary embolism. *Thrombosis and Haemostasis*. 2008; 99(1):229-34
346. Godwin JE, Comp P, Davidson B, Rossi M, Group NCCT. Comparison of the efficacy and safety of subcutaneous RD heparin vs subcutaneous unfractionated heparin for the prevention of deep-vein thrombosis in patients undergoing abdominal or pelvic surgery for cancer. *Thrombosis and Haemostasis*. 1993; 69(6):647
347. Goel DP, Buckley R, deVries G, Abelseth G, Ni A, Gray R. Prophylaxis of deep-vein thrombosis in fractures below the knee: a prospective randomised controlled trial. *Journal of Bone and Joint Surgery (British Volume)*. 2009; 91(3):388-394
348. Goergen SK, Chan T, de Campo JF, Wolfe R, Gan E, Wheeler M et al. Reducing the use of diagnostic imaging in patients with suspected pulmonary embolism: validation of a risk assessment strategy. *Emergency Medicine Australasia*. 2005; 17(1):16-23



349. Goffman D, Fisher N, Kowenski J, Ngai I, Lee S, Chazotte C et al. Utilization of a checklist to evaluate risk for postpartum venous thromboembolism. *American Journal of Obstetrics and Gynecology*. 2009; 1:S297
350. Gomes M, Ramacciotti E, Henriques AC, Araujo GR, Szultan LA, Miranda FJ et al. Generic versus branded enoxaparin in the prevention of venous thromboembolism following major abdominal surgery: report of an exploratory clinical trial. *Clinical and Applied Thrombosis/Hemostasis*. 2011; 17(6):633-639
351. Gomez-Cerezo JF, Gomez-Arrayas I, Suarez-Fernandez C, Betegon-Nicolas L, Salas-Cansado M, Rubio-Terres C. Cost-effectiveness analysis of apixaban compared to dabigatran in the prevention of venous thromboembolism in patients subjected to total knee or hip replacement. *Revista Espanola de Cirugia Ortopedica y Traumatologia*. 2013; 56(6):459-470
352. Gomez-Outes A, Avendano-Sola C, Terleira-Fernandez AI, Vargas-Castrillon E. Pharmacoeconomic evaluation of dabigatran, rivaroxaban and apixaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement in Spain. *Pharmacoeconomics*. 2014; 32(9):919-936
353. Goodacre S, Sampson F, Stevenson M, Wailoo A, Sutton A, Thomas S et al. Measurement of the clinical and cost-effectiveness of non-invasive diagnostic testing strategies for deep vein thrombosis. *Health Technol Assess*. 2006; 10(15)
354. Gordois A, Posnett J, Borris L, Bossuyt P, Jonsson B, Levy E et al. The cost-effectiveness of fondaparinux compared with enoxaparin as prophylaxis against thromboembolism following major orthopedic surgery. *Journal of Thrombosis and Haemostasis*. 2003; 1(10):2167-2174
355. Gould MK, Dembitzer AD, Sanders GD, Garber AM. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A cost-effectiveness analysis. *Annals of Internal Medicine*. 1999; 130(10):789-99
356. Gould MK, Garcia DA, Wren SM, Karanicolas PJ, Arcelus JI, Heit JA et al. Prevention of VTE in nonorthopedic surgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest*. 2012; 141(2 Suppl):e227S-77S
357. Gozzard D, Hutchinson J, Lloyd A, Hutchings A. Economic evaluation of extended and conventional prophylaxis with enoxaparin against venous thromboembolism in patients undergoing surgery for abdominal cancer. *Journal of Medical Economics*. 2004; 7:53-65
358. Grant GH, Merriman JB, Hoffman MK. Implementation and efficacy of a formalized venous thromboembolism prevention strategy in the peripartum population. *American Journal of Obstetrics and Gynecology*. 2016; 1):S227-S228
359. Green D, Rossi EC, Yao JS. Deep vein thrombosis in spinal cord injury : effect of prophylaxis with calf compression, aspirin and dipyridamole. *Paraplegia*. 1982; 20:227-234
360. Green L, Lawrie AS, Patel S, Hossain F, Chitolie A, Mackie IJ et al. The impact of elective knee/hip replacement surgery and thromboprophylaxis with rivaroxaban or dalteparin on thrombin generation. *British Journal of Haematology*. 2010; 151(5):469-476
361. Greenfield LJ, Proctor MC, Rodriguez JL, Luchette FA, Cipolle MD, Cho J. Posttrauma thromboembolism prophylaxis. *Journal of Trauma-Injury Infection & Critical Care*. 1997; 42(1):100-3

362. Grille S, Castro V, Turcatti P, Mussio D, Laporte G, Medici F et al. Prophylaxis for venous thromboembolic disease in pregnancy and postpartum period. *Haematologica*. 2015; 100:626
363. Gronberg T, Hartikainen JE, Nuotio I, Biancari F, Ylitalo A, Airaksinen KE. Anticoagulation, CHA2DS2VASc Score, and Thromboembolic Risk of Cardioversion of Acute Atrial Fibrillation (from the FinCV Study). *American Journal of Cardiology*. 2016; 117(8):1294-8
364. Groote Schuur Hospital Thromboembolus Study Group. Failure of low-dose heparin to prevent significant thromboembolic complications in high-risk surgical patients: interim report of prospective trial. *British Medical Journal*. 1979; 1(6176):1447-1450
365. Gruettner J, Walter T, Lang S, Meyer M, Apfaltrer P, Henzler T et al. Importance of Wells score and Geneva score for the evaluation of patients suspected of pulmonary embolism. *In Vivo*. 2015; 29(2):269-72
366. Haas S, Hohmann V, Bramlage P. Prevention of venous thromboembolism using enoxaparin in day surgery: results of the SMART noninterventional study. *Clinical and Applied Thrombosis/Hemostasis*. 2012; 18(3):265-271
367. Haas S, Stemberger A, Fritsche HM, Welzel D, Wolf H, Lechner F et al. Prophylaxis of deep vein thrombosis in high risk patients undergoing total hip replacement with low molecular weight heparin plus dihydroergotamine. *Arzneimittel-Forschung*. 1987; 37(7):839-843
368. Haas SB, Insall JN, Scuderi GR, Windsor RE, Ghelman B. Pneumatic sequential-compression boots compared with aspirin prophylaxis of deep-vein thrombosis after total knee arthroplasty. *Journal of Bone and Joint Surgery*. 1990; 72(1):27-31
369. Haas SK, Hach-Wunderle V, Mader FH, Paar WD. Venous thromboembolic risk and thromboprophylaxis in acutely ill medical outpatients: Summarized data from the AT-HOME study. *Phlebologie*. 2006; 35(6):286-288
370. Haas SK, Hach-Wunderle V, Mader FH, Ruster K, Paar WD. An evaluation of venous thromboembolic risk in acutely ill medical patients immobilized at home: the AT-HOME Study. *Clinical and Applied Thrombosis/Hemostasis*. 2007; 13(1):7-13
371. Haas SK, Wolf H, Encke A, Fareed J. Prevention of fatal postoperative pulmonary embolism by low molecular weight heparin. A double blind comparison of certoparin and unfractionated heparin. *Thrombosis and Haemostasis*. 1999; 82(5):1548
372. Hachey KJ, Sterbling H, Choi DS, Pinjic E, Hewes PD, Munoz J et al. Prevention of Postoperative Venous Thromboembolism in Thoracic Surgical Patients: Implementation and Evaluation of a Caprini Risk Assessment Protocol. *Journal of the American College of Surgeons*. 2016; 222(6):1019-27
373. Hack V, Schwarz E, Rumpelstein C, Stein EL, Pachmann U. Risk of thrombosis during the course of pregnancy mechanism and individual therapeutic consequences. *Transfusion Medicine and Hemotherapy*. 2012; 39:57
374. Haentjens P, De Groote K, Annemans L. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis. *Archives of Orthopaedic and Trauma Surgery*. 2004; 124(8):507-517
375. Haider M, Gangat N, Lasho T, Abou Hussein AK, Elala YC, Hanson C et al. Validation of the revised international prognostic score of thrombosis for essential thrombocythemia (IPSET-thrombosis) in 585 Mayo clinic patients. *American Journal of Hematology*. 2016; 91(4):390-394



376. Hairon N. New risk assessment tool aims to help nurses prevent VTE. *Nursing Times*. 2008; 104(39):23-5
377. Hajibandeh S, Hajibandeh S, Antoniou GA, Scurr James RH, Torella F. Neuromuscular electrical stimulation for the prevention of venous thromboembolism. *Cochrane Database of Systematic Reviews* 2015, Issue 6. Art. No.: CD011764. DOI: 10.1002/14651858.CD011764.
378. Hamel-Desnos CM, Gillet JL, Desnos PR, Allaert FA. Sclerotherapy of varicose veins in patients with documented thrombophilia: a prospective controlled randomized study of 105 cases. *Phlebology*. 2009; 24(4):176-182
379. Hamersley S, Landy H. Low molecular weight heparin is associated with less peripartum blood loss than unfractionated heparin. *American Journal of Obstetrics and Gynecology*. 1998; 178:S66
380. Hamidi S, Riazi M. Incidence of venous thromboembolic complications in instrumental spinal surgeries with preoperative chemoprophylaxis. *Journal of Korean Neurosurgical Society*. 2015; 57(2):114-118
381. Hamidi V, Ringerike T, Hagen G, Reikvam A, Klemp M. New anticoagulants as thromboprophylaxis after total hip or knee replacement. *International Journal of Technology Assessment in Health Care*. 2013; 29(3):234-243
382. Hampson WG, Harris FC, Lucas HK, Roberts PH, McCall IW, Jackson PC et al. Failure of low-dose heparin to prevent deep-vein thrombosis after hip-replacement arthroplasty. *Lancet*. 1974; 2(7884):795-797
383. Hamulyak K, Lensing AW, van der Meer J, Smid WM, van Ooy A, Hoek JA. Subcutaneous low-molecular weight heparin or oral anticoagulants for the prevention of deep-vein thrombosis in elective hip and knee replacement? Fraxiparine Oral Anticoagulant Study Group. *Thrombosis and Haemostasis*. 1995; 74(6):1428-1431
384. Handley AJ. Low-dose heparin after myocardial infarction. *Lancet*. 1972; 300(7778):623-624
385. Handley AJ, Emerson PA, Fleming PR. Heparin in the prevention of deep vein thrombosis after myocardial infarction. *British Medical Journal*. 1972; 2(5811):436-438
386. Hanison E, Corbett K. Non-pharmacological interventions for the prevention of venous thromboembolism: a literature review. *Nursing Standard*. 2016; 31(8):48-57
387. Hansberry KL, Thompson IM, Jr., Bauman J, Deppe S, Rodriguez FR. A prospective comparison of thromboembolic stockings, external sequential pneumatic compression stockings and heparin sodium /dihydroergotamine mesylate for the prevention of thromboembolic complications in urological surgery. *Journal of Urology*. 1991; 145(6):1205-1208
388. Haque S, Bishnoi A, Khairandish H, Menon D. Thromboprophylaxis in Ambulatory Trauma Patients With Foot and Ankle Fractures: Prospective Study Using a Risk Scoring System. *Foot & Ankle Specialist*. 2016; 9(5):388-93
389. Hardwick ME, Pulido PA, Colwell CWJ. A mobile compression device compared with low-molecular-weight heparin for prevention of venous thromboembolism in total hip arthroplasty. *Orthopaedic Nursing*. 2011; 30(5):312-316
390. Harenberg J, Roebruck P, Heene DL. Randomized controlled study of heparin and low molecular weight heparin for prevention of deep-vein thrombosis in medical patients. *Thrombosis Research*. 1990; 59(3):639-650

391. Harenberg J, Schneider D, Heilmann L, Wolf H. Lack of anti-factor Xa activity in umbilical cord vein samples after subcutaneous administration of heparin or low molecular mass heparin in pregnant women. *Haemostasis*. 1993; 23(6):314-320
392. Harinath G, St John PH. Use of a thromboembolic risk score to improve thromboprophylaxis in surgical patients. *Annals of the Royal College of Surgeons of England*. 1998; 80(5):347-349
393. Harris C, Sulmers C, Groesch K, Wilson T, Delfino K, Taylor F. Venous thromboembolism: Padua prediction score in the obstetric patient. *Obstetrics and Gynecology*. 2016; 127:88S
394. Harris WH, Athanasoulis CA, Waltman AC, Salzman EW. Prophylaxis of deep-vein thrombosis after total hip replacement. Dextran and external pneumatic compression compared with 1.2 or 0.3 gram of aspirin daily. *Journal of Bone and Joint Surgery*. 1985; 67(1):57-62
395. Harris WH, Salzman EW, Athanasoulis CA, Waltman AC, DeSanctis RW. Aspirin prophylaxis of venous thromboembolism after total hip replacement. *New England Journal of Medicine*. 1977; 297(23):1246-1249
396. Hata T, Yasui M, Murata K, Okuyama M, Ohue M, Ikeda M et al. Safety of fondaparinux to prevent venous thromboembolism in Japanese patients undergoing colorectal cancer surgery: a multicenter study. *Surgery Today*. 2014; 44(11):2116-2123
397. Haut ER, Garcia LJ, Shihab HM, Brotman DJ, Stevens KA, Sharma R et al. The effectiveness of prophylactic inferior vena cava filters in trauma patients: a systematic review and meta-analysis. *JAMA Surg*. 2014; 149(2):194-202
398. Haxaire C, Tromeur C, Couturaud F, Leroyer C. A Qualitative Study to Appraise Patients and Family Members Perceptions, Knowledge, and Attitudes towards Venous Thromboembolism Risk. *PloS One*. 2015; 10(11):e0142070
399. Haywood KL, Griffin XL, Achten J, Costa ML. Developing a core outcome set for hip fracture trials. *Bone Joint J*. 2014; 96-b(8):1016-23
400. Healey JS, Eikelboom J, Douketis J, Wallentin L, Oldgren J, Yang S et al. Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the randomized evaluation of long-term anticoagulation therapy (RE-LY) randomized trial. *Circulation*. 2012; 126(3):343-348
401. Health and Social Care Information Centre. Statistics on Obesity, Physical Activity and Diet. 2016. Available from: <http://content.digital.nhs.uk/catalogue/PUB20562/obes-phys-acti-diet-eng-2016-rep.pdf>
402. Heath S, Goodfellow A. Maternal venous thromboembolism (VTE) risk assessment. *Journal of Paediatrics and Child Health*. 2016; 52:69
403. Heaton DC, Han DY, Inder A. Minidose (1 mg) warfarin as prophylaxis for central vein catheter thrombosis. *Internal Medicine Journal*. 2002; 32(3):84-88
404. Hedlund PO, Blombäck M. The effect of prophylaxis with low dose heparin on blood coagulation parameters. A double blind study in connection with transvesical prostatectomy. *Thrombosis and Haemostasis*. 1979; 41(2):337-345
405. Hedlund PO, Blombäck M. The effects of low-dose heparin treatment on patients undergoing transvesical prostatectomy. *Urological Research*. 1981; 9(3):147-152



406. Heilmann L, Heitz R, Koch FU, Ose C. Perioperative prevention of thrombosis in cesarean section: results of a randomized prospective comparative study with 6% hydroxyethyl starch and 0.62 low dose heparin. *Zeitschrift für Geburtshilfe und Perinatologie*. 1991; 195(1):10-15
407. Heilmann L, Kruck M, Schindler AE. (Prevention of thrombosis in gynecology: double-blind comparison of low molecular weight heparin and unfractionated heparin). *Geburtshilfe und Frauenheilkunde*. 1989; 49(9):803-807
408. Heilmann L, von Tempelhoff GF, Kirkpatrick C, Schneider DM, Hommel G, Pollow K. Comparison of unfractionated versus low molecular weight heparin for deep vein thrombosis prophylaxis during breast cancer surgery: efficacy, safety, and follow-up. *Clinical and Applied Thrombosis/Hemostasis*. 1998; 4(4):268-273
409. Heinemann LAJ, DoMinh T, Assmann A, Schramm W, Scurmann R, Hilpert J et al. VTE risk assessment - A prognostic model: BATER cohort study of young women. *Thrombosis Journal*. 2005; 3(5)
410. Heit JA, Elliott CG, Trowbridge AA, Morrey BF, Gent M, Hirsh J. Ardeparin sodium for extended out-of-hospital prophylaxis against venous thromboembolism after total hip or knee replacement. A randomized, double-blind, placebo-controlled trial. *Annals of Internal Medicine*. 2000; 132(11):853-861
411. Heit JA, Scott D, Berkowitz SD, Bona R, Cabanas V, Corson JD et al. Efficacy and safety of low molecular weight heparin (ardeparin sodium) compared to warfarin for the prevention of venous thromboembolism after total knee replacement surgery: A double-blind dose-ranging study. *Thrombosis and Haemostasis*. 1997; 77(1):32-38
412. Heit JA, Silverstein MD, Mohr DN, Petterson TM, Lohse CM, O'Fallon WM et al. The epidemiology of venous thromboembolism in the community. *ThrombHaemost*. 2001; 86(1):452-463
413. Helviz Y, Dzigivker I, Raveh-Brawer D, Hersch M, Zevin S, Einav S. Anti-Factor Xa Activity of Prophylactic Enoxaparin Regimens in Critically Ill Patients. *Israel Medical Association Journal: Imaj*. 2016; 18(2):108-13
414. Hendriksen JM, Geersing GJ, Lucassen WA, Erkens PM, Stoffers HE, van Weert HC et al. Diagnostic prediction models for suspected pulmonary embolism: systematic review and independent external validation in primary care. *BMJ*. 2015; 351:h4438
415. Hewes PD, Hachey KJ, Zhang XW, Tripodis Y, Rosenkranz P, Ebricht MI et al. Evaluation of the Caprini model for venothromboembolism in esophagectomy patients. *Annals of Thoracic Surgery*. 2015; 100(6):2072-8
416. Hill NC, Hill JG, Sargent JM, Taylor CG, Bush PV. Effect of low dose heparin on blood loss at caesarean section. *British Medical Journal*. 1988; 296(6635):1505-1506
417. Hills NH, Pflug JJ, Jeyasingh K, Boardman L, Calnan JS. Prevention of deep vein thrombosis by intermittent pneumatic compression of calf. *British Medical Journal*. 1972; 1(793):131-135
418. Hippisley-Cox J, Coupland C. Development and validation of risk prediction algorithm (QThrombosis) to estimate future risk of venous thromboembolism: prospective cohort study. *BMJ*. 2011; 343:d4656
419. Hippisley-Cox J, Coupland C, Brindle P. The performance of seven QPrediction risk scores in an independent external sample of patients from general practice: a validation study. *BMJ Open*. 2014; 4(8):e005809

420. Hirschl M, Kundi M. New oral anticoagulants in the treatment of acute venous thromboembolism - a systematic review with indirect comparisons. *Zeitschrift für Gefasskrankheiten*. 2014; 43(5):353-364
421. Ho KM, Bham E, Pavey W. Incidence of Venous Thromboembolism and Benefits and Risks of Thromboprophylaxis After Cardiac Surgery: A Systematic Review and Meta-Analysis. *Journal of the American Heart Association*. 2015; 4(10):e002652
422. Ho KM, Tan JA. Stratified meta-analysis of intermittent pneumatic compression of the lower limbs to prevent venous thromboembolism in hospitalized patients. *Circulation*. 2013; 128(9):1003-1020
423. Ho YK, Seow-Choen F, Leong A, Eu KW, Nyam D, Teoh MK. Randomized, controlled trial of low molecular weight heparin vs. no deep vein thrombosis prophylaxis for major colon and rectal surgery in Asian patients. *Diseases of the Colon and Rectum*. 1999; 42(2):196-203
424. Hochegger B, Alves GR, Chaves M, Moreira AL, Kist R, Watte G et al. Interobserver agreement between radiologists and radiology residents and emergency physicians in the detection of PE using CTPA. *Clinical Imaging*. 2014; 38(4):445-7
425. Hoffman R, Largiadèr F, Brüttsch HP. Perioperative thromboembolic prophylaxis with low molecular weight heparin and postoperative bleeding complications. *Langenbecks Archiv für Chirurgie*. 1990; 375(Suppl II):1179-1184
426. Hoffmann R, Largiadèr F. Perioperative prevention of thromboembolism with standard heparin and low molecular weight heparin, evaluation of postoperative hemorrhage. A double-blind, prospective, randomized and mono-center study. *Langenbecks Archiv für Chirurgie*. 1992; 377(5):258-261
427. Hoffmeyer P, Simmen H, Jakob M, Sommer C, Platz A, Ilchmann T et al. Rivaroxaban for Thromboprophylaxis After Nonelective Orthopedic Trauma Surgery in Switzerland. *Orthopedics*. 2017; 40(2):109-116
428. Hohl Moinat C, Periard D, Grueber A, Hayoz D, Magnin JL, Andre P et al. Predictors of venous thromboembolic events associated with central venous port insertion in cancer patients. *Journal of Oncology Print*. 2014; 2014:743181
429. Holley A, King C, Moores L, Jackson JL, Shorr A. The role of twice versus three times daily heparin dosing for thromboembolism prophylaxis in general medical patients admitted to the hospital. *Cochrane Database of Systematic Reviews* 2008, Issue 4. Art. No.: CD007382. DOI: DOI: 10.1002/14651858.CD007382.
430. Holmes M, Carroll C, Papaioannou D. Dabigatran etexilate for the prevention of venous thromboembolism in patients undergoing elective hip or knee surgery: a NICE single technology appraisal. *Pharmacoeconomics*. 2012; 30(2):137-146
431. Hossain Shahcheraghi G, Javid M, Arasteh MM. Thromboembolic disease after knee arthroplasty is rare in Southern Iran. *Journal of orthopaedics*. 2015; 12(2):86-91
432. Howard A, Zaccagnini D, Ellis M, Williams A, Davies AH, Greenhalgh RM. Randomized clinical trial of low molecular weight heparin with thigh-length or knee-length antiembolism stockings for patients undergoing surgery. *British Journal of Surgery*. 2004; 91(7):842-847
433. Howell R, Fidler J, Letsky E, De Swiet M. The risks of antenatal subcutaneous heparin prophylaxis: a controlled trial. *British Journal of Obstetrics and Gynaecology*. 1983; 90(12):1124-1128





434. Huang W, Anderson FA, Spencer FA, Gallus A, Goldberg RJ. Risk-assessment models for predicting venous thromboembolism among hospitalized non-surgical patients: a systematic review. *Journal of Thrombosis and Thrombolysis*. 2013; 35(1):67-80
435. Hui AC, Heras-Palou C, Dunn I, Triffitt PD, Crozier A, Imeson J et al. Graded compression stockings for prevention of deep-vein thrombosis after hip and knee replacement. *Journal of Bone and Joint Surgery (British Volume)*. 1996; 78(4):550-554
436. Huisman MV, Quinlan DJ, Dahl OE, Schulman S. Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: Results of separate pooled analyses of phase III multicenter randomized trials. *Circulation Cardiovascular Quality and Outcomes*. 2010; 3(6):652-660
437. Hull R, Delmore TJ, Hirsch J, Gent M, Armstrong P, Lofthouse R et al. Effectiveness of intermittent pulsative elastic stockings for the prevention of calf and thigh vein thrombosis in patients undergoing elective knee surgery. *Thrombosis Research*. 1979; 16(1-2):37-45
438. Hull R, Raskob G, Pineo G, Rosenbloom D, Evans W, Mallory T et al. A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation. *New England Journal of Medicine*. 1993; 329(19):1370-1376
439. Hull RD, Gersh MH. The current landscape of treatment options for venous thromboembolism: a focus on novel oral anticoagulants. *Current Medical Research and Opinion*. 2015; 31(2):197-210
440. Hull RD, Pineo GF, Francis C, Bergqvist D, Fellenius C, Soderberg K et al. Low-molecular-weight heparin prophylaxis using dalteparin in close proximity to surgery vs warfarin in hip arthroplasty patients: a double-blind, randomized comparison. The North American Fragmin Trial Investigators. *Archives of Internal Medicine*. 2000; 160(14):2199-2207
441. Hull RD, Raskob GE, Gent M, McLoughlin D, Julian D, Smith FC et al. Effectiveness of intermittent pneumatic leg compression for preventing deep vein thrombosis after total hip replacement. *JAMA*. 1990; 263(17):2313-2317
442. Hume M, Kuriakose TX, Zuch L, Turner RH. 125I fibrinogen and the prevention of venous thrombosis. *Archives of Surgery*. 1973; 107(5):803-806
443. Hunter R, Lewis S, Noble S, Rance J, Bennett PD. "Post-thrombotic panic syndrome": A thematic analysis of the experience of venous thromboembolism. *British Journal of Health Psychology*. 2016; 9:9
444. Ibrahim M, Ahmed A, Mohamed WY, El-Sayed Abu Abduo S. Effect of compression devices on preventing deep vein thrombosis among adult trauma patients: A systematic review. *Dimensions of Critical Care Nursing*. 2015; 34(5):289-300
445. Ikesaka R, Delluc A, Le Gal G, Carrier M. Efficacy and safety of weight-adjusted heparin prophylaxis for the prevention of acute venous thromboembolism among obese patients undergoing bariatric surgery: a systematic review and meta-analysis. *Thrombosis Research*. 2014; 133(4):682-687
446. Imberti D, Legnani C, Baldini E, Cini M, Nicolini A, Guerra M et al. Pharmacodynamics of low molecular weight heparin in patients undergoing bariatric surgery: a prospective, randomised study comparing two doses of parnaparin (BAFLUX study). *Thrombosis Research*. 2009; 124(6):667-671



447. Ismail SK, Norris L, Khashan A, Myers J, Simpson N, Dekker G et al. Can calibrated automated thrombogram assay predict venous thrombosis in pregnancy? *Thrombosis Research*. 2015; 135:S67
448. Izadpanah M, Khalili H, Dashti-Khavidaki S, Mohammadi M. Heparin and related drugs for venous thromboembolism prophylaxis: subcutaneous or intravenous continuous infusion? *Journal of comparative effectiveness research*. 2015; 4(2):167-184
449. Jacobso BF, Louw S, Riback WJ. The use of vte prophylaxis in relation to patient risk profiling (TUNE-IN) wave 2 study. *South African Medical Journal*. 2014; 104(12):880-884
450. Jameson SS, Baker PN, Charman SC, Deehan DJ, Reed MR, Gregg PJ et al. The effect of aspirin and low-molecular-weight heparin on venous thromboembolism after knee replacement: a non-randomised comparison using national joint registry data. *Journal of Bone and Joint Surgery (British Volume)*. 2012; 94(7):914-8
451. Jameson SS, Charman SC, Gregg PJ, Reed MR, Van Der Meulen JH. The effect of aspirin and low-molecular-weight heparin on venous thromboembolism after hip replacement: A non-randomised comparison from information in the National Joint Registry. *Journal of Bone and Joint Surgery - Series B*. 2011; 93 B(11):1465-1470
452. Jameson SS, Rymaszewska M, Hui AC, James P, Serrano-Pedraza I, Muller SD. Wound complications following rivaroxaban administration: a multicenter comparison with low-molecular-weight heparins for thromboprophylaxis in lower limb arthroplasty. *Journal of Bone and Joint Surgery (American Volume)*. 2012; 94(17):1554-8
453. Jamula E, Woods K, Verhovsek M, Douketis JD. Comparison of pain and ecchymosis with low-molecular-weight heparin vs. unfractionated heparin in patients requiring bridging anticoagulation after warfarin interruption: A randomized trial. *Journal of Thrombosis and Thrombolysis*. 2009; 28(3):266-268
454. Janssen KJ, Siccama I, Vergouwe Y, Koffijberg H, Debray TP, Keijzer M et al. Development and validation of clinical prediction models: marginal differences between logistic regression, penalized maximum likelihood estimation, and genetic programming. *Journal of Clinical Epidemiology*. 2012; 65(4):404-12
455. Janvrin SB, Davies G, Greenhalgh RM. Postoperative deep vein thrombosis caused by intravenous fluids during surgery. *British Journal of Surgery*. 1980; 67(10):690-693
456. Jiang Y, Du H, Liu J, Zhou Y. Aspirin combined with mechanical measures to prevent venous thromboembolism after total knee arthroplasty: a randomized controlled trial. *Chinese Medical Journal*. 2014; 127(12):2201-2205
457. Johnson MJ, Sproule MW, Paul J. The prevalence and associated variables of deep venous thrombosis in patients with advanced cancer. *Clinical Oncology*. 1999; 11(2):105-10
458. Joint Formulary Committee. *British National Formulary (BNF) July 2016 update*. 2016. Available from: <http://www.bnf.org.uk> Last accessed: 09/08/2017.
459. Jourdan M, McColl I. The use of prophylactic subcutaneous heparin in patients undergoing hernia repairs. *British Journal of Clinical Practice*. 1984; 38(9):298-300
460. Junqueira Daniela RG, Perini E, Penholati Raphael RM, Carvalho MG. Unfractionated heparin versus low molecular weight heparin for avoiding heparin-induced thrombocytopenia in postoperative patients. *Cochrane Database of Systematic Reviews 2012, Issue 9*. Art. No.: CD007557. DOI: 10.1002/14651858.CD007557.pub2.

461. Kabrhel C, McAfee AT, Goldhaber SZ. The contribution of the subjective component of the Canadian Pulmonary Embolism Score to the overall score in emergency department patients. *Academic Emergency Medicine*. 2005; 12(10):915-20
462. Kafeza M, Shalhoub J, Salooja N, Bingham L, Spagou K, Davies AH. A systematic review of clinical prediction scores for deep vein thrombosis. *Phlebology*. 2016; 24:24
463. Kahn SR, Galanaud JP, Vedantham S, Ginsberg JS. Guidance for the prevention and treatment of the post-thrombotic syndrome. *Journal of Thrombosis and Thrombolysis*. 2016; 41(1):144-53
464. Kahn SR, Shapiro S, Wells PS, Rodger MA, Kovacs MJ, Anderson DR et al. Compression stockings to prevent post-thrombotic syndrome: a randomised placebo-controlled trial. *Lancet*. 2014; 383(9920):880-888
465. Kahn SR, Shapiro S, Wells PS, Rodger MA, Kovacs MJ, Anderson RD. A multicenter randomized placebo controlled trial of compression stockings to prevent the post-thrombotic syndrome after proximal deep venous thrombosis: The S.O.X. trial. *Blood*. 2012; 120(21)
466. Kakkar AK, Agnelli G, Fisher W, George D, Lassen MR, Mismetti P et al. Preoperative enoxaparin versus postoperative semuloparin thromboprophylaxis in major abdominal surgery: a randomized controlled trial. *Annals of Surgery*. 2014; 259(6):1073-1079
467. Kakkar AK, Brenner B, Dahl OE, Eriksson BI, Mouret P, Muntz J et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. *Lancet*. 2008; 372(9632):31-39
468. Kakkar VV, Howes J, Sharma V, Kadziola Z. A comparative double-blind, randomised trial of a new second generation LMWH (bemiparin) and UFH in the prevention of post-operative venous thromboembolism. The Bemiparin Assessment group. *Thrombosis and Haemostasis*. 2000; 83(4):523-529
469. Kakkar VV, Murray WJ. Efficacy and safety of low-molecular-weight heparin (CY216) in preventing postoperative venous thrombo-embolism: a co-operative study. *British Journal of Surgery*. 1985; 72(10):786-91
470. Kakkar VV, Stringer MD, Hedges AR, Parker CJ, Welzel D, Ward VP et al. Fixed combinations of low-molecular weight or unfractionated heparin plus dihydroergotamine in the prevention of postoperative deep vein thrombosis. *American Journal of Surgery*. 1989; 157(4):413-418
471. Kakkos SK, Warwick D, Nicolaidis AN, Stansby GP, Tsolakis IA. Combined (mechanical and pharmacological) modalities for the prevention of venous thromboembolism in joint replacement surgery. *Journal of Bone and Joint Surgery (British Volume)*. 2012; 94(6):729-734
472. Kalodiki EP, Hoppensteadt DA, Nicolaidis AN, Fareed J, Gill K, Regan F et al. Deep venous thrombosis prophylaxis with low molecular weight heparin and elastic compression in patients having total hip replacement. A randomised controlled trial. *International Angiology*. 1996; 15(2):162-168
473. Kang N, Sobieraj DM. Indirect treatment comparison of new oral anticoagulants for the treatment of acute venous thromboembolism. *Thrombosis Research*. 2014; 133(6):1145-1151



474. Kapoor A, Chuang W, Radhakrishnan N, Smith KJ, Berlowitz D, Segal JB et al. Cost effectiveness of venous thromboembolism pharmacological prophylaxis in total hip and knee replacement: a systematic review. *Pharmacoeconomics*. 2010; 28(7):521-538
475. Karamat A, Awan S, Hussain MG, Al Hameed F, Butt F, Wahla AS. Usefulness of Clinical Prediction Rules, D-dimer, and Arterial Blood Gas Analysis to Predict Pulmonary Embolism in Cancer Patients. *Oman Medical Journal*. 2017; 32(2):148-153
476. Katsios C, Donadini M, Meade M, Mehta S, Hall R, Granton J et al. Prediction scores do not correlate with clinically adjudicated categories of pulmonary embolism in critically ill patients. *Canadian Respiratory Journal*. 2014; 21(1):36-42
477. Katz DF, Maddox TM, Turakhia M, Gehi A, O'Brien EC, Lubitz SA et al. Analysis from the national cardiovascular data registry's outpatient practice innovation and clinical excellence atrial fibrillation registry. *Circulation: Cardiovascular Quality and Outcomes*. 2017; 10 (5) (no pagination)(e003476)
478. Kawaguchi T, Kumabe T, Kanamori M, Saito R, Yamashita Y, Sonoda Y et al. Risk assessment for venous thromboembolism in patients with neuroepithelial tumors: pretreatment score to identify high risk patients. *Neurologia Medico-Chirurgica*. 2013; 53(7):467-73
479. Kawaji H, Ishii M, Tamaki Y, Hamasaki M, Ishikawa H, Sasaki K. Postoperative prophylactic effect of fondaparinux for prevention of deep venous thrombosis after cemented total hip replacement: a comparative study. *Modern rheumatology*. 2012; 22:216-222
480. Kearon C, Ginsberg JS, Kovacs MJ, Anderson DR, Wells P, Julian JA et al. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. *New England Journal of Medicine*. 2003; 349(7):631-9
481. Keeling D, Davidson S, Watson H. The management of heparin-induced thrombocytopenia. *British Journal of Haematology*. 2006; 133(3):259-269
482. Kessler P, Pour L, Gregora E, Zemanova M, Penka M, Brejcha M et al. Low molecular weight heparins for thromboprophylaxis during induction chemotherapy in patients with multiple myeloma. *Klinika Onkologie*. 2011; 24(4):281-6
483. Kettunen K, Poikolainen E, Karjalainen P, Oksala I, Alhava E, Rehnberg V et al. (Prevention of postoperative deep vein thrombosis with small doses of heparin). *Duodecim*. 1974; 90(11):834-838
484. Khairy P, Aboulhosn J, Broberg CS, Cohen S, Cook S, Dore A et al. Thromboprophylaxis for atrial arrhythmias in congenital heart disease: A multicenter study. *International Journal of Cardiology*. 2016; 223:729-735
485. Khokhar A, Chari A, Murray D, McNally M, Pandit H. Venous thromboembolism and its prophylaxis in elective knee arthroplasty: an international perspective. *Knee*. 2013; 20(3):170-176
486. Khorana AA, Francis CW, Kuderer N, Carrier M, Ortel TL, Wun T et al. Dalteparin Thromboprophylaxis in Cancer Patients at High Risk for Venous Thromboembolism: A Randomized Trial. *Blood*. 2015; 126:427-427
487. Kierkegaard A, Norgren L. Graduated compression stockings in the prevention of deep vein thrombosis in patients with acute myocardial infarction. *European Heart Journal*. 1993; 14(10):1365-1368

488. Kiil J, Jensen FT. The incidence of postoperative pulmonary embolism and the influence of heparin in low dosages on this as assessed by ventilation-perfusion scintigraphy. *Ugeskrift for Laeger*. 1978; 140(21):1215-1217
489. Kiil J, Kiil J, Axelsen F. Heparin in low dosage as prophylaxis of postoperative pulmonary embolism and deep venous thrombosis. *Ugeskrift for Laeger*. 1978; 140(21):1224-1230
490. Kiil J, Kiil J, Axelsen F, Andersen D. Prophylaxis against postoperative pulmonary embolism and deep-vein thrombosis by low-dose heparin. *Lancet*. 1978; 1(8074):1115-1116
491. Kiil J, Møller JC. Postoperative deep thrombosis in the lower limbs and the prophylactic value of heparin in low dosage as assessed by phlebography. *Ugeskrift for Laeger*. 1978; 140(21):1221-1224
492. Kiil J, Møller JC. Postoperative deep vein thrombosis of the lower limb and prophylactic value of heparin evaluated by phlebography. *Acta Radiologica: Diagnosis*. 1979; 20(3):507-512
493. Killewich LA, Aswad MA, Sandager GP, Lilly MP, Flinn WR. A randomized, prospective trial of deep venous thrombosis prophylaxis in aortic surgery. *Archives of Surgery*. 1997; 132(5):499-504
494. Kim SM, Moon YW, Lim SJ, Kim DW, Park YS. Effect of oral factor Xa inhibitor and low-molecular-weight heparin on surgical complications following total hip arthroplasty. *Thrombosis and Haemostasis*. 2016; 115(3):600-7
495. Kind P, Dolan P, Gudex C, Williams A. Variations in population health status: results from a United Kingdom national questionnaire survey. *British Medical Journal*. 1998; 316(7133):736-741
496. Kiudelis M, Gerbutavicius R, Gerbutaviciene R, Griniute R, Mickevicius A, Endzinas Z et al. A combinative effect of low-molecular-weight heparin and intermittent pneumatic compression device for thrombosis prevention during laparoscopic fundoplication. *Medicina*. 2010; 46(1):18-23
497. Klerk CPW, Smorenburg SM, Otten HM. The effect of low molecular weight heparin on survival in patients with advanced malignancy. *Journal of Clinical Oncology*. 2005; 23(10):2130-2135
498. Klok FA, Kruisman E, Spaan J, Nijkeuter M, Righini M, Aujesky D et al. Comparison of the revised Geneva score with the Wells rule for assessing clinical probability of pulmonary embolism. *Journal of Thrombosis and Haemostasis*. 2008; 6(1):40-4
499. Klok FA, Niemann C, Dellas C, Hasenfus G, Konstantinides S, Lankeit M. Performance of five different bleeding-prediction scores in patients with acute pulmonary embolism. *Journal of Thrombosis and Thrombolysis*. 2016; 41(2):312-20
500. Knudson MM. Thromboembolism following multiple trauma. *Journal of Trauma*. 1992; 32(1):2-11
501. Koo KH, Choi JS, Ahn JH, Kwon JH, Cho KT. Comparison of clinical and physiological efficacies of different intermittent sequential pneumatic compression devices in preventing deep vein thrombosis: a prospective randomized study. *Clinics in Orthopedic Surgery*. 2014; 6(4):468-475
502. Kooiman J, van Hagen N, Iglesias Del Sol A, Planken EV, Lip GY, van der Meer FJ et al. The HAS-BLED Score Identifies Patients with Acute Venous Thromboembolism at High Risk of



- Major Bleeding Complications during the First Six Months of Anticoagulant Treatment. *PLoS One*. 2015; 10(4):e0122520
503. Koppenhagen K, Adolf J, Matthes M, Troster E, Roder JD, Hass S et al. Low molecular weight heparin and prevention of postoperative thrombosis in abdominal surgery. *Thrombosis and Haemostasis*. 1992; 67(6):627-630
504. Koppenhagen K, Matthes M. Heparin-dihydergot or heparin alone in thrombosis prophylaxis? *Medizinische Welt*. 1982; 33(6):216-223
505. Koppenhagen K, Matthes M, Haering R, Troester E, Wolf H, Welzel D. Prophylaxis of thromboembolism in elective abdominal surgery: comparison of efficiency and safety of low molecular weight heparin and unfractionated heparin. *Munchener Medizinische Wochenschrift*. 1990; 132(43):677-680
506. Kosir MA, Schmittinger L, Barno WL, Duddella P, Pone M, Perales A et al. Prospective double-arm study of fibrinolysis in surgical patients. *Journal of Surgical Research*. 1998; 74(1):96-101
507. Kourlaba G, Relakis J, Mylonas C, Kapaki V, Kontodimas S, Holm MV et al. The humanistic and economic burden of venous thromboembolism in cancer patients: A systematic review. *Blood Coagulation and Fibrinolysis*. 2015; 26(1):13-31
508. Krasinski Z, Szpurek D, Staniszewski R, Dzieciuchowicz L, Pawlaczyk K, Krasinska B et al. The value of extended preoperative thromboprophylaxis with dalteparin in patients with ovarian cancer qualified to surgical treatment. *International Angiology*. 2014; 33(4):365-371
509. Krauss T, Rath W, Dittmer U, Kuhn W. Prevention of thromboembolism with low molecular weight heparin (Fragmin) in obstetrics. *Zeitschrift für Geburtshilfe und Perinatologie*. 1994; 198(4):120-125
510. Kraytman M, Kutnowski M, Ansay J, Fastrez R. Prophylaxis of postoperative deep vein thromboses by means of weak doses of subcutaneous heparin. *Acta Chirurgica Belgica*. 1976; 75(5):519-529
511. Kresec O, Lebaudy C, Laborde C, Paludetto MN, Fleuriant C, Barkate A et al. Elderly patients and oral anticoagulants: Evaluation of patient's knowledge and the case for a pharmaceutical interview. *International Journal of Clinical Pharmacy*. 2011; 33 (4):704-705
512. Kruse-Blinkenberg HO, Gormsen J. The influence of low dose heparin in elective surgery on blood coagulation, fibrinolysis, platelet function, antithrombin III and antiplasmin. *Acta Chirurgica Scandinavica*. 1980; 146(6):375-382
513. Kucher N, Koo S, Quiroz R, Cooper JM, Paterno MD, Soukonnikov B et al. Electronic alerts to prevent venous thromboembolism among hospitalized patients. *New England Journal of Medicine*. 2005; 352(10):969-977
514. Kuderer NM, Culakova E, Lyman GH, Francis C, Falanga A, Khorana AA. A Validated Risk Score for Venous Thromboembolism Is Predictive of Cancer Progression and Mortality. *Oncologist*. 2016; 21(7):861-7
515. Kuijer PM, Hutten BA, Prins MH, Buller HR. Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. *Archives of Internal Medicine*. 1999; 159(5):457-60
516. Kujath P, Hoffmann M. Physical prophylaxis for thromboembolism: Current state of knowledge on use of medical thromboprophylaxis stockings. *Chirurg*. 2013; 84(12):1057-1061

517. Kurtoglu M, Group RS. An observational study for venous thromboembolism risk assessment among hospitalized patients in general surgery clinics across Turkey. *Phlebology*. 2011; 26(8):344-52
518. Kutnowski M, Vandendris M, Steinberger R, Kravtman M. Prevention of postoperative deep-vein thrombosis by low-dose heparin in urological surgery. A double-blind, randomised study. *Urological Research*. 1977; 5(3):123-125
519. Kwok CS, Pradhan S, Yeong JK-y, Loke YK. Relative effects of two different enoxaparin regimens as comparators against newer oral anticoagulants: meta-analysis and adjusted indirect comparison. *Chest*. 2013; 144(2):593-600
520. La Regina M, Orlandini F, Marchini F, Marinaro A, Bonacci R, Bonanni P et al. Combined assessment of thrombotic and haemorrhagic risk in acute medical patients. *Thrombosis and Haemostasis*. 2016; 115(2):392-8
521. Lahnborg G, Lagergren H, Hedenstierna G. Effect of low-dose heparin prophylaxis on arterial oxygen tension after high laparotomy. *Lancet*. 1976; 1(7950):54-56
522. Landefeld CS, Goldman L. Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. *American Journal of Medicine*. 1989; 87(2):144-52
523. Lankeit M, Friesen D, Schafer K, Hasenfus G, Konstantinides S, Dellas C. A simple score for rapid risk assessment of non-high-risk pulmonary embolism. *Clinical Research in Cardiology*. 2013; 102(1):73-80
524. Laporte S, Chapelle C, Bertoletti L, Lega JC, Cucherat M, Zufferey PJ et al. Indirect comparison meta-analysis of two enoxaparin regimens in patients undergoing major orthopaedic surgery. Impact on the interpretation of thromboprophylactic effects of new anticoagulant drugs. *Thrombosis and Haemostasis*. 2014; 112(3):503-510
525. Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosencher N, Bandel TJ et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. *New England Journal of Medicine*. 2008; 358(26):2776-2786
526. Lassen MR, Bauer KA, Eriksson BI, Turpie AGG. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. *Lancet*. 2002; 359(9319):1715-1720
527. Lassen MR, Borris LC, Anderson BS, Jensen HP, Skejō Bro HP, Andersen G et al. Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) after total hip arthroplasty--the Danish Prolonged Prophylaxis (DaPP) Study. *Thrombosis Research*. 1998; 89(6):281-287
528. Lassen MR, Borris LC, Anderson BS, Jensen HP, Skejo Bro HP, Andersen G et al. Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) after total hip arthroplasty--the Danish Prolonged Prophylaxis (DaPP) Study. *Thrombosis Research*. 1998; 89(6):281-7
529. Lassen MR, Borris LC, Christiansen HM, Boll KL, Eiskjaer SP, Nielsen BW et al. Prevention of thromboembolism in 190 hip arthroplasties. Comparison of LMW heparin and placebo. *Acta Orthopaedica Scandinavica*. 1991; 62(1):33-38
530. Lassen MR, Borris LC, Christiansen HM, Møller-Larsen F, Knudsen VE, Boris P et al. Heparin/dihydroergotamine for venous thrombosis prophylaxis: comparison of low-dose



- heparin and low molecular weight heparin in hip surgery. *British Journal of Surgery*. 1988; 75(7):686-689
531. Lassen MR, Borris LC, Christiansen HM, Møller-Larsen F, Knudsen VE, Boris P et al. Prevention of thromboembolism in hip-fracture patients. Comparison of low-dose heparin and low-molecular-weight heparin combined with dihydroergotamine. *Archives of Orthopaedic and Trauma Surgery*. 1989; 108(1):10-13
532. Lassen MR, Davidson BL, Gallus A, Pineo G, Ansell J, Deitchman D. The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. *Journal of Thrombosis and Haemostasis*. 2007; 5(12):2368-75
533. Lassen MR, Fisher W, Mouret P, Agnelli G, George D, Kakkar A et al. Semuloparin for prevention of venous thromboembolism after major orthopedic surgery: results from three randomized clinical trials, SAVE-HIP1, SAVE-HIP2 and SAVE-KNEE. *Journal of Thrombosis and Haemostasis*. 2012; 10(5):822-832
534. Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LM et al. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. *New England Journal of Medicine*. 2010; 363(26):2487-2498
535. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P et al. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. *Lancet*. 2010; 375(9717):807-815
536. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Portman RJ. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. *New England Journal of Medicine*. 2009; 361(6):594-604
537. Lavitola P, Sampaio RO, Oliveira W, Boer BN, Tarasoutchi F, Spina GS et al. Warfarin or aspirin in embolism prevention in patients with mitral valvulopathy and atrial fibrillation. *Arquivos Brasileiros de Cardiologia*. 2010; 95(6):749-755
538. Lawrence JC, Xabregas A, Gray L, Ham JM. Seasonal variation in the incidence of deep vein thrombosis. *British Journal of Surgery*. 1977; 64(11):777-780
539. Lawton R. Graduated compression as an adjunct to pharmacoprophylaxis in surgery (GAPS): the issues of recruiting to a multicenter trial in venous thromboembolism prevention. *Journal of vascular surgery: venous and lymphatic disorders Conference: 2017 american venous forum annual meeting United states Conference start: 20170214 Conference end: 20170217*. 2017; 5(1):165
540. Le Gagneux F, Steg A, Le Guillou M. Subcutaneous enoxaparine (Lovenox) versus placebo for preventing deep vein thrombosis (DVT) after transurethral prostatectomy (TUP). *Thrombosis and Haemostasis*. 1987; 58:116
541. Le Gal G, Righini M, Roy PM, Sanchez O, Aujesky D, Bounameaux H et al. Prediction of pulmonary embolism in the emergency department: the revised Geneva score. *Annals of Internal Medicine*. 2006; 144(3):165-71
542. Lebeau B, Chastang C, Brechot JM, Capron F, Dautzenberg B, Delaisements C et al. Subcutaneous heparin treatment increases survival in small cell lung cancer. "Petites Cellules" Group. *Cancer*. 1994; 74(1):38-45
543. Leclerc JR, Geerts WH, Desjardins L, Jobin F, Laroche F, Delorme F et al. Prevention of deep vein thrombosis after major knee surgery -- a randomized, double-blind trial comparing a low



- ©
- molecular weight heparin fragment (enoxaparin) to placebo. *Thrombosis and Haemostasis*. 1992; 67(4):417-423
544. Leclerc JR, Geerts WH, Desjardins L, Laflamme GH, L'Espérance B, Demers C et al. Prevention of venous thromboembolism after knee arthroplasty. A randomized, double-blind trial comparing enoxaparin with warfarin. *Annals of Internal Medicine*. 1996; 124(7):619-626
545. Lecumberri R, Lopez VG, Font A, Gonzalez BE, Gurrpide A, Gomez CJ et al. Adjuvant therapy with bemiparin in patients with limited-stage small cell lung cancer: Results from the ABEL study. *Thrombosis Research*. 2013; 132(6):666-670
546. Lecumberri R, Panizo E, Gomez-Guiu A, Varea S, Garcia-Quetglas E, Serrano M et al. Economic impact of an electronic alert system to prevent venous thromboembolism in hospitalised patients. *Journal of Thrombosis and Haemostasis*. 2011; 9(6):1108-1115
547. Legnani C, Maccaferri M, Palareti G, Ludovici S, Guazzaloca G, Marabini A et al. Perioperative prophylaxis with a low molecular weight heparin reduces late PAI-1 levels after gynaecological surgery. *Fibrinolysis*. 1990; 4(4):241-245
548. Lenert LA, Soetikno RM. Automated computer interviews to elicit utilities: potential applications in the treatment of deep venous thrombosis. *Journal of the American Medical Informatics Association*. 1997; 4(1):49-56
549. Lenssen TA, van Steyn MJ, Crijns YH, Waltje EM, Roos GM, Geesink RJ et al. Effectiveness of prolonged use of continuous passive motion (CPM), as an adjunct to physiotherapy, after total knee arthroplasty. *BMC Musculoskeletal Disorders*. 2008; 9:60
550. Levine MN, Gent M, Hirsh J, Weitz J, Turpie AG, Powers P et al. Ardeparin (low-molecular-weight heparin) vs graduated compression stockings for the prevention of venous thromboembolism. A randomized trial in patients undergoing knee surgery. *Archives of Internal Medicine*. 1996; 156(8):851-856
551. Levine MN, Hirsh J, Gent M, Turpie AG, Leclerc J, Powers PJ et al. Prevention of deep vein thrombosis after elective hip surgery. A randomized trial comparing low molecular weight heparin with standard unfractionated heparin. *Annals of Internal Medicine*. 1991; 114(7):545-551
552. Levitan B, Yuan Z, Turpie AGG, Friedman RJ, Homering M, Berlin JA et al. Benefit-risk assessment of rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee arthroplasty. *Vascular Health and Risk Management*. 2014; 10:157-167
553. Li B, Wang K, Zhao X, Lin C, Sun H. Comparison of fondaparinux sodium and low molecular weight heparin in the treatment of hypercoagulability secondary to traumatic infection. *Chinese Journal of Traumatology*. 2015; 18(3):147-9
554. Li L, Geraghty OC, Mehta Z, Rothwell PM. Age-specific risks, severity, time course, and outcome of bleeding on long-term antiplatelet treatment after vascular events: a population-based cohort study. *Lancet*. 2017; 390(10093):490-499
555. Li S, Liu B, Xu D, Xu Y. Bleeding risk and mortality of edoxaban: a pooled meta-analysis of randomized controlled trials. *PLoS One*. 2014; 9(4):e95354
556. Li X-Y, Fan J, Cheng Y-Q, Wang Y, Yao C, Zhong N-S. Incidence and prevention of venous thromboembolism in acutely ill hospitalized elderly Chinese. *Chinese Medical Journal*. 2011; 124(3):335-340



557. Lieberman JR, Huo MM, Hanway J, Salvati EA, Sculco TP, Sharrock NE. The prevalence of deep venous thrombosis after total hip arthroplasty with hypotensive epidural anesthesia. *Journal of Bone and Joint Surgery*. 1994; 76(3):341-348
558. Lieberman JR, Pensak MJ. Prevention of venous thromboembolic disease after total hip and knee arthroplasty. *Journal of Bone and Joint Surgery (American Volume)*. 2013; 95(19):1801-1811
559. Liew A, Douketis J. 4 risk assessment models had good calibration but poor discrimination for VTE in hospitalized medical patients. *Annals of Internal Medicine*. 2016; 165(6):JC35
560. Liew AY, Piran S, Eikelboom JW, Douketis JD. Extended-duration versus short-duration pharmacological thromboprophylaxis in acutely ill hospitalized medical patients: a systematic review and meta-analysis of randomized controlled trials. *Journal of Thrombosis and Thrombolysis*. 2016; 30:30
561. Lim W, Meade M, Lauzier F, Zarychanski R, Mehta S, Lamontagne F et al. Failure of anticoagulant thromboprophylaxis: risk factors in medical-surgical critically ill patients. *Critical Care Medicine*. 2015; 43(2):401-410
562. Limmer J, Ellbruck D, Muller H, Eisele E, Rist J, Schutze F et al. Prospective randomized clinical study in general surgery comparing a new low molecular weight heparin with unfractionated heparin in the prevention of thrombosis. *Clinical Investigator*. 1994; 72(11):913-919
563. Lin FF, Lin CH, Chen B, Zheng K. Combination prophylaxis versus pharmacologic prophylaxis alone for preventing deep vein thrombosis in hip surgery. *Hip International*. 2016; 26(6):561-566
564. Lindqvist PG, Bremme K, Hellgren M. Efficacy of obstetric thromboprophylaxis and long-term risk of recurrence of venous thromboembolism. *Acta Obstetrica et Gynecologica Scandinavica*. 2011; 90(6):648-653
565. Lindqvist PG, Hellgren M. Obstetric thromboprophylaxis: the Swedish guidelines. *Advances in Hematology*. 2011; 2011:157483
566. Lindqvist PG, Kublikas M, Dahlback B. Individual risk assessment of thrombosis in pregnancy. *Acta Obstetrica et Gynecologica Scandinavica*. 2002; 81(5):412-6
567. Lindqvist PG, Torsson J, Almqvist A, Bjorgell O. Postpartum thromboembolism: severe events might be preventable using a new risk score model. *Vascular Health and Risk Management*. 2008; 4(5):1081-1087
568. Lip GYH, Merino J, Ezekowitz M, Ellenbogen K, Zamoryakhin D, Lanz H et al. A prospective evaluation of edoxaban compared to warfarin in subjects undergoing cardioversion of atrial fibrillation: The edoxaban vs. warfarin in subjects undergoing cardioversion of atrial fibrillation (ENSURE-AF) study. *American Heart Journal*. 2015; 169(5):597-604
569. Liu F, Chu X, Huang J, Tian K, Hua J, Tong P. Administration of enoxaparin 24 h after total knee arthroplasty: safer for bleeding and equally effective for deep venous thrombosis prevention. *Archives of Orthopaedic and Trauma Surgery*. 2014; 134(5):679-683
570. Liu X, Liu C, Chen X, Wu W, Lu G. Comparison between Caprini and Padua risk assessment models for hospitalized medical patients at risk for venous thromboembolism: a retrospective study. *Interactive Cardiovascular and Thoracic Surgery*. 2016; 23(4):538-43

571. Liu X, O'Rourke F, Van Nguyen H. Venous thromboembolism in psychogeriatric in-patients--a study of risk assessment, incidence, and current prophylaxis prescribing. *International Psychogeriatrics*. 2013; 25(6):913-7
572. Lobastov K, Barinov V, Laberko L, Obolensky V, Boyarintsev V, Rodoman G. Electrical calf muscle stimulation with Veinoplus device in postoperative venous thromboembolism prevention. *International Angiology*. 2014; 33(1):42-49
573. Locadia M, Bossuyt PM, Stalmeier PF, Sprangers MA, van Dongen CJ, Middeldorp S et al. Treatment of venous thromboembolism with vitamin K antagonists: patients' health state valuations and treatment preferences. *Thrombosis and Haemostasis*. 2004; 92(6):1336-41
574. Loew D, Bruecke P, Simma W. Acetylsalicylic acid, low dose heparin, and a combination of both substances in the prevention of postoperative thromboembolism: a double blind study. *Thrombosis Research*. 1977; 11(1):81-86
575. Loew D, Wellmer HK, Baer U, Merguet H, Rumpf P, Petersen H et al. Postoperative thromboembolie-prophylaxe mit acetylsalicylsaure. *Deutsche Medizinische Wochenschrift*. 1974; 99(12):565-572
576. Loffredo L, Perri L, Catasca E, Del BM, Angelico F, Violi F. Antithrombotic drugs in acutely ill medical patients: Review and meta-analysis of interventional trials with low-molecular-weight heparin and fondaparinux. *Clinical Practice*. 2013; 10(5):615-627
577. Loke YK, Kwok CS. Dabigatran and rivaroxaban for prevention of venous thromboembolism--systematic review and adjusted indirect comparison. *Journal of Clinical Pharmacy and Therapeutics*. 2011; 36(1):111-124
578. Lou J, Zhou YF, Wu MH, Huang JH. Effect of low-molecular heparin on therapeutic effect and renal function in patients with gastric cancer. *World chinese journal of digestology*. 2017; 25(3):276-280
579. Louis SG, Van PY, Riha GM, Barton JS, Kunio NR, Underwood SJ et al. Thromboelastogram-guided enoxaparin dosing does not confer protection from deep venous thrombosis: a randomized controlled pilot trial. *Journal of Trauma and Acute Care Surgery*. 2014; 76(4):937-3
580. Louzada ML, Carrier M, Lazo-Langner A, Dao V, Kovacs MJ, Ramsay TO et al. Development of a clinical prediction rule for risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism. *Circulation*. 2012; 126(4):448-54
581. Low-molecular-weight heparin better than unfractionated heparin for preventing DVT in medical patients. *Journal of the National Medical Association*. 2008; 100(1):151
582. Lowe LW. The role of anticoagulants in hip surgery. 'In:' McKibbin B, editor. *Recent advances in orthopaedics No 3*. Edinburgh: Churchill Livingstone. 1979. p. 31-55.
583. Lowe LW. Venous thrombosis and embolism. *Journal of Bone and Joint Surgery (British Volume)*. 1981; 63(2):155-167
584. Lu J-P, Knudson MM, Bir N, Kallet R, Atkinson K. Fondaparinux for prevention of venous thromboembolism in high-risk trauma patients: A pilot study. *Journal of the American College of Surgeons*. 2009; 209(5):589-594
585. Lubenow N, Hinz P, Thomaschewski S, Lietz T, Vogler M, Ladwig A et al. The severity of trauma determines the immune response to PF4/heparin and the frequency of heparin-induced thrombocytopenia. *Blood*. 2010; 115(9):1797-1803

586. Lunde L. Can EQ-5D and 15D be used interchangeably in economic evaluations? Assessing quality of life in post-stroke patients. *Eur J Health Econ.* 2013; 14(3):539-50
587. Lundkvist J, Bergqvist D, Jonsson B. Cost-effectiveness of fondaparinux vs. enoxaparin as venous thromboembolism prophylaxis in Sweden. *European Journal of Health Economics.* 2003; 4(4):254-262
588. Lyle B, Landercasper J, Johnson JM, Al-Hamadani M, Vang CA, Groshek J et al. Is the American College of Surgeons National Surgical Quality Improvement Program surgical risk calculator applicable for breast cancer patients undergoing breast-conserving surgery? *American Journal of Surgery.* 2016; 211(4):820-823
589. Lyman GH, Bohlke K, Khorana AA, Kuderer NM, Lee AY, Arcelus JI et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 2014. *Journal of Clinical Oncology.* 2015; 33(6):654-656
590. Lynd LD, Goeree R, Crowther MA, O'Brien BJ. A probabilistic cost-effectiveness analysis of enoxaparin versus unfractionated heparin for the prophylaxis of deep-vein thrombosis following major trauma. *Canadian Journal of Clinical Pharmacology.* 2007; 14(2):e215-e226
591. M.D. Anderson Cancer Center. Dalteparin for Primary Venous Thromboembolism (VTE) Prophylaxis in Pancreatic Cancer Patients. NCT00966277. 2013. Available from: <https://clinicaltrials.gov/show/NCT00966277> Last accessed: 28/06/17.
592. Ma G, Zhang R, Wu X, Wang D, Ying K. Direct factor Xa inhibitors (rivaroxaban and apixaban) versus enoxaparin for the prevention of venous thromboembolism after total knee replacement: A meta-analysis of 6 randomized clinical trials. *Thrombosis Research.* 2015; 135(5):816-822
593. Macatangay C, Todd SR, Tyroch AH. Thromboembolic prophylaxis with intermittent pneumatic compression devices in trauma patients: a false sense of security? *Journal of Trauma Nursing.* 2008; 15(1):12-15
594. Macbeth F, Noble S, Evans J, Ahmed S, Cohen D, Hood K et al. Randomized Phase III Trial of Standard Therapy Plus Low Molecular Weight Heparin in Patients With Lung Cancer: FRAGMATIC Trial. *Journal of Clinical Oncology.* 2016; 34(5):488-94
595. MacCallum PK, Thomson JM, Poller L. Effects of fixed minidose warfarin on coagulation and fibrinolysis following major gynaecological surgery. *Thrombosis and Haemostasis.* 1990; 64(4):511-515
596. Macht R, Gardner I, Talutis S, Rosenkranz P, Doherty G, McAneny D. Evaluation of a Standardized Risk-Based Venous Thromboembolism Prophylaxis Protocol in the Setting of Thyroid and Parathyroid Surgery. *Journal of the American College of Surgeons.* 2017; 01:01
597. MacIntyre IMC, Vasilescu C, Jones DRB. Heparin versus dextran in the prevention of deep-vein thrombosis. A multi-unit controlled trial. *Lancet.* 1974; 2(7873):118-120
598. Macoviak JA, Melnik G, McLean G. The effect of the low-dose heparin on the prevention of venous thrombosis in patients receiving short-term parenteral nutrition. *Current Surgery.* 1984; 41:98-100
599. Maestre A, Trujillo-Santos J, Riera-Mestre A, Jimenez D, Di Micco P, Bascunana J et al. Identification of low-risk patients with acute symptomatic pulmonary embolism for outpatient therapy. *Annals of the American Thoracic Society.* 2015; 12(8):1122-9



600. Mahan CE, Liu Y, Turpie AG, Vu JT, Heddle N, Cook RJ et al. External validation of a risk assessment model for venous thromboembolism in the hospitalised acutely-ill medical patient (VTE-VALOURR). *Thrombosis and Haemostasis*. 2014; 112(4):692-9
601. Manganelli D, Pazzagli M, Mazzantini D, Punzi G, Manca M, Vignali C et al. Prolonged prophylaxis with unfractionated heparin is effective to reduce delayed deep vein thrombosis in total hip replacement. *Respiration*. 1998; 65(5):369-374
602. Maniscalco P, Caforio M, Imberti D, Porcellini G, Benedetti R. Apixaban versus enoxaparin in elective major orthopedic surgery: A clinical review. *Clinical and Applied Thrombosis/Hemostasis*. 2015; 21(2):115-119
603. Manns BJ, Scott-Douglas N, Tonelli M, Ravani P, LeBlanc M, Dorval M et al. An economic evaluation of rt-PA locking solution in dialysis catheters. *Journal of the American Society of Nephrology*. 2014; 25(12):2887-95
604. Mannucci PM, Citterio LE, Panajotopoulos N. Low-dose heparin and deep-vein thrombosis after total hip replacement. *Thrombosis and Haemostasis*. 1976; 36(1):157-164
605. Mansfield AS, Tafur AJ, Wang CE, Kourelis TV, Wysokinska EM, Yang P. Predictors of active cancer thromboembolic outcomes: validation of the Khorana score among patients with lung cancer. *Journal of Thrombosis and Haemostasis*. 2016; 14(9):1773-8
606. Manson JE. Current recommendations: what is the clinician to do? *Fertility and Sterility*. 2014; 101(4):916-21
607. Maraveyas A, Ettelaie C, Echrish H, Li C, Gardiner E, Greenman J et al. Weight-adjusted dalteparin for prevention of vascular thromboembolism in advanced pancreatic cancer patients decreases serum tissue factor and serum-mediated induction of cancer cell invasion. *Blood Coagulation and Fibrinolysis*. 2010; 21(5):452-458
608. Maraveyas A, Waters J, Roy R, Fyfe D, Propper D, Lofts F et al. Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer. *European Journal of Cancer*. 2012; 48(9):1283-1292
609. Marchetti M, Pistorio A, Barone M, Serafini S, Barosi G. Low-molecular-weight heparin versus warfarin for secondary prophylaxis of venous thromboembolism: a cost-effectiveness analysis. *American Journal of Medicine*. 2001; 111(2):130-139
610. Marchetti V, Beati C, Pogliani EM, Vincre G. Low-dose calcium-heparin prophylaxis in thoracic surgery. Bleeding, changes in coagulation and fibrinolysis. *Minerva Medica*. 1983; 74(28-29):1745-1748
611. Marcy TR, Truong T, Rai A. Comparing Direct Oral Anticoagulants and Warfarin for Atrial Fibrillation, Venous Thromboembolism, and Mechanical Heart Valves. *Consultant Pharmacist*. 2015; 30(11):644-56
612. Mariani F, Marone EM, Gasbarro V, Bucalossi M, Spelta S, Amsler F et al. Multicenter randomized trial comparing compression with elastic stocking versus bandage after surgery for varicose veins. *Journal of Vascular Surgery*. 2011; 53(1):115-122
613. Maurer LH, Herndon IJ, Hollis DR, Aisner J, Carey RW, Skarin AT. Randomized trial of chemotherapy and radiation therapy with or without warfarin for limited-stage small-cell lung cancer: a Cancer and Leukemia Group B study. *Journal of Clinical Oncology*. 1997; 15(11):3378-3387

614. Maynard GA, Morris TA, Jenkins IH, Stone S, Lee J, Renvall M et al. Optimizing prevention of hospital-acquired venous thromboembolism (VTE): prospective validation of a VTE risk assessment model. *Journal of Hospital Medicine (Online)*. 2010; 5(1):10-8
615. Mayor S. Older patients should take PPIs to cut risk of bleed from aspirin, study says. *BMJ*. 2017; 357:j2865
616. McAlister FA, Wiebe N, Jun M, Sandhu R, James MT, McMurtry MS et al. Are existing risk scores for nonvalvular atrial fibrillation useful for prediction or risk adjustment in patients with chronic kidney disease? *Canadian Journal of Cardiology*. 2017; 33(2):243-252
617. McAlpine K, Breau RH, Mallick R, Clossen S, Cagiannos I, Morash C et al. Current guidelines do not sufficiently discriminate venous thromboembolism risk in urology. *Urologic Oncology*. 2017; 14:14
618. McBride JA, Turpie AG, Kraus V, Hilz C. Failure of aspirin and dipyridamole to influence the incidence of leg scan detected venous thrombosis after elective hip surgery. *Thrombosis et Diathesis Haemorrhagica*. 1975; 34(2):564
619. McCaffrey R, Bishop M, Adonis-Rizzo M, Williamson E, McPherson M, Cruikshank A et al. Development and testing of a DVT risk assessment tool: providing evidence of validity and reliability. *Worldviews on Evidence-Based Nursing*. 2007; 4(1):14-20
620. McCullagh L, Tilson L, Walsh C, Barry M. A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the Irish healthcare setting. *Pharmacoeconomics*. 2009; 27(10):829-846
621. McCullagh L, Walsh C, Barry M. Value-of-information analysis to reduce decision uncertainty associated with the choice of thromboprophylaxis after total hip replacement in the Irish healthcare setting. *Pharmacoeconomics*. 2012; 30(10):941-959
622. McDonald H, Diamantopoulos A, Wells P, Lees M, Folkerts K, Forster F et al. Cost-effectiveness of rivaroxaban in the prevention of venous thromboembolism: a Canadian analysis using the Ontario Ministry of Health perspective. *Journal of Medical Economics*. 2012; 15(5):817-828
623. McGoldrick DM, Redmond HP. Venous thromboembolism prophylaxis risk assessment in a general surgery cohort: a closed-loop audit. *Irish Journal of Medical Science*. 2016:1-3
624. McKenna R, Galante J, Bachmann F, Wallace DL, Kaushal PS, Meredith P. Prevention of venous thromboembolism after total knee replacement by high-dose aspirin or intermittent calf and thigh compression. *British Medical Journal*. 1980; 280(6213):514-517
625. McLean S, Ryan K, O'Donnell JS. Primary thromboprophylaxis in the palliative care setting: a qualitative systematic review. *Palliative Medicine*. 2010; 24(4):386-395
626. McLintock C, Brighton T, Chunilal S, Dekker G, McDonnell N, McRae S et al. Recommendations for the prevention of pregnancy-associated venous thromboembolism. *Australian and New Zealand Journal of Obstetrics and Gynaecology*. 2012; 52(1):3-13
627. Meads DM, McKenna SP, Doughty N, Das C, Gin-Sing W, Langley J et al. The responsiveness and validity of the CAMPHOR Utility Index. *European Respiratory Journal*. 2008; 32(6):1513-9
628. Mearns BM. Thrombosis: a new scoring system for simple risk prediction in patients with unprovoked venous thromboembolism. *Nature Reviews Cardiology*. 2010; 7(6):299



629. Mega JL, Braunwald E, Mohanavelu S, Burton P, Poulter R, Misselwitz F et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. *Lancet*. 2009; 374(9683):29-38
630. Meizoso JP, Karcutskie CA, Ray JJ, Ruiz X, Ginzburg E, Namias N et al. A simplified stratification system for venous thromboembolism risk in severely injured trauma patients. *Journal of Surgical Research*. 2017; 207:138-144
631. Melillo SN, Scanlon JV, Exter BP, Steinberg M, Jarvis C. Rivaroxaban for thromboprophylaxis in patients undergoing major orthopedic surgery. *Annals of Pharmacotherapy*. 2010; 44(6):1061-1071
632. Mellbring G, Palmér K. Prophylaxis of deep vein thrombosis after major abdominal surgery. Comparison between dihydroergotamine-heparin and intermittent pneumatic calf compression and evaluation of added graduated static compression. *Acta Chirurgica Scandinavica*. 1986; 152:597-600
633. Melon E, Keravel Y, Gaston A, Huet Y, Combes S, Group N. Deep venous thrombosis prophylaxis by low molecular weight heparin in neurosurgical patients. *Anesthesiology*. 1991; 75:A214
634. Messori A, Fadda V, Maratea D, Trippoli S, Marinai C. Testing the therapeutic equivalence of novel oral anticoagulants for thromboprophylaxis in orthopedic surgery and for prevention of stroke in atrial fibrillation. *International Journal of Clinical Pharmacology and Therapeutics*. 2015; 53(3):211-219
635. Metzger A, Nagaraj T. New oral anticoagulants: clinical parameters and uses in practice. *Consultant Pharmacist*. 2015; 30(6):329-345
636. Meyer G, Sanchez O, Jimenez D. Risk assessment and management of high and intermediate risk pulmonary embolism. *Presse Medicale*. 2015; 44(12 Pt 2):e401-8
637. Michot M, Conen D, Holtz D, Erni D, Zumstein MD, Ruffin GB et al. Prevention of deep-vein thrombosis in ambulatory arthroscopic knee surgery: A randomized trial of prophylaxis with low-molecular weight heparin. *Arthroscopy*. 2002; 18(3):257-263
638. Migliaccio-Walle K, Rublee D, Simon TA. Anticoagulation prophylaxis in orthopedic surgery: an efficiency frontier approach. *Postgraduate Medicine*. 2012; 124(1):41-49
639. Mihaljevic Z, Dimnjakovic D, Tripkovic B, Buljan M, Aljinovic A, Delimar D et al. Influence of fondaparinux versus nadroparin calcium thromboprophylaxis on clinical parameters following total knee arthroplasty. *Acta Clinica Croatica*. 2016; 55(3):414-420
640. Millar JA, Gee AL. Estimation of clinical and economic effects of prophylaxis against venous thromboembolism in medical patients, including the effect of targeting patients at high-risk. *Internal Medicine Journal*. 2016; 46(3):315-24
641. Mirdamadi A, Dashtkar S, Kaji M, Pazhang F, Haghpanah B, Gharipour M. Dabigatran versus Enoxaparin in the prevention of venous thromboembolism after total knee arthroplasty: A randomized clinical trial. *ARYA Atherosclerosis*. 2014; 10(6):292-297
642. Mirhosseini SJ, Forouzannia SK, Mostafavi Pour Manshadi SMY, Ali-Hassan-Sayegh S, Naderi N, Sanatkar M. Comparison of aspirin plus heparin with heparin alone on asymptomatic perioperative deep vein thrombosis in candidates for elective off-pump coronary artery bypass graft: a randomized clinical trial. *Cardiology Journal*. 2013; 20(2):139-143

643. Miron MJ, Perrier A, Bounameaux H. Clinical assessment of suspected deep vein thrombosis: comparison between a score and empirical assessment. *Journal of Internal Medicine*. 2000; 247(2):249-54
644. Mismetti P, Laporte-Simitsidis S, Tardy B, Cucherat M, Buchmüller A, Juillard-Delsart D et al. Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular-weight heparins: a meta-analysis of randomised clinical trials. *Thrombosis and Haemostasis*. 2000; 83(1):14-19
645. Mismetti P, Laporte S, Darmon JY, Buchmuller A, Decousus H. Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. *British Journal of Surgery*. 2001; 88(7):913-930
646. Mismetti P, Laporte S, Zufferey P, Epinat M, Decousus H, Cucherat M. Prevention of venous thromboembolism in orthopedic surgery with vitamin K antagonists: a meta-analysis. *Journal of Thrombosis and Haemostasis : JTH*. 2004; 2(7):1058-1070
647. Mitchell L, Andrew M, Hanna K, Abshire T, Halton J, Wu J et al. Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l-asparaginase for acute lymphoblastic leukemia. Results of the PAARKA study. *Thrombosis and Haemostasis*. 2003; 90(2):235-44
648. Mockler A, O'Brien B, Emed J, Ciccotosto G. The experience of patients with cancer who develop venous thromboembolism: an exploratory study. *Oncology Nursing Forum*. 2012; 39(3):E233-40
649. Modi S, Deisler R, Gozel K, Reicks P, Irwin E, Brunsvold M et al. Wells criteria for DVT is a reliable clinical tool to assess the risk of deep venous thrombosis in trauma patients. *World Journal of Emergency Surgery*. 2016; 11:24
650. Mokhtari M, Attarian H, Norouzi M, Kouchek M, Kashani BS, Sirati F et al. Venous thromboembolism risk assessment, prophylaxis practices and interventions for its improvement (AVAIL-ME Extension Project, Iran). *Thrombosis Research*. 2014; 133(4):567-73
651. Monreal M, Folkerts K, Diamantopoulos A, Imberti D, Brosa M. Cost-effectiveness impact of rivaroxaban versus new and existing prophylaxis for the prevention of venous thromboembolism after total hip or knee replacement surgery in France, Italy and Spain. *Thrombosis and Haemostasis*. 2013; 110(5)
652. Monreal M, Lafoz E, Roca J, Granero X, Soler J, Salazar X et al. Platelet count, antiplatelet therapy and pulmonary embolism -- a prospective study in patients with hip surgery. *Thrombosis and Haemostasis*. 1995; 73(3):380-385
653. Morgan ES, Wilson E, Watkins T, Gao F, Hunt BJ. Maternal obesity and venous thromboembolism. *International Journal of Obstetric Anesthesia*. 2012; 21(3):253-63
654. Morimoto A, Ueda Y, Yokoi T, Tokizawa Y, Yoshino K, Fujita M et al. Perioperative venous thromboembolism in patients with gynecological malignancies: a lesson from four years of recent clinical experience. *Anticancer Research*. 2014; 34(7):3589-3595
655. Morris GK, Mitchell JR. Preventing venous thromboembolism in elderly patients with hip fractures: studies of low-dose heparin, dipyridamole, aspirin, and flurbiprofen. *British Medical Journal*. 1977; 1(6060):535-537
656. Morris RJ, Woodcock JP. Intermittent pneumatic compression or graduated compression stockings for deep vein thrombosis prophylaxis? A systematic review of direct clinical comparisons. *Annals of Surgery*. 2010; 251(3):393-396



657. Moskovitz PA, Ellenberg SS, Feffer HL, Kenmore P, I, Neviasser RJ, Rubin BE et al. Low-dose heparin for prevention of venous thromboembolism in total hip arthroplasty and surgical repair of hip fractures. *Journal of Bone and Joint Surgery*. 1978; 60(8):1065-1070
658. Mozafar M, Samsami M, Sobhiyeh MR, Jabbehdari S, Fallah Zavareh M. Effectiveness of aspirin on double lumen permanent catheter efficacy in ESRD. *Nephrourol Mon*. 2013; 5(2):762-5
659. Mueller K, Bernaitis N, Badrick T, Anoopkumar-Dukie S. HAS-BLED Predicts Warfarin Control in Australian Patients treated for Deep Vein Thrombosis. *Basic & Clinical Pharmacology & Toxicology*. 2016; 08:08
660. Muir KW. The PREVAIL trial and low-molecular-weight heparin for prevention of venous thromboembolism. *Stroke*. 2008; 39(7):2174-2176
661. Murugesan A, Srivastava DN, Ballehaninna UK, Chumber S, Dhar A, Misra MC et al. Detection and prevention of post-operative deep vein thrombosis [DVT] using nadroparin among patients undergoing major abdominal operations in India; a randomised controlled trial. *Indian Journal of Surgery*. 2010; 72(4):312-317
662. Myhre HO, Holen A. Thrombosis prophylaxis. Dextran or warfarin-sodium? A controlled clinical study. *Nordisk Medicin*. 1969; 82(49):1534-1538
663. Naccarato M, Chiodo GF, Dennis M, Sandercock Peter AG. Physical methods for preventing deep vein thrombosis in stroke. *Cochrane Database of Systematic Reviews* 2010, Issue 8. Art. No.: CD001922. DOI: 10.1002/14651858.CD001922.pub3.
664. Nakase J, Toribatake Y, Mouri Y, Seki H, Kitaoka K, Tomita K. Heparin versus danaproid for prevention of venous thromboembolism after hip surgery. *Journal of Orthopaedic Surgery*. 2009; 17(1):6-9
665. Nam D, Nunley RM, Johnson SR, Keeney JA, Clohisy JC, Barrack RL. The Effectiveness of a Risk Stratification Protocol for Thromboembolism Prophylaxis After Hip and Knee Arthroplasty. *Journal of Arthroplasty*. 2016; 31(6):1299-306
666. National Clinical Guideline Centre. Venous thromboembolism: reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) inpatients admitted to hospital. NICE clinical guideline 92. London. National Clinical Guideline Centre, 2010. Available from: <http://www.nice.org.uk/CG92>
667. National Clinical Guideline Centre. Lower limb peripheral arterial disease: Diagnosis and management. NICE clinical guideline 147. London. National Clinical Guideline Centre, 2012. Available from: <http://guidance.nice.org.uk/CG147>
668. National Clinical Guideline Centre. Venous thromboembolic diseases: the management of venous thromboembolic diseases and the role of thrombophilia testing. NICE clinical guideline 144. London. National Clinical Guideline Centre, 2012. Available from: <http://guidance.nice.org.uk/CG144>
669. National Clinical Guideline Centre. Type 1 diabetes in adults: diagnosis and management. NICE guideline 17. London. National Clinical Guideline Centre, 2015. Available from: <https://www.nice.org.uk/guidance/ng17>
670. National Collaborating Centre for Acute Care. Reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in inpatients undergoing surgery. NICE clinical guideline CG46. London. National Institute for Health and Clinical Excellence, 2007. Available from: <http://guidance.nice.org.uk/CG46>



671. National Horizon Scanning Centre. Rivaroxaban (Xarelto) for prevention of venous thromboembolism in medically ill patients. Birmingham. National Horizon Scanning Centre (NHSC), 2010. Available from: <http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32010001209/frame.html>
672. National Horizon Scanning Centre (NHSC). Apixaban for prevention of venous thromboembolism after joint replacement or with acute medical illness. (NHSC) NHSC, 2008. Available from: <http://www.hsric.nihr.ac.uk/topics/apixaban-bms-562247-01-for-venous-thromboembolism-prevention-after-joint-replacement-and-acute-medical-illness/>
673. National Institute for Health and Care Excellence. Developing NICE guidelines: the manual. London. National Institute for Health and Care Excellence, 2014. Available from: <http://www.nice.org.uk/article/PMG20/chapter/1%20Introduction%20and%20overview>
674. National Institute for Health and Care Excellence. Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism. NICE technology appraisal guidance 354. London. National Institute for Health and Care Excellence, 2015. Available from: <https://www.nice.org.uk/guidance/ta354/resources/edoxaban-for-treating-and-for-preventing-deep-vein-thrombosis-and-pulmonary-embolism-82602668308165>
675. National Institute for Health and Clinical Excellence. Dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults. NICE technology appraisal guidance 157. London. National Institute for Health and Clinical Excellence, 2008. Available from: <http://guidance.nice.org.uk/TA157>
676. National Institute for Health and Clinical Excellence. Social value judgements: principles for the development of NICE guidance. 2nd ed. London. National Institute for Health and Clinical Excellence, 2008. Available from: <https://www.nice.org.uk/media/default/about/what-we-do/research-and-development/social-value-judgements-principles-for-the-development-of-nice-guidance.pdf>
677. National Institute for Health and Clinical Excellence. Rivaroxaban for the prevention of venous thromboembolism. NICE technology appraisal guidance 170. London. National Institute for Health and Clinical Excellence, 2009. Available from: <http://guidance.nice.org.uk/TA170>
678. National Institute for Health and Clinical Excellence. Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adults. NICE technology appraisal guidance 245. London. National Institute for Health and Clinical Excellence, 2012. Available from: <http://guidance.nice.org.uk/TA245>
679. Navarro LM, Trufelli DC, Bonito DR, Del Giglio A, Bollmann PW. Application of Prognostic Score IPSET-thrombosis In patients with essential thrombocythemia of a brazilian public service. *Revista da Associacao Medica Brasileira*. 2016; 62(7):647-651
680. Nemeth B, van Adrichem RA, van Hylckama Vlieg A, Bucciarelli P, Martinelli I, Baglin T et al. Venous thrombosis risk after cast immobilization of the lower extremity: derivation and validation of a clinical prediction score, L-TRIP(cast), in three population-based case-control studies. *PLoS Medicine*. 2015; 12(11):e1001899; discussion e1001899
681. Nendaz MR, Bandelier P, Aujesky D, Cornuz J, Roy PM, Bounameaux H et al. Validation of a risk score identifying patients with acute pulmonary embolism, who are at low risk of clinical adverse outcome. *Thrombosis and Haemostasis*. 2004; 91(6):1232-6
682. NHS Business Services Authority. NHS electronic drug tariff June 2016. 2015. Available from: <http://www.nhsbsa.nhs.uk/PrescriptionServices/4940.aspx> Last accessed: 09/08/2017.



683. NHS Digital. Finalised Patient Reported Outcome Measures (PROMs) in England: April 2014 to March 2015. NHS Digital, 2016. Available from: <http://content.digital.nhs.uk/catalogue/PUB21189>
684. NHS Supply Chain Catalogue. Chain NS, 2015. Available from: <http://www.supplychain.nhs.uk/>
685. NHS Supply Chain Catalogue. 2015. Available from: <http://www.supplychain.nhs.uk/> Last accessed: 22/08/2016.
686. Nicolaidis AN, Dupont PA, Desai S, Lewis JD, Douglas JN, Dodsworth H et al. Small doses of subcutaneous sodium heparin in preventing deep venous thrombosis after major surgery. *Lancet*. 1972; 2(7783):890-893
687. Nieto JA, Solano R, Trapero Iglesias N, Ruiz-Gimenez N, Fernandez-Capitan C, Valero B et al. Validation of a score for predicting fatal bleeding in patients receiving anticoagulation for venous thromboembolism. *Thrombosis Research*. 2013; 132(2):175-9
688. Nighoghossian N, Berthezene Y, Mechtouff L, Derex L, Cho TH, Ritzenthaler T et al. Cyclosporine in acute ischemic stroke. *Neurology*. 2015; 84(22):2216-2223
689. NIHR Horizon Scanning Centre (NIHR HSC). Apixaban (Eliquis) for the treatment and prevention of venous thromboembolic events. Birmingham. NIHR Horizon Scanning Centre (NIHR HSC), 2013. Available from: <http://www.hsrc.nihr.ac.uk/topics/apixaban-eliquis-for-the-treatment-and-long-term-prevention-of-deep-vein-thrombosis-and-pulmonary-embolism/>
690. NIHR Horizon Scanning Centre (NIHR HSC). Betrixaban for the prevention of venous thromboembolism ? first line. Birmingham. NIHR Horizon Scanning Centre (NIHR HSC), 2014. Available from: [file:///C:/Users/clairewallnutt/Downloads/2671.05e728c7.Betrixaban\\_Sept14.pdf](file:///C:/Users/clairewallnutt/Downloads/2671.05e728c7.Betrixaban_Sept14.pdf)
691. Ning GZ, Kan SL, Chen LX, Shangguan L, Feng SQ, Zhou Y. Rivaroxaban for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis with trial sequential analysis of randomized controlled trials. *Scientific Reports*. 2016; 6:23726
692. Noble S, Lewis R, Whithers J, Lewis S, Bennett P. Long-term psychological consequences of symptomatic pulmonary embolism: a qualitative study. *BMJ Open*. 2014; 4(4):e004561
693. Noble S, Maraveyas A, Matzdorff A, Holm MV, Pisa G. Patients' preferences for the treatment of cancer associated thrombosis. *Journal of Thrombosis and Haemostasis*. 2015; 13:548-549
694. Noble S, Matzdorff A, Maraveyas A, Holm MV, Pisa G. Assessing patients' anticoagulation preferences for the treatment of cancer-associated thrombosis using conjoint methodology. *Haematologica*. 2015; 100(11):1486-92
695. Noble S, Prout H, Nelson A. Patients' Experiences of Living with CANcer-associated thrombosis: The PELICAN study. *Patient Preference and Adherence*. 2015; 9:337-345
696. Noble S, Seaman S, Nelson A. Attitudes of cancer associated thrombosis patients to the novel oral anticoagulants: Insights from qualitative interviews. *Thrombosis Research*. 2014; 133:S219
697. Noble S, Seaman S, Nelson A. The burden of venous thromboembolism on the cancer patient experience: A qualitative study. *Thrombosis Research*. 2014; 133:S212-S213

698. Noble SIR, Nelson A, Finlay IG. Factors influencing hospice thromboprophylaxis policy: A qualitative study. *Palliative Medicine*. 2008; 22(7):808-813
699. Nordenholz KE, Thompson E, Trujillo T, Misky G. Qualitative follow up of emergency department (ED) patients discharged on rivaroxaban for low risk venous thromboembolism. *Journal of Thrombosis and Haemostasis*. 2015; 13:644
700. Norgren L, S. T-L, Magyar G, Lindstrand A, Albrechtsson U. Prevention of deep vein thrombosis in knee arthroplasty. Preliminary results from a randomized controlled study of low molecular weight heparin vs foot pump compression. *International Angiology*. 1998; 17(2):93-96
701. Novis SJ, Havelka GE, Ostrowski D, Levin B, Blum-Eisa L, Prystowsky JB et al. Prevention of thromboembolic events in surgical patients through the creation and implementation of a computerized risk assessment program. *Journal of Vascular Surgery*. 2010; 51(3):648-54
702. Nurmohamed MT, van Riel AM, Henkens CM, Koopman MM, Que GT, d'Azemar P et al. Low molecular weight heparin and compression stockings in the prevention of venous thromboembolism in neurosurgery. *Thrombosis and Haemostasis*. 1996; 75(2):233-238
703. Nurmohamed MT, Verhaeghe R, Haas S, Iriarte JA, Vogel G, van Rij AM et al. A comparative trial of a low molecular weight heparin (enoxaparin) versus standard heparin for the prophylaxis of postoperative deep vein thrombosis in general surgery. *American Journal of Surgery*. 1995; 169(6):567-71
704. O'Connor C, Moriarty J, Walsh J, Murray J, Coulter-Smith S, Boyd W. The application of a clinical risk stratification score may reduce unnecessary investigations for pulmonary embolism in pregnancy. *Journal of Maternal-Fetal & Neonatal Medicine*. 2011; 24(12):1461-4
705. O'Sullivan EF, Renney JT. Antiplatelet drugs in the prevention of postoperative deep vein thrombosis. *Proceedings of III Congress of International Society for Thrombosis and Haemostasis (Washington)*. 1972. p. 438.
706. Obi AT, Alvarez R, Reames BN, Moote MJ, Thompson MA, Wakefield TW et al. A prospective evaluation of standard versus battery-powered sequential compression devices in postsurgical patients. *American Journal of Surgery*. 2015; 209(4):675-681
707. Obolenskiy VN, Karpenko AV. Efficacy of electrical muscle stimulation in the treatment of patients with shin bone fractures. *Wound Medicine*. 2014; 5:25-28
708. Office for National Statistics. 'Average' Briton highlighted on UN World Statistics Day. Office for National Statistics. Available from: <https://www.google.co.uk/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&ved=0ahUKEwih1-mazv7UAhVBDMAKHcuABxQQFggpMAA&url=https%3A%2F%2Fwww.ons.gov.uk%2Fons%2Fabout-ons%2Fget-involved%2Fevents%2Fevents%2Fun-world-statistics-day%2F-average--briton-highlighted-on-un-world-statistics-day.pdf&usq=AFQjCNGiyo3NVKsSFZ8tV6sYiYtVWQPd2w>
709. Okoye O, Gelbard R, Inaba K, Esparza M, Belzberg H, Talving P et al. Dalteparin versus Enoxaparin for the prevention of venous thromboembolic events in trauma patients. *European Journal of Trauma and Emergency Surgery*. 2014; 40(2):183-189
710. Okumus G, Engin Unver R, Kiyan E, Tabak L, Issever H, Arseven O. Comparison of three clinical scoring methods in patients with pulmonary thromboembolism. *Tuberkuloz ve Toraks*. 2009; 57(2):163-8

711. Olesen JB, Lip GY, Hansen ML, Hansen PR, Tolstrup JS, Lindhardsen J et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. *BMJ*. 2011; 342:d124
712. Olesen JB, Lip GY, Lane DA, Kober L, Hansen ML, Karasoy D et al. Vascular disease and stroke risk in atrial fibrillation: a nationwide cohort study. *American Journal of Medicine*. 2012; 125(8):826.e13-23
713. Ollenberger GP, Worsley DF. Effect of patient location on the performance of clinical models to predict pulmonary embolism. *Thrombosis Research*. 2006; 118(6):685-90
714. Ongen G, Demir M, Molinas N, Ince B, Ongen Z. Evaluation of the practice pattern of medical patients' VTE Prophylaxis with a standard risk assessment model form: MERAM study. *Clinical and Applied Thrombosis/Hemostasis*. 2015; 21(5):412-9
715. Organisation for Economic Co-operation and Development (OECD). Purchasing power parities (PPP). 2012. Available from: <http://www.oecd.org/std/ppp> Last accessed: 09/05/2016.
716. Orken DN, Kenangil G, Ozkurt H, Guner C, Gundogdu L, Basak M et al. Prevention of deep venous thrombosis and pulmonary embolism in patients with acute intracerebral hemorrhage. *Neurologist*. 2009; 15(6):329-331
717. Overcash RT, Somers AT, Lacoursiere DY. Enoxaparin dosing after cesarean delivery in morbidly obese women. *Obstetrics and Gynecology*. 2015; 125(6):1371-1376
718. Oz N, Alon D, Chezar-Azerrad C, Cooper L, Levi Y, Fuchs S et al. Estimating Risk of Venous-Thromboembolic Events in Hospitalized Medical Patients: Comparison between 2008 and 2012 Guidelines. *Israel Medical Association Journal: Imaj*. 2016; 18(6):346-9
719. Ozler T, Ulucay C, Onal A, Altintas F. Comparison of switch-therapy modalities (enoxaparin to rivaroxaban/dabigatran) and enoxaparin monotherapy after hip and knee replacement. *Acta Orthopaedica et Traumatologica Turcica*. 2015; 49(3):255-259
720. Paciaroni M, Ageno W, Agnelli G. Prevention of venous thromboembolism after acute spinal cord injury with low-dose heparin or low-molecular-weight heparin. *Thrombosis and Haemostasis*. 2008; 99(5):978-980
721. Pai M, Lloyd NS, Cheng J, Thabane L, Spencer FA, Cook DJ et al. Strategies to enhance venous thromboprophylaxis in hospitalized medical patients (SENTRY): a pilot cluster randomized trial. *Implementation Science*. 2013; 8:1
722. Paiement GD, Wessinger SJ, Walter AC, Harris WH. Low dose warfarin versus external pneumatic compression against venous thromboembolism following total hip replacement. *Journal of Arthroplasty*. 1987; 2(1):23-26
723. Palareti G, Borghi B, Coccheri S, Leali N, Golfieri R, Montebugnoli M et al. Postoperative versus preoperative initiation of deep-vein thrombosis prophylaxis with a low-molecular-weight heparin (Nadroparin) in elective hip replacement. *Clinical and Applied Thrombosis/Hemostasis*. 1996; 2(1):18-24
724. Palumbo A, Cavo M, Bringhen S, Zamagni E, Romano A, Patriarca F et al. Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. *Journal of Clinical Oncology*. 2011; 29(8):986-993



725. Pannucci C, Laird S, Campbell D, Dimick J, Henke P. Creation of a Simple VTE Risk Stratification Tool for Inpatient Surgical Procedures. *Journal of Vascular Surgery*. 2013; 1(1):101-2
726. Pannucci CJ, Bailey SH, Dreszer G, Fisher Wachtman C, Zumsteg JW, Jaber RM et al. Validation of the Caprini risk assessment model in plastic and reconstructive surgery patients. *Journal of the American College of Surgeons*. 2011; 212(1):105-12
727. Pannucci CJ, Barta RJ, Portschy PR, Dreszer G, Hoxworth RE, Kalliainen LK et al. Assessment of postoperative venous thromboembolism risk in plastic surgery patients using the 2005 and 2010 Caprini risk score. *Plastic and Reconstructive Surgery*. 2012; 130(2):343-53
728. Pannucci CJ, Basta MN, Fischer JP, Kovach SJ. Creation and validation of a condition-specific venous thromboembolism risk assessment tool for ventral hernia repair. *Surgery*. 2015; 158(5):1304-13
729. Pannucci CJ, Swistun L, MacDonald JK, Henke PK, Brooke BS. Individualized venous thromboembolism risk stratification using the 2005 Caprini score to identify the benefits and harms of chemoprophylaxis in surgical patients: a meta-analysis. *Annals of Surgery*. 2017; Epublication
730. Parilla BV, Fournogerakis R, Archer A, Sulo S, Laurent L, Lee P et al. Diagnosing pulmonary embolism in pregnancy: are biomarkers and clinical predictive models useful? *American Journal of Perinatology Reports*. 2016; 6(2):e160-4
731. Parodi JC, Grandi A, Font E, Rotondaro D, Iorio J, Manrique J. El dipiridamol y el acido acetilsalicilico en la profilaxis de las trombosis venosas postoperatorias de los miembros inferiores. *Dia Medico*. 1973; 45:92-93
732. Patel AA, Nelson WW, Schein J. Impact of CHA<sub>2</sub>DS<sub>2</sub>-VASc Score on Candidacy for Anticoagulation in Patients With Atrial Fibrillation: A Multi-payer Analysis. *Clinical Therapeutics*. 2016; 38(10):2196-2203
733. Patel AR, Crist MK, Nemitz J, Mayerson JL. Aspirin and compression devices versus low-molecular-weight heparin and PCD for VTE prophylaxis in orthopedic oncology patients. *Journal of Surgical Oncology*. 2010; 102(3):276-281
734. Patel N, Khakha R, Gibbs J. Review article: Anti-embolism stockings. *Journal of Orthopaedic Surgery*. 2013; 21(3):361-364
735. Pathak R, Karmacharya P, Giri S, Poudel DR, Aryal MR, Bhatt VR et al. Meta-analysis on efficacy and safety of new oral anticoagulants for venous thromboembolism prophylaxis in overweight and obese postarthroplasty patients. *Blood Coagulation and Fibrinolysis*. 2015; 26(6):635-642
736. Pathak R, Pandit A, Karmacharya P, Aryal MR, Ghimire S, Poudel DR et al. Meta-analysis on risk of bleeding with apixaban in patients with renal impairment. *American Journal of Cardiology*. 2015; 115(3):323-327
737. Pavon JM, Williams JW, Jr., Adam SS, Razouki ZA, McDuffie JR, Lachiewicz PF et al. Effectiveness of intermittent pneumatic compression devices for venous thromboembolism prophylaxis in high-risk surgical and medical patients. Durham, NC. Evidence-based Synthesis Program (ESP) Center, 2015. Available from: [http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0084045/pdf/PubMedHealth\\_PMH0084045.pdf](http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0084045/pdf/PubMedHealth_PMH0084045.pdf)



738. Pebanco GD, Kaiser SA, Haines ST. New pharmacologic methods to prevent venous thromboembolism in older adults: a meta-analysis. *Annals of Pharmacotherapy*. 2013; 47(5):605-616
739. Penalzoza A, Melot C, Motte S. Comparison of the Wells score with the simplified revised Geneva score for assessing pretest probability of pulmonary embolism. *Thrombosis Research*. 2011; 127(2):81-4
740. Pengo V, Banzato A, Bison E, Zoppellaro G, Padayattil Jose S, Denas G. Efficacy and safety of rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome: Rationale and design of the Trial on Rivaroxaban in AntiPhospholipid Syndrome (TRAPS) trial. *Lupus*. 2016; 25(3):301-6
741. Perka C. Preoperative versus postoperative initiation of thromboprophylaxis following major orthopedic surgery: Safety and efficacy of postoperative administration supported by recent trials of new oral anticoagulants. *Thrombosis Journal*. 2011; 16(9):17
742. Pettila V, Kaaja R, Leinonen P, Ekblad U, Kataja M, Ikkala E. Thromboprophylaxis with low molecular weight heparin (dalteparin) in pregnancy. *Thrombosis Research*. 1999; 96(4):275-282
743. Pezzuoli G, Neri-Serneri GG, Settembrini PG, Coggi G, Olivari N, Negri G et al. Effectiveness and safety of the low-molecular-weight heparin CY 216 in the prevention of fatal pulmonary embolism and thromboembolic death in general surgery. A multicentre, double-blind, randomized, controlled clinical trial versus placebo (STEP). STEP Study Group. *Haemostasis*. 1990; 20(Suppl 1):193-204
744. Pezzuoli G, Neri Serneri GG, Settembrini P, Coggi G, Olivari N, Buzzetti G et al. Prophylaxis of fatal pulmonary embolism in general surgery using low-molecular weight heparin Cy 216: a multicentre, double-blind, randomized, controlled, clinical trial versus placebo (STEP). STEP-Study Group. *International Surgery*. 1989; 74(4):205-210
745. Phan M, John S, Casanegra AI, Rathbun S, Mansfield A, Stoner JA et al. Primary venous thromboembolism prophylaxis in patients with solid tumors: a meta-analysis. *Journal of Thrombosis and Thrombolysis*. 2014; 38(2):241-249
746. Phelan HA, Wolf SE, Norwood SH, Aldy K, Brakenridge SC, Eastman AL et al. A randomized, double-blinded, placebo-controlled pilot trial of anticoagulation in low-risk traumatic brain injury: The Delayed Versus Early Enoxaparin Prophylaxis I (DEEP I) study. *Journal of Trauma and Acute Care Surgery*. 2012; 73(6):1434-1441
747. Philippart R, Brunet-Bernard A, Clementy N, Bourguignon T, Mirza A, Babuty D et al. Prognostic value of CHA2DS2-VASc score in patients with 'non-valvular atrial fibrillation' and valvular heart disease: the Loire Valley Atrial Fibrillation Project. *European Heart Journal*. 2015; 36(28):1822-30
748. Phung OJ, Kahn SR, Cook DJ, Murad MH. Dosing frequency of unfractionated heparin thromboprophylaxis: a meta-analysis. *Chest*. 2011; 140(2):374-381
749. Piazza G, Rosenbaum EJ, Pendergast W, Jacobson JO, Pendleton RC, McLaren GD et al. Physician alerts to prevent symptomatic venous thromboembolism in hospitalized patients. *Circulation*. 2009; 119(16):2196-201
750. Pince J. Thromboses veineuses des membres inferieurs et embolies pulmonaires au cours des accidents vasculaires cerebraux. A propos d'un essai comparatif de traitement preventif (These pour le doctorat d'etat en medecine). 1981.



751. Pineo GF, Gallus AS, Raskob GE, Chen D, Ramirez LM, Ramacciotti E et al. Apixaban after hip or knee arthroplasty versus enoxaparin: efficacy and safety in key clinical subgroups. *Journal of Thrombosis and Haemostasis*. 2013; 11(3):444-451
752. Pinto DJ. Controlled trial of an anticoagulant (warfarin sodium) in the prevention of venous thrombosis following hip surgery. *British Journal of Surgery*. 1970; 57(5):349-352
753. Piovella C, Dalla Valle F, Trujillo-Santos J, Pesavento R, Lopez L, Font L et al. Comparison of four scores to predict major bleeding in patients receiving anticoagulation for venous thromboembolism: findings from the RIETE registry. *Internal and Emergency Medicine*. 2014; 9(8):847-52
754. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. *Chest*. 2010; 138(5):1093-100
755. Pitt A, Anderson ST, Habersberger PG, Rosengarten DS. Low dose heparin in the prevention of deep-vein thromboses in patients with acute myocardial infarction. *American Heart Journal*. 1980; 99(5):574-578
756. Pitto RP, Young S. Foot pumps without graduated compression stockings for prevention of deep-vein thrombosis in total joint replacement: efficacy, safety and patient compliance. A comparative, prospective clinical trial. *International Orthopaedics*. 2008; 32(3):331-336
757. Planes A, Vochelle N, Darmon JY, Fagola M, Bellaud M, Compan D et al. Efficacy and safety of postdischarge administration of enoxaparin in the prevention of deep venous thrombosis after total hip replacement. A prospective randomised double-blind placebo-controlled trial. *Drugs*. 1996; 52 Suppl 7:47-54
758. Planès A, Vochelle N, Fagola M, Bellaud M, Feret J, Salzard C et al. Once-daily dosing of enoxaparin (a low molecular weight heparin) in prevention of deep vein thrombosis after total hip replacement. *Acta Chirurgica Scandinavica Supplementum*. 1990; 556:108-115
759. Planes A, Vochelle N, Mazas F, Mansat C, Zucman J, Landais A et al. Prevention of postoperative venous thrombosis: a randomized trial comparing unfractionated heparin with low molecular weight heparin in patients undergoing total hip replacement. *Thrombosis and Haemostasis*. 1988; 60(3):407-410
760. Plante J, Boneu B, Vaysse C. Dipyridamole-aspirin versus low doses of heparin in the prophylaxis of deep venous thrombosis in abdominal surgery. *Thrombosis Research*. 1979; 14(2-3):399-403
761. Plitt A, Giugliano RP. Edoxaban: Review of pharmacology and key phase I to III clinical trials. *Journal of Cardiovascular Pharmacology and Therapeutics*. 2014; 19(5):409-416
762. Ploumis A, Ponnappan RK, Maltenfort MG, Patel RX, Bessey JT, Albert TJ et al. Thromboprophylaxis in patients with acute spinal injuries: an evidence-based analysis. *Journal of Bone and Joint Surgery American Volume*. 2009; 91(11):2568-2576
763. Pohar R, Argaez C. Fondaparinux versus enoxaparin for the prevention of venous thromboembolism: a comparative clinical and cost-effectiveness review. Toronto. Canadian Agency for Drugs and Technologies in Health (CADTH), 2008. Available from: <https://www.cadth.ca/sites/default/files/pdf/htis/L0051%20%20Fondaparinux%20vs.%20Enoxaparin%20for%20Thromboembolism%20final.pdf>





764. Poller L, McKernan A, Thomson JM, Elstein M, Hirsch PJ, Jones JB. Fixed minidose warfarin: a new approach to prophylaxis against venous thrombosis after major surgery. *British Medical Journal*. 1987; 295(6609):1309-1312
765. Poller L, Thomson JM, MacCallum PK, Nicholson DA, Weighill FJ, Lemon JG. Minidose warfarin and failure to prevent deep vein thrombosis after joint replacement surgery despite inhibiting the postoperative rise in plasminogen activator inhibitor activity. *Clinical and Applied Thrombosis/Hemostasis*. 1995; 1(4):267-273
766. Postma MJ, Kappelhoff BS, Hulst M, Brouwers JR. Economic evaluation of dabigatran etexilate for the primary prevention of venous thromboembolic events following major orthopedic surgery in the Netherlands. *Journal of Medical Economics*. 2012; 15(5):878-886
767. Poulsen BK, Grove EL, Husted SE. New oral anticoagulants: a review of the literature with particular emphasis on patients with impaired renal function. *Drugs*. 2012; 72(13):1739-1753
768. Poultsides LA, Gonzalez Della Valle A, Memtsoudis SG, Ma Y, Roberts T, Sharrock N et al. Meta-analysis of cause of death following total joint replacement using different thromboprophylaxis regimens. *Journal of Bone and Joint Surgery (British Volume)*. 2012; 94(1):113-121
769. Pour AE, Keshavarzi NR, Purtill JJ, Sharkey PF, Parvizi J. Is venous foot pump effective in prevention of thromboembolic disease after joint arthroplasty: a meta-analysis. *Journal of Arthroplasty*. 2013; 28(3):410-417
770. Powers PJ, Gent M, Jay RM, Julian DH, Turpie AG, Levine M et al. A randomized trial of less intense postoperative warfarin or aspirin therapy in the prevention of venous thromboembolism after surgery for fractured hip. *Archives of Internal Medicine*. 1989; 149(4):771-774
771. Prandoni P, Bruchi O, Sabbion P, Tanduo C, Scudeller A, Sardella C et al. Prolonged thromboprophylaxis with oral anticoagulants after total hip arthroplasty: a prospective controlled randomized study. *Archives of Internal Medicine*. 2002; 162(17):1966-1971
772. Prandoni P, Noventa F, Quintavalla R, Bova C, Cosmi B, Siragusa S et al. Thigh-length versus below-knee compression elastic stockings for prevention of the postthrombotic syndrome in patients with proximal-venous thrombosis: a randomized trial. *Blood*. 2012; 119(6):1561-1565
773. Press A, Rosenberg D, Fishbein J, Batliwalla F, Spyropoulos AC. External validation of a risk assessment model for bleeding risk in medical patients: findings from the improve investigators in a tertiary health system. *Blood*. 2015; 126(23):748-748
774. Prins MH, Bamber L, Cano SJ, Wang MY, Erkens P, Bauersachs R et al. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of pulmonary embolism; results from the EINSTEIN PE trial. *Thrombosis Research*. 2015; 135(2):281-288
775. Prins MH, Lensing, Brighton TA, Lyons RM, Rehm J, Trajanovic M et al. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): A pooled subgroup analysis of two randomised controlled trials. *Lancet Haematology*. 2014; 1(1):e37-e46



776. Pulmonary Embolism Prevention (PEP) Trial Collaborative Group. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. *Lancet*. 2000; 355(9212):1295-1302
777. Qaseem A, Chou R, Humphrey LL, Starkey M, Shekelle P, Physicians CGCotACo. Venous thromboembolism prophylaxis in hospitalized patients: a clinical practice guideline from the American college of physicians. *Annals of Internal Medicine*. 2011; 155(9):625-632
778. Quinlan DJ. Association between asymptomatic deep vein thrombosis detected by venography and symptomatic venous thromboembolism in patients undergoing elective hip or knee surgery. *Journal of Thrombosis and Haemostasis*. 2007; 5(7):1438-1443
779. Qushmaq NA, Al-Emadi SA. Review on effectiveness of primary prophylaxis in aPLs with and without risk factors for thrombosis: efficacy and safety. *ISRN Rheumatology*. 2014; 2014:348726
780. Rachidi S, Aldin ES, Greenberg C, Sachs B, Streiff M, Zeidan AM. The use of novel oral anticoagulants for thromboprophylaxis after elective major orthopedic surgery. *Expert Review of Hematology*. 2013; 6(6):677-695
781. Rada G, Schunemann HJ, Labedi N, El-Hachem P, Kairouz VF, Akl EA. Systematic evaluation of the methodology of randomized controlled trials of anticoagulation in patients with cancer. *BMC Cancer*. 2013; 13:76
782. Rahn DD, Mamik MM, Sanses TVD, Matteson KA, Aschkenazi SO, Washington BB et al. Venous thromboembolism prophylaxis in gynecologic surgery: a systematic review. *Obstetrics and Gynecology*. 2011; 118(5):1111-1125
783. Rai R, Cohen H, Dave M, Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). *British Medical Journal*. 1997; 314(7076):253-257
784. Rajasekhar A, Lottenberg L, Lottenberg R, Feezor RJ, Armen SB, Liu H et al. A pilot study on the randomization of inferior vena cava filter placement for venous thromboembolism prophylaxis in high-risk trauma patients. *Journal of Trauma*. 2011; 71(2):323-9
785. Ramos J, Perrotta C, Badariotti G, Berenstein G. Interventions for preventing venous thromboembolism in adults undergoing knee arthroscopy. *Cochrane Database of Systematic Reviews* 2008, Issue 4. Art. No.: CD005259. DOI: 10.1002/14651858.CD005259.pub3.
786. Ramos JD, Casey MF, Bamias A, De Giorgi U, Bellmunt J, Harshman LC et al. The Khorana Score in Predicting Venous Thromboembolism for Patients With Metastatic Urothelial Carcinoma and Variant Histology Treated With Chemotherapy. *Clinical and Applied Thrombosis/Hemostasis*. 2016; 16:16
787. Ramos R, Salem B, I, De Pawlikowski MP, Coordes C, Eisenberg S, Leidenfrost R. The efficacy of pneumatic compression stockings in the prevention of pulmonary embolism after cardiac surgery. *Chest*. 1996; 109(1):82-85
788. Raskob GE, Gallus AS, Pineo GF, Chen D, Ramirez LM, Wright RT et al. Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE-2 and ADVANCE-3 trials. *Journal of Bone and Joint Surgery (British Volume)*. 2012; 94(2):257-264



789. Raskob GE, Spyropoulos AC, Zrubek J, Ageno W, Albers G, Elliott CG et al. The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE. Design, rationale, and clinical implications. *Thrombosis and Haemostasis*. 2016; 115(6):1240-8
790. Rasmussen MS, Jørgensen LN, Wille-Jørgensen P. Prolonged thromboprophylaxis with Low Molecular Weight heparin for abdominal or pelvic surgery. *Cochrane Database of Systematic Reviews* 2009, Issue 1. Art. No.: CD004318. DOI: 10.1002/14651858.CD004318.pub2.
791. RE-MOBILIZE Writing Committee. The oral thrombin inhibitor dabigatran etexilate vs the North American enoxaparin regimen for the prevention of venous thromboembolism after knee arthroplasty surgery. *Journal of Arthroplasty*. 2009; 24(1):1-9
792. RE-MOBILIZE Writing Committee, Ginsberg JS, Davidson BL, Comp PC, Francis CW, Friedman RJ et al. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. *Journal of Arthroplasty*. 2009; 24(1):1-9
793. Reeves P, Cooke J, Lloyd A, Hutchings A. An economic evaluation of the costs and benefits of heparin rationalisation in a hospital pharmacy. *Pharmacy World and Science*. 2004; 26(3):160-168
794. Registry NJ. National Joint Registry for England and Wales 6th annual report. 2009. Available from: <http://www-new.njrcentre.org.uk/njrcentre/Portals/0/Sixth%20annual%20NJR%20report.pdf>
795. Reilmann H, Bosch U, Creutzig H, Oetting G, Fuchs I, Tscherne H. Thromboseprophylaxe mit niedermolekularem Heparin plus Dihydroergotamin bei Operationen an den unteren Extremitäten. *Perfusion*. 1989:230-234
796. Renney JT, O'Sullivan EF, Burke PF. Prevention of postoperative deep vein thrombosis with dipyridamole and aspirin. *British Medical Journal*. 1976; 1(6016):992-994
797. Revankar N, Patterson J, Kadambi A, Raymond V, El-Hadi W. A Canadian study of the cost-effectiveness of apixaban compared with enoxaparin for post-surgical venous thromboembolism prevention. *Postgraduate Medicine*. 2013; 125(4):141-153
798. Ribaudo JM, Hoellrich RG, McKinnon W-MP, Shuler SE. Evaluation of mini dose heparin administration as a prophylaxis against postoperative pulmonary embolization: a prospective double blind study. *Review of Surgery*. 1975; 32(4):297-299
799. Ribaudo JM, Hoellrich RG, McKinnon WM, Shuler SE. Evaluation of mini-dose heparin administration as a prophylaxis against postoperative pulmonary embolism: a prospective double-blind study. *American Surgeon*. 1975; 41(5):289-295
800. Ribic C, Lim W, Cook D, Crowther M. Low-molecular-weight heparin thromboprophylaxis in medical-surgical critically ill patients: a systematic review. *Journal of Critical Care*. 2009; 24(2):197-205
801. Riemsma R, Joore MA, Armstrong N, Misso K, Noake C. Apixaban for the prevention of venous thromboembolism in people undergoing elective knee and hip replacement surgery. Southampton. NETSCC, 2011. Available from: [http://www.nets.nihr.ac.uk/\\_\\_data/assets/pdf\\_file/0003/96501/STARreport-09-124-01.pdf](http://www.nets.nihr.ac.uk/__data/assets/pdf_file/0003/96501/STARreport-09-124-01.pdf)
802. Riess H, Pelzer U, Deuschinoff G, Opitz B, Stauch M, Reitzig P et al. A prospective, randomized trial of chemotherapy with or without the low molecular weight heparin (LMWH) enoxaparin in patients (pts) with advanced pancreatic cancer (APC): Results of the CONKO 004 trial. *Journal of Clinical Oncology*. 2009; 27(18 Suppl. 1):LBA4506



803. Righini M, Jobic C, Boehlen F, Broussaud J, Becker F, Jaffrelot M et al. Predicting deep venous thrombosis in pregnancy: external validation of the LEFT clinical prediction rule. *Haematologica*. 2013; 98(4):545-8
804. Riordan MN, Horgan R, Arya A. Pharmokinetics of low molecular weight heparins in the postpartum period. *Irish Perinatal Society Annual Meetings*. 2008; April(10)
805. Riva N, Bellesini M, Di Minno MN, Mumoli N, Pomero F, Franchini M et al. Poor predictive value of contemporary bleeding risk scores during long-term treatment of venous thromboembolism. A multicentre retrospective cohort study. *Thrombosis and Haemostasis*. 2014; 112(3):511-21
806. Rivard C, Nahum R, Slagle E, Duinincq M, Isaksson Vogel R, Teoh D. Evaluation of the performance of the ACS NSQIP surgical risk calculator in gynecologic oncology patients undergoing laparotomy. *Gynecologic Oncology*. 2016; 141(2):281-6
807. Roark CD, Haines S. Pharmacological anticoagulation and mechanical compression versus mechanical compression alone for venous thromboembolism prophylaxis for post-operative neurosurgical patients. *Cochrane Database of Systematic Reviews* 2009, Issue 2. Art. No.: CD007713. DOI: 10.1002/14651858.CD007713.
808. Robertson L, Kesteven P. Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of pulmonary embolism. *Cochrane Database of Systematic Reviews* 2014, Issue 2. Art. No.: CD010957. DOI: 10.1002/14651858.CD010957.
809. Robertson L, Roche A. Primary prophylaxis for venous thromboembolism in people undergoing major amputation of the lower extremity. *Cochrane Database of Systematic Reviews* 2013, Issue 12. Art. No.: CD010525. DOI: 10.1002/14651858.CD010525.pub2.
810. Robinson S, Zincuk A, Larsen UL, Ekstrom C, Nybo M, Rasmussen B et al. A comparative study of varying doses of enoxaparin for thromboprophylaxis in critically ill patients: a double-blinded, randomised controlled trial. *Critical Care*. 2013; 17(2):R75
811. Robinson S, Zincuk A, Strom T, Larsen TB, Rasmussen B, Toft P. Enoxaparin, effective dosage for intensive care patients: double-blinded, randomised clinical trial. *Critical Care*. 2010; 14(2):R41
812. Rocha AT, Paiva EF, Lichtenstein A, Milani J, Cavalheiro-Filho C, Maffei FH. Risk-assessment algorithm and recommendations for venous thromboembolism prophylaxis in medical patients. *Vascular Health and Risk Management*. 2007; 3(4):533-553
813. Roderick P, Ferris G, Wilson K, Halls H, Jackson D, Collins R et al. Towards evidence-based guidelines for the prevention of venous thromboembolism: systematic reviews of mechanical methods, oral anticoagulation, dextran and regional anaesthesia as thromboprophylaxis. *Health Technology Assessment*. 2005; 9(49)
814. Rodger MA, Hague WM, Kingdom J, Kahn SR, Karovitch A, Sermer M et al. Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): a multinational open-label randomised trial. *Lancet*. 2014; 384(9955):1673-1683
815. Rodger MA, Phillips P, Kahn SR, James AH, Konkle BA, PROSPER I. Low-molecular-weight heparin to prevent postpartum venous thromboembolism. A pilot randomised placebo-controlled trial. *Thrombosis and Haemostasis*. 2015; 113(1):212-216



816. Rodger MA, Ramsay T, MacKinnon M, Westphal M, Wells PS, McCormick B et al. Tinzaparin versus dalteparin for periprocedure prophylaxis of thromboembolic events in hemodialysis patients: a randomized trial. *American Journal of Kidney Diseases*. 2012; 60(3):427-434
817. Rokito SE, Schwartz MC, Neuwirth MG. Deep vein thrombosis after major reconstructive spinal surgery. *Spine*. 1996; 21(7):853-858
818. Romera-Villegas A, Cairols-Castellote MA, Vila-Coll R, Gomez AP-P, Marti-Mestre X, Bonell-Pascual A et al. Early mobilisation in patients with acute deep vein thrombosis does not increase the risk of a symptomatic pulmonary embolism. *International Angiology*. 2008; 27(6):494-499
819. Rondelli F, Manina G, Agnelli G, Becattini C. Venous thromboembolism after laparoscopic cholecystectomy: clinical burden and prevention. *Surgical Endoscopy*. 2013; 27(6):1860-1864
820. Rondina MT, Pendleton RC, Chaudhry SS, Freeman AF. Comparison of two weight-based enoxaparin dosing algorithms to prevent venous thromboembolism in morbidly obese medically ill patients. *Journal of Thrombosis and Thrombolysis*. 2011; 31(3):391-392
821. Rosenberg D, Eichorn A, Alarcon M, McCullagh L, McGinn T, Spyropoulos AC. External validation of the risk assessment model of the International Medical Prevention Registry on Venous Thromboembolism (IMPROVE) for medical patients in a tertiary health system. *Journal of the American Heart Association*. 2014; 3(6):e001152
822. Rosenberg DJ, Ansell J. Oral rivaroxaban for acute DVT, or long term for VTE, is as effective as enoxaparin followed by a vitamin K antagonist for preventing recurrence, with no increase in bleeding complications. *Evidence-Based Medicine*. 2011; 16(5):139-140
823. Rosencher N, Albaladejo P. A new approach with anticoagulant development: tailoring anticoagulant therapy with dabigatran etexilate according to patient risk. *Expert Opinion on Pharmacotherapy*. 2012; 13(2):217-226
824. Rosengarten DS, Laird J. The effect of leg elevation on the incidence of deep-vein thrombosis after operation. *British Journal of Surgery*. 1971; 58(3):182-184
825. Roth P. Prophylaxis of deep vein thrombosis in outpatients undergoing arthroscopic meniscus operation. *Orthopädische Praxis*. 1995; 5(5):3458
826. Rothberg MB, Pekow PS, Lahti M, Lindenauer PK. Comparative effectiveness of low-molecular-weight heparin versus unfractionated heparin for thromboembolism prophylaxis for medical patients. *Journal of Hospital Medicine*. 2012; 7(6):457-463
827. Royal College of Obstetricians and Gynaecologists. Thrombosis and embolism during pregnancy and the puerperium, reducing the risk. Green-top Guideline No. 37a. London. Royal College of Obstetricians and Gynaecologists, 2015. Available from: <https://www.rcog.org.uk/en/guidelines-research-services/guidelines/gtg37a/>
828. Royal College of Physicians. National Hip Fracture Database annual report 2016. London. RCP, 2016. Available from: <http://web1.crownaudit.org/Report2016/NHFD2016Report.pdf>
829. Ruiz-Gimenez N, Suarez C, Gonzalez R, Nieto JA, Todoli JA, Samperiz AL et al. Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry. *Thrombosis and Haemostasis*. 2008; 100(1):26-31



830. Russell RD, Huo MH. Apixaban and rivaroxaban decrease deep venous thrombosis but not other complications after total hip and total knee arthroplasty. *Journal of Arthroplasty*. 2013; 28(9):1477-1481
831. Ruttimann S, Danner M, Glaser MG. Explicit versus implicit risk assessment for the indication of antithrombotic prophylaxis in acutely ill medical in-patients. *Swiss Medical Weekly*. 2005; 135(15-16):228-34
832. Ryan MG, Westrich GH, Potter HG, Sharrock N, Maun LM, Macaulay W et al. Effect of mechanical compression on the prevalence of proximal deep venous thrombosis as assessed by magnetic resonance venography. *Journal of Bone and Joint Surgery*. 2002; 84-A(11):1998-2004
833. Rytberg L, Diamantopoulos A, Forster F, Lees M, Frasccke A, Bjorholt I. Cost-effectiveness of rivaroxaban versus heparins for prevention of venous thromboembolism after total hip or knee surgery in Sweden. *Expert Review of Pharmacoeconomics and Outcomes Research*. 2011; 11(5):601-615
834. Sachdeva A, Dalton M, Amaragiri SV, Lees T. Graduated compression stockings for prevention of deep vein thrombosis. *Cochrane Database of Systematic Reviews* 2014, Issue 12. Art. No.: CD001484. DOI: 10.1002/14651858.CD001484.pub3.
835. Saeed CR, Frank JB, Pravin M, Aziz RH, Serasheini M, Dominique TG. A prospective trial showing the safety of adjusted-dose enoxaparin for thromboprophylaxis of pregnant women with mechanical prosthetic heart valves. *Clinical and Applied Thrombosis/Hemostasis*. 2011; 17(4):313-319
836. Sagar S. Heparin prophylaxis against fatal postoperative pulmonary embolism. *British Medical Journal*. 1974; 2(5911):153-155
837. Sagar S, Massey J, Sanderson JM. Low-dose heparin prophylaxis against fatal pulmonary embolism. *British Medical Journal*. 1975; 4(5991):257-259
838. Saigal S, Sharma JP, Joshi R, Singh DK. Thrombo-prophylaxis in acutely ill medical and critically ill patients. *Indian Journal of Critical Care Medicine*. 2014; 18(6):382-391
839. Sajid MS, Desai M, Morris RW, Hamilton G. Knee length versus thigh length graduated compression stockings for prevention of deep vein thrombosis in postoperative surgical patients. *Cochrane Database of Systematic Reviews* 2012, Issue 5. Art. No.: CD007162. DOI: 10.1002/14651858.CD007162.pub2.
840. Salcuni PF, Azzarone M, Palazzini E. A new low molecular weight heparin for deep vein thrombosis prevention: effectiveness in postoperative patients. *Current Therapeutic Research, Clinical and Experimental*. 1988; 43:824-831
841. Saleh HE, Pennings AL, ElMaraghy AW. Venous thromboembolism after shoulder arthroplasty: a systematic review. *Journal of Shoulder and Elbow Surgery*. 2013; 22(10):1440-1448
842. Salmaggi A, Simonetti G, Trevisan E, Beecher D, Carapella CM, DiMeco F et al. Perioperative thromboprophylaxis in patients with craniotomy for brain tumours: a systematic review. *Journal of Neuro-Oncology*. 2013; 113(2):293-303
843. Salvo F. Risk of major bleeding and the standard doses of dabigatran. *European Journal of Internal Medicine*. 2014; 25(6):e73-e75



844. Samama CM, Clergue F, Barre J, Montefiore A, Ill P, Samii K. Low molecular weight heparin associated with spinal anaesthesia and gradual compression stockings in total hip replacement surgery. Arar study group. *British Journal of Anaesthesia*. 1997; 78(6):660-665
845. Samama CM, Vray M, Barré J, Fiessinger JN, Rosencher N, Lecompte T et al. Extended venous thromboembolism prophylaxis after total hip replacement: a comparison of low-molecular-weight heparin with oral anticoagulant. *Archives of Internal Medicine*. 2002; 162(19):2191-2196
846. Samama M, Bernard P, Bonnardot JP, Combe-Tamzali S, Lanson Y, Tissot E. Low molecular weight heparin compared with unfractionated heparin in prevention of postoperative thrombosis. *British Journal of Surgery*. 1988; 75(2):128-131
847. Samama MM, Dahl OE, Mismetti P, Quinlan DJ, Rosencher N, Cornelis M et al. An electronic tool for venous thromboembolism prevention in medical and surgical patients. *Haematologica*. 2006; 91(1):64-70
848. Sandercock Peter AG, Counsell C, Tseng M. Low-molecular-weight heparins or heparinoids versus standard unfractionated heparin for acute ischaemic stroke. *Cochrane Database of Systematic Reviews* 2008, Issue 3. Art. No.: CD000119. DOI: 10.1002/14651858.CD000119.pub3.
849. Sant'Anna RT, Leiria TL, Nascimento T, Sant'Anna JRM, Kalil RAK, Lima GG et al. Meta-analysis of continuous oral anticoagulants versus heparin bridging in patients undergoing CIED surgery: Reappraisal after the BRUISE study. *PACE - Pacing and Clinical Electrophysiology*. 2015; 38(4):417-423
850. Santori FS, Vitullo A, Stopponi M, Santori N, Ghera S. Prophylaxis against deep-vein thrombosis in total hip replacement. Comparison of heparin and foot impulse pump. *Journal of Bone and Joint Surgery (British Volume)*. 1994; 76(4):579-583
851. Santoro R, Iannaccaro P, Prejano S, Muleo G. Efficacy and safety of the long-term administration of low-molecular-weight heparins in pregnancy. *Blood Coagulation and Fibrinolysis*. 2009; 20(4):240-243
852. Santos R, Barros VV, Igai AK, Francisco RP, Zugaib M. Maternal death and venous thromboembolism (VTE) in patients admitted in a maternity of high risk: Results pre and post application of a risk score. *Journal of Thrombosis and Haemostasis*. 2015; 13:679
853. Saraiya B, Goodin S. Management of venous thromboembolism and the potential to impact overall survival in patients with cancer. *Pharmacotherapy*. 2009; 29(11):1344-1356
854. Sarela AI, Dexter SP, McMahon MJ. Use of the obesity surgery mortality risk score to predict complications of laparoscopic bariatric surgery. *Obesity Surgery*. 2011; 21(11):1698-703
855. Sarkar RK, Abbas M, Warreth N. A complete audit cycle of the implementation of guidelines on thromboprophylaxis in pregnancy. *BJOG: An International Journal of Obstetrics and Gynaecology*. 2013; 120:167-168
856. Sasahara AA, DiSerio FJ, Singer JM. Dihydroergotamine-heparin prophylaxis of postoperative deep vein thrombosis. A multicenter trial. *JAMA*. 1984; 251(22):2960-2966
857. Sasahara AA, Koppenhagen K, Häring R, Welzel D, Wolf H. Low molecular weight heparin plus dihydroergotamine for prophylaxis of postoperative deep vein thrombosis. *British Journal of Surgery*. 1986; 73(9):697-700



858. Sasaki S, Miyakoshi N, Matsuura H, Saitoh H, Kudoh D, Shimada Y. Prospective randomized controlled trial on the effect of fondaparinux sodium for prevention of venous thromboembolism after hip fracture surgery. *Journal of Orthopaedic Science*. 2009; 14(5):491-496
859. Sasaki SM. Prospective study on the efficacies of fondaparinux and enoxaparin in preventing venous thromboembolism after hip fracture surgery. *Journal of Orthopaedic Science*. 2011; 16(1):64-70
860. Sautter RD, Koch EL, Myers WO, Ray JR, III, Mazza JJ, Larson DE et al. Aspirin-sulfinpyrazone in prophylaxis of deep venous thrombosis in total hip replacement. *JAMA*. 1983; 250(19):2649-2654
861. Scherz N, Mean M, Limacher A, Righini M, Jaeger K, Beer HJ et al. Prospective, multicenter validation of prediction scores for major bleeding in elderly patients with venous thromboembolism. *Journal of Thrombosis and Haemostasis*. 2013; 11(3):435-43
862. Schiele F. Fondaparinux and acute coronary syndromes: update on the OASIS 5-6 studies. *Vascular Health and Risk Management*. 2010; 6:179-187
863. Schmitz-Huebner U, Bunte H, Freise G, Reers B, Ruschemeyer C, Scherer R et al. Clinical efficacy of low molecular weight heparin in postoperative thrombosis prophylaxis. *Klinische Wochenschrift*. 1984; 62(8):349-353
864. Schneider AL, Deig CR, Prasad KG, Nelson BG, Mantravadi AV, Brigance JS et al. Ability of the National Surgical Quality Improvement Program Risk Calculator to Predict Complications Following Total Laryngectomy. *JAMA Otolaryngology-- Head & Neck Surgery*. 2016; 142(10):972-979
865. Schoenbeck D, Nicolle A, Newbegin K, Hanley J, Loughney AD. The use of a scoring system to guide thromboprophylaxis in a high-risk pregnant population. *Thrombosis*. 2011; 2011:652796
866. Schouten HJ, Geersing GJ, Oudega R, van Delden JJ, Moons KG, Koek HL. Accuracy of the Wells clinical prediction rule for pulmonary embolism in older ambulatory adults. *Journal of the American Geriatrics Society*. 2014; 62(11):2136-41
867. Schreiber U, Hartung B. Postoperative thromboembolieprophylaxe bei patienten mit allgemeinchirurgischen operationen. *Zentralblatt für Chirurgie*. 1979; 104(18):1214-1220
868. Schulman S. Is the network meta-analysis (NETMA) bringing us closer to the truth? insights from recent antithrombotic drug data. *Thrombosis and Haemostasis*. 2012; 108(5):872-875
869. Schulman S, Baanstra D, Eriksson H, Goldhaber S, Kakkar A, Kearon C. Dabigatran vs. placebo for extended maintenance therapy of venous thromboembolism. *Journal of Thrombosis and Haemostasis*. 2011; 9(Suppl 2):22
870. Schulman S, Goldhaber SZ, Kearon C, Kakkar AK, Schellong S, Eriksson H et al. Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer. *Thrombosis and Haemostasis*. 2015; 114(1):150-157
871. Schweikert B, Pittrow D, Vizza CD, Pepke-Zaba J, Hoepfer MM, Gabriel A et al. Demographics, clinical characteristics, health resource utilization and cost of chronic thromboembolic pulmonary hypertension patients: retrospective results from six European countries. *BMC Health Services Research*. 2014; 14:246





872. Scott A, Argaez C. Knee-high versus thigh-high compression devices: a review of the clinical and cost-effectiveness. Toronto. Canadian Agency for Drugs and Technologies in Health (CADTH), 2008. Available from: <https://www.cadth.ca/sites/default/files/pdf/htis/may-2015/RB0861%20Knee%20Length%20Sequential%20Compression%20Devices%20Final.pdf>
873. Scurr JH, Coleridge-Smith PD, Hasty JH. Regimen for improved effectiveness of intermittent pneumatic compression in deep venous thrombosis prophylaxis. *Surgery*. 1987; 102(5):816-820
874. Scurr JH, Ibrahim SZ, Faber RG, Le Quesne LP. The efficacy of graduated compression stockings in the prevention of deep vein thrombosis. *British Journal of Surgery*. 1977; 64(5):371-373
875. Seaman S, Nelson A, Noble S. Cancer-associated thrombosis, low-molecular-weight heparin, and the patient experience: a qualitative study. *Patient Preference and Adherence*. 2014; 8:453-61
876. Sermsathanasawadi N, Suparatchatpun P, Pumpuang T, Hongku K, Chinsakchai K, Wongwanit C et al. Comparison of clinical prediction scores for the diagnosis of deep vein thrombosis in unselected population of outpatients and inpatients. *Phlebology*. 2015; 30(7):469-74
877. Sharma M, Cornelius VR, Patel JP, Davies JG, Molokhia M. Efficacy and harms of direct oral anticoagulants in the elderly for stroke prevention in atrial fibrillation and secondary prevention of venous thromboembolism: systematic review and meta-analysis. *Circulation*. 2015; 132(3):194-204
878. Shea-Budgell MA, Wu CMJ, Easaw JC. Evidence-based guidance on venous thromboembolism in patients with solid tumours. *Current Oncology*. 2014; 21(3):e504-e514
879. Sheard L, Prout H, Dowding D, Noble S, Watt I, Maraveyas A et al. The ethical decisions UK doctors make regarding advanced cancer patients at the end of life--the perceived (in) appropriateness of anticoagulation for venous thromboembolism: a qualitative study. *BMC Medical Ethics*. 2012; 13:22
880. Sheard L, Prout H, Dowding D, Noble S, Watt I, Maraveyas A et al. Barriers to the diagnosis and treatment of venous thromboembolism in advanced cancer patients: A qualitative study. *Palliative Medicine*. 2013; 27(4):339-348
881. Shelkrot M, Miraka J, Perez ME. Appropriate enoxaparin dose for venous thromboembolism prophylaxis in patients with extreme obesity. *Hospital Pharmacy*. 2014; 49(8):740-747
882. Shen JH, Chen HL, Chen JR, Xing JL, Gu P, Zhu BF. Comparison of the Wells score with the revised Geneva score for assessing suspected pulmonary embolism: a systematic review and meta-analysis. *Journal of Thrombosis and Thrombolysis*. 2016; 41(3):482-92
883. Shirai N. Study on prophylaxis of postoperative deep vein thrombosis. *Acta Scholae Medicinalis Universitatis in Gifu*. 1985; 33(6):1173-1183
884. Shlebak A, Sandhu P, Ali V, Jones G, Baker C. The impact of the DoH Commissioning for Quality and Innovation incentive on the success of venous thromboembolism risk assessment in hospitalised patients. A single institution experience in a quality outcome improvement over a 4-year cycle. *JRSM Open*. 2016; 7(6):2054270416632702
885. Shorr AF, Jackson WL, Sherner JH, Moores LK. Differences between low-molecular-weight and unfractionated heparin for venous thromboembolism prevention following ischemic stroke: a metaanalysis. *Chest*. 2008; 133(1):149-155



886. Shosha RI, Ibrahim OM, Setiha ME, Abdelwahab AA. The efficacy and safety of rivaroxaban as an alternative to warfarin for the prevention of thromboembolism in patients with atrial fibrillation. *International Journal of Pharmaceutical Sciences Review and Research*. 2017; 43(2):38-48
887. Shukla PJ, Siddachari R, Ahire S, Arya S, Ramani S, Barreto SG et al. Postoperative deep vein thrombosis in patients with colorectal cancer. *Indian Journal of Gastroenterology*. 2008; 27(2):71-73
888. Shuman AG, Hu HM, Pannucci CJ, Jackson CR, Bradford CR, Bahl V. Stratifying the risk of venous thromboembolism in otolaryngology. *Otolaryngology - Head & Neck Surgery*. 2012; 146(5):719-24
889. Sideras K, Schaefer PL, Okuno SH, Sloan JA, Kutteh L, Fitch TR et al. Low-molecular-weight heparin in patients with advanced cancer: a phase 3 clinical trial. *Mayo Clinic Proceedings*. 2006; 81(6):758-67
890. Silveira PC, Ip IK, Goldhaber SZ, Piazza G, Benson CB, Khorasani R. Performance of Wells score for deep vein thrombosis in the inpatient setting. *JAMA Internal Medicine*. 2015; 175(7):1112-7
891. Simard JM, Aldrich EF, Schreiber D, James RF, Polifka A, Beaty N. Low-dose intravenous heparin infusion in patients with aneurysmal subarachnoid hemorrhage: a preliminary assessment. *Journal of Neurosurgery*. 2013; 119(6):1611-1619
892. Simes J, Becattini C, Agnelli G, Eikelboom JW, Kirby AC, Mister R et al. Aspirin for the prevention of recurrent venous thromboembolism: the INSPIRE collaboration. *Circulation*. 2014; 130(13):1062-1071
893. Simonetti G, Trevisan E, Silvani A, Gaviani P, Botturi A, Lamperti E et al. Safety of bevacizumab in patients with malignant gliomas: a systematic review. *Neurological Sciences*. 2014; 35(1):83-89
894. Singh S, Haut ER, Brotman DJ, Sharma R, Chelladurai Y, Shermock KM et al. Pharmacologic and mechanical prophylaxis of venous thrombolism among special populations: Comparative Effectiveness Review 116. Rockville, MD. Agency for Healthcare Research and Quality, 2013.
895. Singh SK, Kallhfallah A. The prevent trial-prevention of venous thromboembolism with enoxaparin vs rivaroxaban following hip and knee replacement surgeries. *Internal Medicine Journal*. 2012; 42(S2):21
896. Siragusa S, Vicentini L, Carbone S, Barone M, Beltrametti C, Piovella F. Intermittent pneumatic leg compression (IPLC) and unfractionated heparin (UFH) in the prevention of post-operative deep vein thrombosis in hip surgery. *Blood*. 1994; 84(10 Suppl 1):70a
897. Sjalander A, Jansson JH, Bergqvist D, Eriksson H, Carlberg B, Svensson P. Efficacy and safety of anticoagulant prophylaxis to prevent venous thromboembolism in acutely ill medical inpatients: a meta-analysis. *Journal of Internal Medicine*. 2008; 263(1):52-60
898. Skeith L, Taylor J, Lazo-Langner A, Kovacs MJ. Conservative perioperative anticoagulation management in patients with chronic venous thromboembolic disease: a cohort study. *Journal of Thrombosis and Haemostasis*. 2012; 10(11):2298-2304
899. Skillman JJ, Collins RE, Coe NP, Goldstein BS, Shapiro RM, Zervas NT et al. Prevention of deep vein thrombosis in neurosurgical patients: a controlled, randomized trial of external pneumatic compression boots. *Surgery*. 1978; 83(3):354-358



900. Slawson D. Optimal treatment of acute venous thromboembolism. *American Family Physician*. 2015; 91(7):492-494
901. Smith TO, Daniell H, Hing C. Upper extremity deep vein thrombosis in orthopaedic and trauma surgery: A systematic review. *European Journal of Orthopaedic Surgery & Traumatology*. 2011; 21(2):79-85
902. Snook GA, Chrisman OD, Wilson TC. Thromboembolism after surgical treatment of hip fractures. *Clinical Orthopaedics and Related Research*. 1981; 155:21-24
903. Snowden S, Silus L. Oral anticoagulation with warfarin for patients with left ventricular systolic dysfunction. *Cardiology in Review*. 2011; 19(1):36-40
904. Sobieraj-Teague M, Hirsh J, Yip G, Gastaldo F, Stokes T, Sloane D et al. Randomized controlled trial of a new portable calf compression device (Venowave) for prevention of venous thrombosis in high-risk neurosurgical patients. *Journal of Thrombosis and Haemostasis*. 2012; 10(2):229-235
905. Sobieraj DM, Coleman CI, Tongbram V, Chen W, Colby J, Lee S et al. Comparative effectiveness of combined pharmacologic and mechanical thromboprophylaxis versus either method alone in major orthopedic surgery: a systematic review and meta-analysis. *Pharmacotherapy*. 2013; 33(3):275-283
906. Sobieraj DM, Coleman CI, Tongbram V, Lee S, Colby J, Chen WT et al. Venous thromboembolism prophylaxis in orthopedic surgery. *AHRQ Comparative Effectiveness Reviews 49*. Rockville (MD). Agency for Healthcare Research and Quality (US), 2012. Available from: <http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0041828/>
907. Sobieraj DM, Lee S, Coleman CI, Tongbram V, Chen W, Colby J et al. Prolonged versus standard-duration venous thromboprophylaxis in major orthopedic surgery: a systematic review. *Annals of Internal Medicine*. 2012; 156(10):720-727
908. Soomro Q, Yousuf N, Bhutto AA, Abro HA, Memon AA. Venous thromboembolism (VTE): risk assessment in hospitalized patients. *Journal of the College of Physicians & Surgeons - Pakistan*. 2014; 24(7):455-8
909. Soreff J, Johnsson H, Diener L, Goransson L. Acetylsalicylic acid in a trial to diminish thromboembolic complications after elective hip surgery. *Acta Orthopaedica Scandinavica*. 1975; 46(2):246-255
910. Sourmelis S, Patoulis G, Tzortzis G. Prevention of deep vein thrombosis with low molecular weight heparin in fractures of the hip. *Journal of Bone and Joint Surgery (British Volume)*. 1995; 77(Suppl 2):173
911. Specialised Commissioning Team NHS, England. A11/P/c Targeted Therapies for use in Pulmonary Hypertension in Adults. 2015.
912. Spencer A, Cawood T, Frampton C, Jardine D. Heparin-based treatment to prevent symptomatic deep venous thrombosis, pulmonary embolism or death in general medical inpatients is not supported by best evidence. *Internal Medicine Journal*. 2014; 44(11):1054-1065
913. Spyropoulos AC, Anderson FA, Jr., Fitzgerald G, Decousus H, Pini M, Chong BH et al. Predictive and associative models to identify hospitalized medical patients at risk for VTE. *Chest*. 2011; 140(3):706-14



914. Spyropoulos AC, McGinn T, Khorana AA. The use of weighted and scored risk assessment models for venous thromboembolism. *Thrombosis and Haemostasis*. 2012; 108(6):1072-6
915. Stannard JP, Harris RM, Bucknell AL, Cossi A, Ward J, Arrington ED. Prophylaxis of deep venous thrombosis after total hip arthroplasty by using intermittent compression of the plantar venous plexus. *American Journal of Orthopedics*. 1996; 25(2):127-134
916. Stannard JP, Riley RS, McClenney MD, Lopez-Ben RR, Volgas DA, Alonso JE. Mechanical prophylaxis against deep-vein thrombosis after pelvic and acetabular fractures. *Journal of Bone and Joint Surgery*. 2001; 83-A(7):1047-1051
917. Stashenko GJ, Hargett CW, Tapson VF. Thrombolytic therapy for venous thromboembolism: Current clinical practice. *Journal of Hospital Medicine*. 2009; 4(5):313-316
918. Stephenson ML, Serra AE, Neeper JM, Caballero DC, McNulty J. A randomized controlled trial of differing doses of postcesarean enoxaparin thromboprophylaxis in obese women. *Journal of Perinatology*. 2016; 36(2):95-9
919. Sterne J, Bodialia P, Bryden P, Davies P, Lopez-Lopez A, Okoli GN. Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost-effectiveness analysis [unpublished]. 2016.
920. Stevens SM, Douketis JD. Deep vein thrombosis prophylaxis in hospitalized medical patients: current recommendations, general rates of implementation, and initiatives for improvement. *Clinics in Chest Medicine*. 2010; 31(4):675-689
921. Stevenson M, Scope A, Holmes M, Rees A, Kaltenthaler E. Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal. *Health Technology Assessment*. 2009; 13(Suppl 3):43-48
922. Stewart DW, Freshour JE. Aspirin for the prophylaxis of venous thromboembolic events in orthopedic surgery patients: a comparison of the AAOS and ACCP guidelines with review of the evidence. *Annals of Pharmacotherapy*. 2013; 47(1):63-74
923. Stone MH, Limb D, Campbell P, Stead D, Culleton G. A comparison of intermittent calf compression and enoxaparin for thromboprophylaxis in total hip replacement. A pilot study. *International Orthopaedics*. 1996; 20(6):367-369
924. Stranks GJ, MacKenzie NA, Grover ML, Fail T. The A-V Impulse System reduces deep-vein thrombosis and swelling after hemiarthroplasty for hip fracture. *Journal of Bone and Joint Surgery (British Volume)*. 1992; 74(5):775-778
925. Stroud W, Whitworth JM, Miklic M, Schneider KE, Finan MA, Scalici J et al. Validation of a venous thromboembolism risk assessment model in gynecologic oncology. *Gynecologic Oncology*. 2014; 134(1):160-3
926. Stuck AK, Spirk D, Schaudt J, Kucher N. Risk assessment models for venous thromboembolism in acutely ill medical patients. A systematic review. *Thrombosis and Haemostasis*. 2017; 02:02
927. Sullivan P, Fraessdorf M, Feuring M, Schulman S, Hass B. Health-related quality of life after venous thromboembolism. *Value in Health*. 2011; 14(7):A384
928. Sultan MJ, Zheng TT, Kurdy N, McCollum CN. Role of engineered compression stockings in preventing deep vein thrombosis following ankle fractures. *Phlebology*. 2011; 26(3):267



929. Summers JA, Clinch J, Radhakrishnan M, Healy A, McMillan V, Morris E et al. The geko™ electro-stimulation device for venous thromboembolism prophylaxis: a NICE medical technology guidance. *Applied Health Economics and Health Policy*. 2015; 13(2):135-147
930. Sun Y, Chen D, Xu Z, Shi D, Dai J, Qin J et al. Deep venous thrombosis after knee arthroscopy: a systematic review and meta-analysis. *Arthroscopy*. 2014; 30(3):406-412
931. Tamizifar B, Fereyduni F, Esfahani MA, Kheyri S. Comparing three clinical prediction rules for primarily predicting the 30-day mortality of patients with pulmonary embolism: The "Simplified Revised Geneva Score," the "Original PESI," and the "Simplified PESI". *Advanced Biomedical Research*. 2016; 5:137
932. Tardy B, Lafond P, Viallon A, Buchmuller A, Zeni F, Decousus H. Older people included in a venous thrombo-embolism clinical trial: A patients' viewpoint. *Age and Ageing*. 2003; 32(2):149-153
933. Ten Cate-Hoek AJ, Ten Cate H, Tordoir J, Hamulyak K, Prins MH. Individually tailored duration of elastic compression therapy in relation to incidence of the postthrombotic syndrome. *Journal of Vascular Surgery*. 2010; 52(1):132-138
934. Testa S, Passamonti SM, Paoletti O, Zimmermann A, Bucciarelli P, Ronca E et al. The pregnancy health-care program: A model for the prevention of venous thromboembolism in pregnancy. *Journal of Thrombosis and Haemostasis*. 2013; 11:606
935. Testroote M, Stigter WAH, Janssen L, Janzing HMJ. Low molecular weight heparin for prevention of venous thromboembolism in patients with lower-leg immobilization. *Cochrane Database of Systematic Reviews* 2014, Issue 4. Art. No.: CD006681. DOI: 10.1002/14651858.CD006681.pub3.
936. Tetri S, Hakala J, Juvela S, Saloheimo P, Pyhtinen J, Rusanen H et al. Safety of low-dose subcutaneous enoxaparin for the prevention of venous thromboembolism after primary intracerebral haemorrhage. *Thrombosis Research*. 2008; 123(2):206-212
937. The German Hip Arthroplasty Trial (GHAT) Group. Prevention of deep vein thrombosis with low molecular-weight heparin in patients undergoing total hip replacement. A randomized trial. *Archives of Orthopaedic and Trauma Surgery*. 1992; 111(2):110-120
938. Thourani VH, Gunter RL, Hurst S, Kilgo P, Padala M, Puskas JD et al. Postoperative warfarin following mitral valve repair or bioprosthetic valve replacement. *Journal of Heart Valve Disease*. 2013; 22(5):716-723
939. Tomita M, Motokawa S. Intraoperative heparin injection reduced D-dimer and TAT levels after total hip arthroplasty. *Acta Medica Nagasakiensia*. 2008; 53(1):9-13
940. Tomkowski W, Kuca P, Andziak P, Dziki A, Nizankowski R, Staszkiwicz W et al. A scoring system for thromboembolic risk assessment in patients hospitalised on non-surgical wards developed by the Polish Working Group. *Acta Angiologica*. 2011; 17(1):77-88
941. Tørholm C, Broeng L, Jørgensen PS, Bjerregaard P, Josephsen L, Jørgensen PK et al. Thromboprophylaxis by low-molecular-weight heparin in elective hip surgery. A placebo controlled study. *Journal of Bone and Joint Surgery (British Volume)*. 1991; 73(3):434-438
942. Torngren S. Low dose heparin and compression stockings in the prevention of postoperative deep venous thrombosis. *British Journal of Surgery*. 1980; 67(7):482-484



943. Traby L, Kaider A, Schmid R, Kranz A, Quehenberger P, Kyrle PA et al. The effects of low-molecular-weight heparin at two different dosages on thrombin generation in cancer patients. A randomised controlled trial. *Thrombosis and Haemostasis*. 2010; 104(1):92-99
944. Trkulja V, Kolundzic R. Rivaroxaban vs dabigatran for thromboprophylaxis after joint-replacement surgery: exploratory indirect comparison based on meta-analysis of pivotal clinical trials. *Croatian Medical Journal*. 2010; 51(2):113-123
945. Tsutsumi S, Yajima R, Tabe Y, Takaaki T, Fujii F, Morita H et al. The efficacy of fondaparinux for the prophylaxis of venous thromboembolism after resection for colorectal cancer. *Hepato-Gastroenterology*. 2012; 59(120):2477-2479
946. Turner RM, Jackson D, Wei Y, Thompson SG, Higgins JPT. Predictive distributions for between-study heterogeneity and simple methods for their application in Bayesian meta-analysis. *Statistics in Medicine*. 2015; 34(6):984-998
947. Turpie AG, Delmore T, Hirsh J, Hull R, Genton E, Hiscoe C et al. Prevention of venous thrombosis by intermittent sequential calf compression in patients with intracranial disease. *Thrombosis Research*. 1979; 15(5-6):611-616
948. Turpie AG, Fisher WD, Bauer KA, Kwong LM, Irwin MW, Kalebo P et al. BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study. *Journal of Thrombosis and Haemostasis*. 2005; 3(11):2479-86
949. Turpie AG, Gallus A, Beattie WS, Hirsh J. Prevention of venous thrombosis in patients with intracranial disease by intermittent pneumatic compression of the calf. *Neurology*. 1977; 27(5):435-438
950. Turpie AG, Haas S, Kreutz R, Mantovani LG, Pattanayak CW, Holberg G et al. A non-interventional comparison of rivaroxaban with standard of care for thromboprophylaxis after major orthopaedic surgery in 17,701 patients with propensity score adjustment. *Thrombosis and Haemostasis*. 2014; 111(1):94-102
951. Turpie AG, Hirsh J, Gent M, Julian D, Johnson J. Prevention of deep vein thrombosis in potential neurosurgical patients. A randomized trial comparing graduated compression stockings alone or graduated compression stockings plus intermittent pneumatic compression with control. *Archives of Internal Medicine*. 1989; 149(3):679-681
952. Turpie AG, Levine MN, Hirsh J, Carter CJ, Jay RM, Powers PJ et al. A randomized controlled trial of a low-molecular-weight heparin (enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery. *New England Journal of Medicine*. 1986; 315(15):925-929
953. Turpie AG, Schmidt AC, Kreutz R, Lassen MR, Jamal W, Mantovani L et al. Rationale and design of XAMOS: noninterventional study of rivaroxaban for prophylaxis of venous thromboembolism after major hip and knee surgery. *Vascular Health & Risk Management*. 2012; 8:363-70
954. Turpie AGG, Bauer KA, Eriksson BI, Lassen MR. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. *Lancet*. 2002; 359(9319):1721-1726
955. Turpie AGG, Hull RD, Schellong SM, Tapson VF, Monreal M, Samama MM et al. Venous thromboembolism risk in ischemic stroke patients receiving extended-duration enoxaparin prophylaxis: results from the EXCLAIM study. *Stroke*. 2013; 44(1):249-251



956. Turpie AGG, Lassen MR, Davidson BL, Bauer KA, Gent M, Kwong LM et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. *Lancet*. 2009; 373(9676):1673-1680
957. U.M.I.N. Randomized study of anti-coagulant therapy to prevent postoperative deep venous thrombosis/pulmonary embolism. UMIN000002444. 2009. Available from: <https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr.cgi?function=brows&action=brows&type=summary&recptno=R000002991&language=E> Last accessed: 28/06/17.
958. U.M.I.N. Phase III study of efficacy of fondaparinux on the prevention of post-operative venous thromboembolism in patients undergoing with laparoscopic colorectal cancer surgery. UMIN000008435. 2012. Available from: <https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr.cgi?function=brows&action=brows&type=summary&recptno=R000009923&language=E> Last accessed: 28/06/17.
959. U.M.I.N. The efficacy and safety of anticoagulant therapy Arixtra Injection for the prevention of the vein thromboembolism in laparoscopic colorectal surgery. UMIN000007005. 2013. Available from: <https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr.cgi?function=brows&action=brows&type=summary&recptno=R000008265&language=E> Last accessed: 28/06/17.
960. Uchino K. Review: Dabigatran increases MI and reduces mortality compared with warfarin, enoxaparin, or placebo. *Annals of Internal Medicine*. 2012; 156(12):JC6-JC11
961. Valle I, Sola G, Origone A. Controlled clinical study of the efficacy of a new low molecular weight heparin administered subcutaneously to prevent post-operative deep venous thrombosis. *Current Medical Research and Opinion*. 1988; 11(2):80-86
962. Van der Pol LM, Mairuhu AT, Tromeur C, Couturaud F, Huisman MV, Klok FA. Use of clinical prediction rules and D-dimer tests in the diagnostic management of pregnant patients with suspected acute pulmonary embolism. *Blood Reviews*. 2016; 29:29
963. van der Veen L, van Raay JJ, Gerritsma-Bleeker CLE, Veeger NJ, van Hulst M. Direct treatment comparison of DABigatran and Rivaroxaban versus NADroparin in the prevention of venous thromboembolism after total knee arthroplasty surgery: design of a randomised pilot study (DARINA). *BMJ Open*. 2013; 3(1)
964. van Doormaal FF, Di Nisio M, Otten HM, Richel DJ, Prins M, Buller HR. Randomized trial of the effect of the low molecular weight heparin nadroparin on survival in patients with cancer. *Journal of Clinical Oncology*. 2011; 29(15):2071-2076
965. Van Es N, Coppens M, Schulman S, Middeldorp S, Buller HR. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: Evidence from phase 3 trials. *Blood*. 2014; 124(12):1968-1975
966. van Es N, Kraaijpoel N, Klok FA, Huisman MV, Den Exter PL, Mos IC et al. The original and simplified Wells rules and age-adjusted D-dimer testing to rule out pulmonary embolism: an individual patient data meta-analysis. *Journal of Thrombosis and Haemostasis*. 2017; 20:20
967. van Geloven F, Wittebol P, Sixma JJ. Comparison of postoperative coumarin, dextran 40 and subcutaneous heparin in the prevention of postoperative deep vein thrombosis. *Acta Medica Scandinavica*. 1977; 202(5):367-372



968. Vanassche T, Vandenbrielle C, Peerlinck K, Verhamme P. Pharmacotherapy with oral Xa inhibitors for venous thromboembolism. *Expert Opinion on Pharmacotherapy*. 2015; 16(5):645-658
969. Vardi M, Steinberg M, Haran M, Cohen S. Benefits versus risks of pharmacological prophylaxis to prevent symptomatic venous thromboembolism in unselected medical patients revisited. Meta-analysis of the medical literature. *Journal of Thrombosis and Thrombolysis*. 2012; 34(1):11-19
970. Vazquez-Acosta JA, Ramirez-Gutierrez AE, Cerecedo-Rosendo MA, Olivera-Barrera FM, Tenorio-Sanchez SS, Nieto-Villarreal J et al. Characterization of thromboembolic risk in a Mexican population with non-valvular atrial fibrillation (AF) and its effect on the indication of anticoagulation (MAYA study). *Gaceta Medica de México*. 2016; 152(4):473-478
971. Vedovati MC, Becattini C, Rondelli F, Boncompagni M, Camporese G, Balzarotti R et al. A randomized study on 1-week versus 4-week prophylaxis for venous thromboembolism after laparoscopic surgery for colorectal cancer. *Annals of Surgery*. 2014; 259(4):665-669
972. Vedovati MC, Germini F, Agnelli G, Becattini C. Direct oral anticoagulants in patients with VTE and cancer: a systematic review and meta-analysis. *Chest*. 2015; 147(2):475-483
973. Velmahos GC, Petrone P, Chan LS, Hanks SE, Brown CV, Demetriades D. Electrostimulation for the prevention of deep venous thrombosis in patients with major trauma: a prospective randomized study. *Surgery*. 2005; 137(5):493-8
974. Venous Thrombosis Clinical Study Group. Prevention of fatal postoperative pulmonary embolism by low doses of heparin. An international multicentre trial. *Lancet*. 1975; 306(7924):45-51
975. Verardi S, Cortese F, Baroni B, Boffo V, Casciani CU. (Role of low molecular weight heparin in the prevention of postoperative deep venous thrombosis. Our experience in 88 cases. *Giornale di Chirurgia*. 1989; 10(11):674-678
976. Verdecchia P, Angeli F, Lip GYH, Reboldi G. Edoxaban in the evolving scenario of non vitamin K antagonist oral anticoagulants imputed placebo analysis and multiple treatment comparisons. *PloS One*. 2014; 9(6)
977. Verdecchia P, Molini G, Bartolini C, De F, V, Valecchi F, Martone S et al. Safety of dabigatran in an elderly population: Single center experience in Italy. *Current Drug Safety*. 2015; 10(2):165-169
978. Verso M, Gussoni G, Agnelli G. Prevention of venous thromboembolism in patients with advanced lung cancer receiving chemotherapy: a combined analysis of the PROTECT and TOPIC-2 studies. *Journal of Thrombosis and Haemostasis*. 2010; 8(7):1649-1651
979. Villa LA, Malone DC, Ross D. Evaluating the efficacy and safety of apixaban, a new oral anticoagulant, using Bayesian meta-analysis. *International Journal of Hematology*. 2013; 98(4):390-397
980. Voigt J, Hamelmann H, Hedderich J, Seifert J, Buchhammer T, Kohler A. Effectiveness and side effects of low-molecular weight heparin-dihydroergotamine in preventing thromboembolism in abdominal surgery. *Zentralblatt für Chirurgie*. 1986; 111(21):1269-1305
981. Vollans S, Chaturvedi A, Sivasankaran K, Madhu T, Hadland Y, Allgar V et al. Symptomatic venous thromboembolism following circular frame treatment for tibial fractures. *Injury*. 2015; 46(6):1108-1111





982. Wade R. Graduated compression stockings for prevention of deep vein thrombosis in postoperative surgical patients. HTA - 13/72/01. 2014. Available from: <http://www.nets.nihr.ac.uk/projects/hta/137201> Last accessed: 28/06/17.
983. Wade R, Paton F, Rice S, Stansby G, Millner P, Flavell H et al. Thigh length versus knee length antiembolism stockings for the prevention of deep vein thrombosis in postoperative surgical patients; a systematic review and network meta-analysis. *BMJ Open*. 2016; 6:009456
984. Wade R, Paton F, Woolacott N. Systematic review of patient preference and adherence to the correct use of graduated compression stockings to prevent deep vein thrombosis in surgical patients. *Journal of Advanced Nursing*. 2017; 73(2):336-348
985. Wade R, Sideris E, Paton F, Rice S, Palmer S, Fox D et al. Graduated compression stockings for the prevention of deep-vein thrombosis in postoperative surgical patients: a systematic review and economic model with a value of information analysis. *Health Technology Assessment*. 2015; 19(98):1-220
986. Wang SV, Franklin JM, Glynn RJ, Schneeweiss S, Eddings W, Gagne JJ. Prediction of rates of thromboembolic and major bleeding outcomes with dabigatran or warfarin among patients with atrial fibrillation: new initiator cohort study. *BMJ*. 2016; 353:i2607
987. Wang Y, Ivany JN, Perkovic V, Gallagher MP, Woodward M, Jardine MJ. Anticoagulants and antiplatelet agents for preventing central venous haemodialysis catheter malfunction in patients with end-stage kidney disease. *Cochrane Database Syst Rev* 2016, Issue 4. Art. No.: CD009631. DOI: 10.1002/14651858.CD009631.pub2.
988. Wang Z, Anderson FA, Jr., Ward M, Bhattacharyya T. Surgical site infections and other postoperative complications following prophylactic anticoagulation in total joint arthroplasty. *PLoS One*. 2014; 9(4):e91755
989. Ward B, Pradhan S. Comparison of low molecular weight heparin (Fragmin) with sodium heparin for prophylaxis against postoperative thrombosis in women undergoing major gynaecological surgery. *Australian and New Zealand Journal of Obstetrics and Gynaecology*. 1998; 38(1):91-92
990. Ward DR, Moist LM, MacRae JM, Scott-Douglas N, Zhang J, Tonelli M et al. Risk factors associated with hemodialysis central venous catheter malfunction; a retrospective analysis of a randomized controlled trial. *Can J Kidney Health Dis*. 2014; 1:15
991. Warlow C, Beattie AG, Terry G, Ogston D, Kenmure ACF, Douglas AS. A double-blind trial of low doses of subcutaneous heparin in the prevention of deep-vein thrombosis after myocardial infarction. *Lancet*. 1973; 302(7835):934-936
992. Warwick D, Bannister GC, Glew D, Mitchelmore A, Thornton M, Peters TJ et al. Perioperative low-molecular-weight heparin. Is it effective and safe. *Journal of Bone and Joint Surgery (British Volume)*. 1995; 77(5):715-719
993. Warwick D, Friedman RJ, Agnelli G, Gil-Garay E, Johnson K, Fitzgerald G et al. Insufficient duration of venous thromboembolism prophylaxis after total hip or knee replacement when compared with the time course of thromboembolic events: findings from the global orthopaedic registry. *Journal of Bone and Joint Surgery British Volume*. 2007; 89B(6):799-807
994. Warwick D, Harrison J, Glew D, Mitchelmore A, Peters TJ, Donovan J. Comparison of the use of a foot pump with the use of low-molecular-weight heparin for the prevention of deep-vein thrombosis after total hip replacement. A prospective, randomized trial. *Journal of Bone and Joint Surgery (American Volume)*. 1998; 80(8):1158-1166

995. Warwick D, Harrison J, Whitehouse S, Mitchelmore A, Thornton M. A randomised comparison of a foot pump and low-molecular-weight heparin in the prevention of deep-vein thrombosis after total knee replacement. *Journal of Bone and Joint Surgery (British Volume)*. 2002; 84(3):344-350
996. Warwick D, Williams MH, Bannister GC. Death and thromboembolic disease after total hip replacement. A series of 1162 cases with no routine chemical prophylaxis. *Journal of Bone and Joint Surgery British Volume*. 1995; 77(1):6-10
997. Wasserlauf G, Grandi SM, Filion KB, Eisenberg MJ. Meta-analysis of rivaroxaban and bleeding risk. *American Journal of Cardiology*. 2013; 112(3):454-460
998. Watson U, Hickey BA, Jones HM, Perera A. A critical evaluation of venous thromboembolism risk assessment models used in patients with lower limb cast immobilisation. *Journal of Foot and Ankle Surgery*. 2016; 22(3):191-5
999. Weber C, Merminod T, Herrmann FR, Zulian GB. Prophylactic anti-coagulation in cancer palliative care: a prospective randomised study. *Supportive Care in Cancer*. 2008; 16(7):847-852
1000. Weill-Engerer S, Meaume S, Lahlou A, Piette F, Saint-Jean O, Sachet A et al. Risk factors for deep vein thrombosis in inpatients aged 65 and older: a case-control multicenter study. *Journal of the American Geriatrics Society*. 2004; 52(8):1299-304
1001. Weiss V, Jekiel M, Ritschard J, Bouvier CA. Prevention de la maladie thrombo-embolique post-operatoire par les anti-agregeants en chirurgie gynecologique. *Médecine et Hygiène*. 1977; 35:943-944
1002. Weitz J, Michelsen J, Gold K, Owen J, Carpenter D. Effects of intermittent pneumatic calf compression on postoperative thrombin and plasmin activity. *Thrombosis and Haemostasis*. 1986; 56(2):198-201
1003. Welin-Berger T, Bygdeman S, Mebius C. Deep vein thrombosis following hip surgery. Relation to activated factor X inhibitor activity: effect of heparin and dextran. *Acta Orthopaedica Scandinavica*. 1982; 53(6):937-945
1004. Wells PS, Forgie MA, Simms M, Greene A, Touchie D, Lewis G et al. The outpatient bleeding risk index: validation of a tool for predicting bleeding rates in patients treated for deep venous thrombosis and pulmonary embolism. *Archives of Internal Medicine*. 2003; 163(8):917-20
1005. Welti H. Thrombo-embolytic prophylaxis using physiotherapy with and without low doses of heparin in gynecology and obstetrics. Results of a controlled and randomized mult-cancer study. *Revue Médicale de la Suisse Romande*. 1981; 101(11):925-934
1006. Westrich GH, Bottner F, Windsor RE, Laskin RS, Haas SB, Sculco TP. VenaFlow plus Lovenox vs VenaFlow plus aspirin for thromboembolic disease prophylaxis in total knee arthroplasty. *Journal of Arthroplasty*. 2006; 21(6 Suppl 2):139-143
1007. Wilbur K, Lynd LD, Sadatsafavi M. Low-molecular-weight heparin versus unfractionated heparin for prophylaxis of venous thromboembolism in medicine patients: a pharmaco-economic analysis. *Clinical and Applied Thrombosis/Hemostasis*. 2011; 17(5):454-465
1008. Wild D, Murray M, Donatti C. Patient perspectives on taking vitamin K antagonists: a qualitative study in the UK, USA and Spain. *Expert Review of Pharmacoeconomics & Outcomes Research*. 2009; 9(5):467-74



1009. Wilkieson TJ, Ingram AJ, Crowther MA, Soroka SD, Nagai R, Jindal KK et al. Low-intensity adjusted-dose warfarin for the prevention of hemodialysis catheter failure: a randomized, controlled trial. *Clinical Journal of the American Society of Nephrology*. 2011; 6(5):1018-24
1010. Wille-Jorgensen P, Jorgensen LN, Crawford M. Asymptomatic postoperative deep vein thrombosis and the development of postthrombotic syndrome. A systematic review and meta-analysis. *Thrombosis and Haemostasis*. 2005; 93(2):236-241
1011. Willett KC, Alsharhan M, Durand C, Cooper MR. Dosing of enoxaparin for venous thromboembolism prophylaxis in obese patients. *Annals of Pharmacotherapy*. 2013; 47(12):1717-1720
1012. Williams JT, Palfrey SM. Cost effectiveness and efficacy of below knee against above knee graduated compression stockings in the prevention of deep vein thrombosis. *Phlebologie*. 1988; 41(4):809-811
1013. Williams JW, Eikman EA, Greenberg SH, Hewitt JC, Lopez-Cuenca E, Jones GP et al. Failure of low dose heparin to prevent pulmonary embolism after hip surgery or above the knee amputation. *Annals of Surgery*. 1978; 188(4):468-474
1014. Wilson NV, Das SK, Kakkar VV, Maurice HD, Smibert JG, Thomas EM et al. Thrombo-embolic prophylaxis in total knee replacement. Evaluation of the A-V impulse system. *Journal of Bone and Joint Surgery (British Volume)*. 1992; 74(1):50-52
1015. Windisch C, Kolb W, Kolb K, Grutzner P, Venbrocks R, Anders J. Pneumatic compression with foot pumps facilitates early postoperative mobilisation in total knee arthroplasty. *International Orthopaedics*. 2011; 35(7):995-1000
1016. Woller SC, Stevens SM, Jones JP, Lloyd JF, Evans RS, Aston VT et al. Derivation and validation of a simple model to identify venous thromboembolism risk in medical patients. *American Journal of Medicine*. 2011; 124(10):947-954.e2
1017. Wolowacz SE, Roskell NS, Maciver F, Beard SM, Robinson PA, Plumb JM et al. Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism after total knee and hip replacement surgery. *Clinical Therapeutics*. 2009; 31(1):194-212
1018. Wolowacz SE, Roskell NS, Plumb JM, Clemens A, Noack H, Robinson PA et al. Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism in patients aged over 75 years or with moderate renal impairment undergoing total knee or hip replacement. *Thrombosis and Haemostasis*. 2010; 103(2):360-371
1019. Wong A, Kraus PS, Lau BD, Streiff MB, Haut ER, Hobson DB et al. Patient preferences regarding pharmacologic venous thromboembolism prophylaxis. *Journal of Hospital Medicine*. 2015; 10(2):108-11
1020. Wong A, Streiff MB, Haut ER, Kraus PS, Lau BD, Brown VT et al. Patient perspectives on pharmacological venous thromboembolism prophylaxis at the Johns Hopkins Hospital. *Journal of Thrombosis and Thrombolysis*. 2013; 35 (3):416
1021. Wood EH, Prentice CR, McGrouther DA, Sinclair J, McNicol GP. Trial of aspirin and RA233 in prevention of post-operative deep vein thrombosis. *Thrombosis et Diathesis Haemorrhagica*. 1973; 30(1):18-24
1022. Woolson ST, Watt JM. Intermittent pneumatic compression to prevent proximal deep venous thrombosis during and after total hip replacement. A prospective, randomized study of compression alone, compression and aspirin, and compression and low-dose warfarin. *Journal of Bone and Joint Surgery (American Volume)*. 1991; 73(4):507-512

1023. Wu C, Alotaibi GS, Alsaleh K, Linkins LA, McMurtry MS. Case-fatality of recurrent venous thromboembolism and major bleeding associated with aspirin, warfarin, and direct oral anticoagulants for secondary prevention. *Thrombosis Research*. 2015; 135(2):243-248
1024. Wu TK, Tsapogas MJ, Jordan FR. Prophylaxis of deep venous thrombosis by hydroxychloroquine sulfate and heparin. *Surgery, Gynecology and Obstetrics*. 1977; 145(5):714-718
1025. Xing Y, Ma Q, Ma X, Wang C, Zhang D, Sun Y. CHADS<sub>2</sub> score has a better predictive value than CHA<sub>2</sub>DS<sub>2</sub>-VASc score in elderly patients with atrial fibrillation. *Clinical Interventions in Aging*. 2016; 11:941-946
1026. Yanar H, Kurtoglu M, Taviloglu K, Guloglu R, Ertekin C. Is intermittent pneumatic compression make low molecular weight heparin more efficient in the prophylaxis of venous thromboembolism in trauma patients. *European Journal of Trauma and Emergency Surgery*. 2007; 33(3 Suppl 2):79-80
1027. Yarlagadda BB, Brook CD, Stein DJ, Jalisi S. Venous thromboembolism in otolaryngology surgical inpatients receiving chemoprophylaxis. *Head and Neck*. 2014; 36(8):1087-93
1028. Yeo DXW, Junnarkar S, Balasubramaniam S, Tan YP, Low JK, Woon W et al. Incidence of venous thromboembolism and its pharmacological prophylaxis in Asian general surgery patients: a systematic review. *World Journal of Surgery*. 2015; 39(1):150-157
1029. Yoo HH, Queluz TH, El Dib R. Anticoagulant treatment for subsegmental pulmonary embolism. *Cochrane Database Syst Rev* 2016, Issue 1. Art. No.: CD010222. DOI: 10.1002/14651858.CD010222.pub3.
1030. Yoo MC, Kang CS, Kim YH, Kim SK. A prospective randomized study on the use of nadroparin calcium in the prophylaxis of thromboembolism in Korean patients undergoing elective total hip replacement. *International Orthopaedics*. 1997; 21(6):399-402
1031. Yoshida RdA, Yoshida WB, Maffei FHdA, El Dib R, Nunes R, Rollo HA. Systematic review of randomized controlled trials of new anticoagulants for venous thromboembolism prophylaxis in major orthopedic surgeries, compared with enoxaparin. *Annals of Vascular Surgery*. 2013; 27(3):355-369
1032. Young AM, Billingham LJ, Begum G, Kerr DJ, Hughes AI, Rea DW et al. Warfarin thromboprophylaxis in cancer patients with central venous catheters (WARP): an open-label randomised trial. *Lancet*. 2009; 373(9663):567-574
1033. Young MD, Daniels AH, Evangelista PT, Reinert SE, Ritterman S, Christino MA et al. Predicting pulmonary embolus in orthopedic trauma patients using the Wells score. *Orthopedics*. 2013; 36(5):e642-7
1034. Yusen RD, Hull RD, Schellong SM, Tapson VF, Monreal M, Samama MM et al. Impact of age on the efficacy and safety of extended-duration thromboprophylaxis in medical patients. Subgroup analysis from the EXCLAIM randomised trial. *Thrombosis and Haemostasis*. 2013; 110(6):1152-63
1035. Zacharski LR, Henderson WG, Rickles FR, Forman WB, Cornell CJ, Forcier RJ. Effect of warfarin on survival in small cell carcinoma of the lung. Veterans administration study No. 75. *JAMA : the journal of the American Medical Association*. 1981; 245(8):831-835
1036. Zacharski LR, Henderson WG, Rickles FR, Forman WB, Cornell CJ, Forcier RJ. Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate. Final report of VA Cooperative Study #75. *Cancer*. 1984; 53(10):2046-2052

1037. Zaghiyan KN, Sax HC, Miraflor E, Cossman D, Wagner W, Mirocha J et al. Timing of Chemical Thromboprophylaxis and Deep Vein Thrombosis in Major Colorectal Surgery: A Randomized Clinical Trial. *Annals of Surgery*. 2016; 264(4):632-9
1038. Zakai NA, Callas PW, Repp AB, Cushman M. Venous thrombosis risk assessment in medical inpatients: the medical inpatients and thrombosis (MITH) study. *Journal of Thrombosis and Haemostasis*. 2013; 11(4):634-41
1039. Zanasi R, Fioretta G, Ciocia G, Bergonzi M. Prevention of deep venous thrombosis in orthopedic surgery: effects of defibrotide. *Clinical Therapeutics*. 1988; 10(4):350-357
1040. Zareba P, Wu C, Agzarian J, Rodriguez D, Kearon C. Meta-analysis of randomized trials comparing combined compression and anticoagulation with either modality alone for prevention of venous thromboembolism after surgery. *British Journal of Surgery*. 2014; 101(9):1053-1062
1041. Zekert F, Schemper M, Neumann K. Acetylsalicylic acid in combination with dihydroergotamine for preventing thromboembolism. *Haemostasis*. 1982; 11(3):149-153
1042. Zhang C, Zeng W, Zhou H, Zheng BX, Cheng JC, Li XY et al. [The efficacy of intermittent pneumatic compression in the prevention of venous thromboembolism in medical critically ill patients]. *Zhongguo Wei Zhong Bing Ji Jiu Yi Xue Chinese Critical Care Medicine*. 2011; 23(9):563-5
1043. Zhao JM, He ML, Xiao ZM, Li TS, Wu H, Jiang H. Different types of intermittent pneumatic compression devices for preventing venous thromboembolism in patients after total hip replacement. *Cochrane Database of Systematic Reviews* 2014, Issue 12. Art. No.: CD009543. DOI: 10.1002/14651858.CD009543.pub3.
1044. Zheng X, Li DY, Wangyang Y, Zhang XC, Guo KJ, Zhao FC et al. Effect of Chemical Thromboprophylaxis on the Rate of Venous Thromboembolism After Treatment of Foot and Ankle Fractures. *Foot and Ankle International*. 2016; 37(11):1218-1224
1045. Zhou H, Wang L, Wu X, Tang Y, Yang J, Wang B et al. Validation of a venous thromboembolism risk assessment model in hospitalized Chinese patients: a case-control study. *Journal of Atherosclerosis & Thrombosis*. 2014; 21(3):261-72
1046. Zhou HX, Peng LQ, Yan Y, Yi Q, Tang YJ, Shen YC et al. Validation of the Caprini risk assessment model in Chinese hospitalized patients with venous thromboembolism. *Thrombosis Research*. 2012; 130(5):735-40
1047. Zhou X, Varadhachary GR, Milind J, Fogelman D, Shroff R, Bueso-Ramos CE et al. Randomized Controlled Trial Of Dalteparin For Primary Thromboprophylaxis For Venous Thromboembolism (VTE) In Patients With Advanced Pancreatic Cancer (APC): Risk Factors Predictive Of VTE. *Blood*. 2013; 122:580-580
1048. Zhu W, Fu L, Ding Y, Huang L, Xu Z, Hu J et al. Meta-analysis of ATRIA versus CHA<sub>2</sub>DS<sub>2</sub>-VASc for predicting stroke and thromboembolism in patients with atrial fibrillation. *International Journal of Cardiology*. 2017; 227:436-442
1049. Ziemiński JM, Kostrzevska E, Marchlewski S, Wieczorek K, Rudowski W, Michalski R et al. Efficacy of small doses of heparin given during 2 to 6 days in the prevention of postoperative deep vein thrombosis. *Polski Tygodnik Lekarski*. 1979; 34(5):161-164
1050. Zilio M, Mazzai L, Sartori MT, Barbot M, Ceccato F, Daidone V et al. A venous thromboembolism risk assessment model for patients with Cushing's syndrome. *Endocrine*. 2016; 52(2):322-32



1051. Zindel S, Stock S, Muller D, Stollenwerk B. A multi-perspective cost-effectiveness analysis comparing rivaroxaban with enoxaparin sodium for thromboprophylaxis after total hip and knee replacement in the German healthcare setting. *BMC Health Services Research*. 2012; 12:192(2)
1052. Zou Y, Tian S, Wang Y, Sun K. Administering aspirin, rivaroxaban and low-molecular-weight heparin to prevent deep venous thrombosis after total knee arthroplasty. *Blood Coagulation and Fibrinolysis*. 2014; 25(7):660-664
1053. Zufferey P, Laporte S, Quenet S, Molliex S, Auboyer C, Decousus H et al. Optimal low-molecular-weight heparin regimen in major orthopaedic surgery. A meta-analysis of randomised trials. *Thrombosis and Haemostasis*. 2003; 90(4):654-661
1054. Zwicker JI, Liebman HA, Bauer KA, Caughey T, Campigotto F, Rosovsky R et al. Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factor-bearing microparticles: a randomized-controlled phase II trial (the Microtec study). *British Journal of Haematology*. 2013; 160(4):530-7